|
England and Wales
(State or other jurisdiction of Incorporation or organization) |
| |
2834
(Primary standard industrial classification code number) |
| |
Not applicable
(I.R.S. Employer Identification Number) |
|
|
Steven V. Bernard
Bradley L. Finkelstein Melissa Rick Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 (650) 493-9300 |
| |
Charles Waddell
Pinsent Masons LLP 30 Crown Place Earl Street London EC2A 4ES United Kingdom +44(0) 20 7418 7000 |
| |
Duncan Peyton
Chief Executive Officer 4D pharma plc 5th Floor, 9 Bond Court Leeds LS1 2JZ United Kingdom +44(0) 113 895 0130 |
| |
Matthew Chen
Longevity Acquisition Corporation Yongda International Tower No. 2277 Longyang Road, Pudong District, Shanghai People’s Republic of China (86) 21-60832028 |
| |
Arila Zhou
John Wu Hunter Taubman Fischer & Li LLC 800 Third Avenue, Suite 2800 New York, New York 10022 (212) 530-0000 |
|
| | ||||||||||||||||||||||||||||
Title Of Each Class Of Security To Be Registered
|
| | |
Amount To Be
Registered(1) |
| | |
Proposed Maximum
Offering Price Per Security(2) |
| | |
Proposed Maximum
Aggregate Offering Price(2) |
| | |
Amount of
Registration Fee |
| ||||||||||||
Ordinary Shares, nominal value £0.0025 per
share(3)(4) |
| | | | | 31,055,000 | | | | | | $ | 1.4539 | | | | | | $ | 45,150,865 | | | | | | $ | 4,926 | | |
| , 2020 | | | By Order of the Longevity Board | |
| | | |
/s/
Chairman of Longevity Board, Chief Financial Officer
|
|
|
Yongda International Tower No. 2277
Longyang Road, Pudong District, Shanghai People’s Republic of China |
| |
4D Pharma PLC
5th Floor, 9 Bond Court Leeds, LS1 2JZ United Kingdom ir@4dpharmaplc.com |
|
| | | | | 10 | | | |
| | | | | 12 | | | |
| | | | | 14 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 31 | | | |
| | | | | 36 | | | |
| | | | | 37 | | | |
| | | | | 38 | | | |
| | | | | 95 | | | |
| | | | | 96 | | | |
| | | | | 97 | | | |
| | | | | 105 | | | |
| | | | | 109 | | | |
| | | | | 121 | | | |
| | | | | 134 | | | |
| | | | | 136 | | | |
| | | | | 137 | | | |
| | | | | 146 | | | |
| | | | | 147 | | | |
| | | | | 151 | | | |
| | | | | 157 | | | |
| | | | | 199 | | | |
| | | | | 215 | | | |
| | | | | 217 | | | |
| | | | | 225 | | | |
| | | | | 231 | | | |
| | | | | 241 | | | |
| | | | | 254 | | | |
| | | | | 267 | | | |
| | | | | 268 | | | |
| | | | | 269 | | | |
| | | | | 270 | | | |
| | | | | A-1 | | | |
| | | | | B-1 | | | |
| | | | | C-1 | | | |
| | | | | D-1 | | |
Month
|
| |
High
|
| |
Low
|
| ||||||
November (through November 24), 2020
|
| | | | 1.3299 | | | | | | 1.2904 | | |
October 2020
|
| | | | 1.3143 | | | | | | 1.2890 | | |
September 2020
|
| | | | 1.3416 | | | | | | 1.2706 | | |
August 2020
|
| | | | 1.3375 | | | | | | 1.3043 | | |
July 2020
|
| | | | 1.3133 | | | | | | 1.2469 | | |
June 2020
|
| | | | 1.2758 | | | | | | 1.2279 | | |
Year
|
| |
Average
Rate(1) |
| |||
2019
|
| | | | 1.2803 | | |
2018
|
| | | | 1.3309 | | |
2017
|
| | | | 1.3016 | | |
2016
|
| | | | 1.3444 | | |
2015
|
| | | | 1.5250 | | |
|
Advantage Proxy, Inc.
P.O. Box 13581 Des Moines, WA 98198 Attn: Karen Smith Toll Free: (877) 870-8565 Collect: (206) 870-8565 |
| |
or
|
| |
Longevity
Acquisition Corporation Yongda International Tower No. 2277 Longyang Road, Pudong District, Shanghai People’s Republic of China (86) 21-60832028 |
|
U.S. dollars in thousands, except share and per share data
|
| |
Six months ended
August 31, |
| |
Year ended
February 29, |
| |
March 9, 2018
(inception) to February 28 |
| |||||||||||||||
| | |
2020
|
| |
2019
|
| |
2020
|
| |
2019
|
| ||||||||||||
Income Statement Data: | | | | | | | | | | | | | | | | | | | | | | | | | |
Operating costs
|
| | | $ | 370 | | | | | $ | 570 | | | | | $ | 1,079 | | | | | $ | 439 | | |
Interest income
|
| | | | 46 | | | | | | 455 | | | | | | 788 | | | | | | 430 | | |
Unrealized gain (loss)
|
| | | | — | | | | | | 6 | | | | | | — | | | | | | (5) | | |
Net Loss
|
| | | $ | (324) | | | | | $ | (109) | | | | | $ | (291) | | | | | $ | (14) | | |
Weighted average number of Longevity Shares outstanding, basic and diluted(1)
|
| | | | 1,997,943 | | | | | | 1,809,240 | | | | | | 1,859,697 | | | | | | 1,522,527 | | |
Basic and diluted net loss per Longevity Share(2)
|
| | | $ | (0.17) | | | | | $ | (0.28) | | | | | $ | (0.50) | | | | | $ | (0.25) | | |
U.S. dollars in thousands
|
| |
August 31,
2020 |
| |
February 29,
2020 |
| ||||||
Balance Sheet Data: | | | | | | | | | | | | | |
Current Assets
|
| | | $ | 32 | | | | | $ | 138 | | |
Marketable securities held in Trust Account
|
| | | | 14,506 | | | | | | 42,413 | | |
Total assets
|
| | | | 14,538 | | | | | | 42,551 | | |
Longevity Shares subject to possible Redemption
|
| | | | 6,409 | | | | | | 34,789 | | |
Total shareholders’ equity
|
| | | | 5,000 | | | | | | 5,000 | | |
| | |
Six Months Ended
June 30, (unaudited) |
| |
Year Ended
December 31, |
| ||||||||||||||||||
U.S. dollars in thousands, except share and per share data
|
| |
2020
|
| |
2019
|
| |
2019
|
| |
2018
|
| ||||||||||||
Revenues
|
| | | $ | 239 | | | | | $ | — | | | | | $ | 269 | | | | | $ | — | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development expenses
|
| | | | 13,493 | | | | | | 11,701 | | | | | | 29,193 | | | | | | 27,830 | | |
General and administrative expenses
|
| | | | 5,509 | | | | | | 5,400 | | | | | | 10,380 | | | | | | 11,294 | | |
Foreign currency losses (gains)
|
| | | | (1,491) | | | | | | 148 | | | | | | 957 | | | | | | (234) | | |
Total operating expenses
|
| | | | 17,511 | | | | | | 17,249 | | | | | | 40,530 | | | | | | 38,890 | | |
Loss from operations
|
| | | | (17,272) | | | | | | (17,249) | | | | | | (40,261) | | | | | | (38,890) | | |
Other income (expense), net:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Interest income
|
| | | | 6 | | | | | | 84 | | | | | | 78 | | | | | | 379 | | |
Interest expense
|
| | | | (1) | | | | | | (1) | | | | | | — | | | | | | (3) | | |
Other income
|
| | | | 2,502 | | | | | | 2,720 | | | | | | 6,883 | | | | | | 6,378 | | |
Change in fair value of contingent consideration payable
|
| | | | — | | | | | | (252) | | | | | | 2,967 | | | | | | (465) | | |
Total other income (expense), net
|
| | | | 2,507 | | | | | | 2,551 | | | | | | 9,928 | | | | | | 6,289 | | |
Net loss
|
| | | $ | (14,765) | | | | | $ | (14,698) | | | | | $ | (30,333) | | | | | $ | (32,601) | | |
Other comprehensive loss: | | | | | | | | | | | | | | | | | | | | | | | | | |
Foreign currency translation adjustment
|
| | | | (2,081) | | | | | | 111 | | | | | | 1,113 | | | | | | (3,995) | | |
Comprehensive loss
|
| | | | (16,846) | | | | | | (14,587) | | | | | | (29,220) | | | | | | (36,596) | | |
Basic and diluted net loss per common share
|
| | | $ | (0.15) | | | | | $ | (0.22) | | | | | $ | (0.46) | | | | | $ | (0.50) | | |
Weighted average common shares used in computing basic and diluted net loss per common share
|
| | | | 97,647,688 | | | | | | 65,493,842 | | | | | | 65,493,842 | | | | | | 65,493,842 | | |
|
U.S. dollars in thousands
|
| |
As of
June 30, 2020 (unaudited) |
| |
As of
December 31, 2019 |
| ||||||
Balance Sheet Data: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 12,413 | | | | | $ | 5,031 | | |
Total assets
|
| | | | 50,318 | | | | | | 40,826 | | |
Total non-current liabilities
|
| | | | 1,936 | | | | | | 3,150 | | |
Accumulated deficit
|
| | | | (132,505) | | | | | | (117,740) | | |
Total shareholders’ equity
|
| | | | 40,879 | | | | | | 31,187 | | |
| | |
Historical
June 30, 2020 |
| |
Historical
August 31, 2020 |
| |
Pro
Forma Adjustments |
| | | | |
Pro
Forma Combined |
| ||||||||||||
| | |
4D Pharma
|
| |
Longevity
|
| |
Notes
|
| ||||||||||||||||||
Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 12,413 | | | | | $ | 7 | | | | | | 20,827 | | | |
B, C, D, H, I, J
|
| | | $ | 33,247 | | |
Research and development tax credits receivable
|
| | | | 8,999 | | | | | | — | | | | | | — | | | | | | | | | 8,999 | | |
Prepaid expenses and other current assets
|
| | | | 4,208 | | | | | | 25 | | | | | | — | | | | | | | | | 4,233 | | |
Total current assets
|
| | | | 25,620 | | | | | | 32 | | | | | | 20,827 | | | | | | | | | 46,479 | | |
Cash and marketable securities held in Trust Account
|
| | | | — | | | | | | 14,506 | | | | | | (14,506) | | | |
I
|
| | | | — | | |
Property and equipment, net
|
| | | | 5,219 | | | | | | — | | | | | | — | | | | | | | | | 5,219 | | |
Right-of-use assets (operating leases)
|
| | | | 1,117 | | | | | | — | | | | | | — | | | | | | | | | 1,117 | | |
Intangible assets, net
|
| | | | 5,826 | | | | | | — | | | | | | — | | | | | | | | | 5,826 | | |
Goodwill
|
| | | | 12,300 | | | | | | — | | | | | | — | | | | | | | | | 12,300 | | |
Research and development tax credits receivable
|
| | | | 236 | | | | | | — | | | | | | — | | | | | | | | | 236 | | |
Total assets
|
| | | $ | 50,318 | | | | | $ | 14,538 | | | | | | 6,321 | | | | | | | | $ | 71,177 | | |
Liabilities and Stockholders’ Equity | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 4,012 | | | | | $ | 337 | | | | | | — | | | | | | | | $ | 4,349 | | |
Accrued expenses and other current
liabilities |
| | | | 2,160 | | | | | | — | | | | | | 2,785 | | | |
E, F, G, H
|
| | | | 4,945 | | |
Current portion of operating lease
liabilities |
| | | | 79 | | | | | | — | | | | | | — | | | | | | | | | 79 | | |
Deferred revenues, current
|
| | | | 1,252 | | | | | | — | | | | | | — | | | | | | | | | 1,252 | | |
Total current liabilities
|
| | | | 7,503 | | | | | | 337 | | | | | | 2,785 | | | | | | | | | 10,625 | | |
Convertible promissory notes – related
party |
| | | | — | | | | | | 1,792 | | | | | | (1,792) | | | |
B, C, J, K
|
| | | | — | | |
Long-term operating lease liabilities, net
|
| | | | 1,088 | | | | | | — | | | | | | — | | | | | | | | | 1,088 | | |
Deferred revenues, net
|
| | | | 644 | | | | | | — | | | | | | — | | | | | | | | | 644 | | |
Deferred tax
|
| | | | 32 | | | | | | — | | | | | | — | | | | | | | | | 32 | | |
Deferred underwriting fee payable
|
| | | | — | | | | | | 1,000 | | | | | | (1,000) | | | |
F
|
| | | | — | | |
Other liabilities
|
| | | | 172 | | | | | | — | | | | | | — | | | | | | | | | 172 | | |
Total liabilities
|
| | | | 9,439 | | | | | | 3,129 | | | | | | (7) | | | | | | | | | 12,561 | | |
Ordinary shares subject to possible redemption
|
| | | | — | | | | | | 6,409 | | | | | | (6,409) | | | |
A
|
| | | | — | | |
Stockholders’ equity: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Common stock
|
| | | | 405 | | | | | | 5,629 | | | | | | (5,453) | | | |
A, D, G, K, L, M
|
| | | | 581 | | |
Additional paid-in capital
|
| | | | 200,775 | | | | | | — | | | | | | 17,561 | | | |
D, E, G, L, M
|
| | | | 218,336 | | |
Accumulated other comprehensive loss
|
| | | | (27,796) | | | | | | — | | | | | | — | | | | | | | | | (27,796) | | |
Accumulated deficit
|
| | | | (132,505) | | | | | | (629) | | | | | | 629 | | | |
F, L
|
| | | | (132,505) | | |
Total stockholders’ equity
|
| | | | 40,879 | | | | | | 5,000 | | | | | | 12,737 | | | | | | | | | 58,616 | | |
Total liabilities and stockholders’ equity
|
| | | $ | 50,318 | | | | | $ | 14,538 | | | | | | 6,321 | | | | | | | | $ | 71,177 | | |
| | |
Historical
June 30, 2020 |
| |
Historical
August 31, 2020 |
| |
Pro Forma
Adjustments |
| | | | |
Pro Forma
Combined |
| ||||||||||||
| | |
4D Pharma
|
| |
Longevity
|
| |
Notes
|
| ||||||||||||||||||
Revenues
|
| | | $ | 239 | | | | | $ | — | | | | | $ | — | | | | | | | | $ | 239 | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | | 13,493 | | | | | | — | | | | | | — | | | | | | | | | 13,493 | | |
General and administrative
|
| | | | 5,509 | | | | | | 370 | | | | | | | | | | | | | | | 5,879 | | |
Foreign currency gains, net
|
| | | | (1,491) | | | | | | — | | | | | | — | | | | | | | | | (1,491) | | |
Total operating expenses
|
| | | | 17,511 | | | | | | 370 | | | | | | | | | | | | | | | 17,881 | | |
Loss from operations
|
| | | | (17,272) | | | | | | (370) | | | | | | | | | | | | | | | (17,642) | | |
Other income (expense), net: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Interest income
|
| | | | 6 | | | | | | 46 | | | | | | — | | | | | | | | | 52 | | |
Interest expense
|
| | | | (1) | | | | | | — | | | | | | — | | | | | | | | | (1) | | |
Other income
|
| | | | 2,502 | | | | | | — | | | | | | — | | | | | | | | | 2,502 | | |
Total other income (expense), net
|
| | | | 2,507 | | | | | | 46 | | | | | | — | | | | | | | | | 2,553 | | |
Net loss
|
| | | $ | (14,765) | | | | | $ | (324) | | | | | $ | | | | | | | | $ | (15,089) | | | |
Net loss per share, basic and diluted
|
| | | $ | (0.15) | | | | | $ | (0.17) | | | | | | | | | | | | | | $ | (0.10) | | |
Weighted average common shares outstanding, basic and diluted
|
| | | | 97,647,688 | | | | | | 1,997,943 | | | | | | 50,960,024 | | | |
N
|
| | | | 150,605,655 | | |
| | |
Historical
December 31, 2019 |
| |
Historical
February 29, 2020 |
| |
Pro Forma
Adjustments |
| | | | |
Pro Forma
Combined |
| ||||||||||||
| | |
4D Pharma
|
| |
Longevity
|
| |
Notes
|
| ||||||||||||||||||
Revenues
|
| | | $ | 269 | | | | | $ | — | | | | | $ | — | | | | | | | | $ | 269 | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | | 29,193 | | | | | | — | | | | | | — | | | | | | | | | 29,193 | | |
General and administrative
|
| | | | 10,380 | | | | | | 1,079 | | | | | | — | | | | | | | | | 11,459 | | |
Foreign currency losses, net
|
| | | | 957 | | | | | | — | | | | | | — | | | | | | | | | 957 | | |
Total operating expenses
|
| | | | 40,530 | | | | | | 1,079 | | | | | | — | | | | | | | | | 41,609 | | |
Loss from operations
|
| | | | (40,261) | | | | | | (1,079) | | | | | | — | | | | | | | | | (41,340) | | |
Other income (expense), net: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Interest income
|
| | | | 78 | | | | | | 788 | | | | | | — | | | | | | | | | 866 | | |
Other income
|
| | | | 6,883 | | | | | | — | | | | | | — | | | | | | | | | 6,883 | | |
Change in fair value of contingent consideration payable
|
| | | | 2,967 | | | | | | — | | | | | | — | | | | | | | | | 2,967 | | |
Total other income (expense), net
|
| | | | 9,928 | | | | | | 788 | | | | | | — | | | | | | | | | 10,716 | | |
Net loss
|
| | | $ | (30,333) | | | | | $ | (291) | | | | | $ | — | | | | | | | | $ | (30,624) | | |
Net loss per share, basic and diluted
|
| | | $ | (0.46) | | | | | $ | (0.50) | | | | | | | | | | | | | | $ | (0.22) | | |
Weighted average common shares outstanding, basic and diluted
|
| | | | 65,493,842 | | | | | | 1,859,697 | | | | | | 70,031,052 | | | |
K
|
| | | | 137,384,591 | | |
| | |
Six Months
Ended June 30, 2020 |
| |
Year Ended
December 31, 2019 |
| ||||||
Basic and Diluted EPS: | | | | | | | | | | | | | |
As reported (4D Pharma)
|
| | | $ | (0.15) | | | | | $ | (0.46) | | |
As reported (Longevity)
|
| | | $ | (0.17) | | | | | $ | (0.50) | | |
Pro forma
|
| | | $ | (0.10) | | | | | $ | (0.22) | | |
Net loss (in thousands): | | | | | | | | | | | | | |
As reported (4D Pharma)
|
| | | $ | (14,765) | | | | | $ | (30,333) | | |
As reported (Longevity)
|
| | | $ | (324) | | | | | $ | (291) | | |
Pro forma
|
| | | $ | (15,089) | | | | | $ | (30,624) | | |
Basic and Diluted Weighted Average Shares: | | | | | | | | | | | | | |
As reported (4D Pharma)
|
| | | | 97,647,688 | | | | | | 65,493,842 | | |
As reported (Longevity)
|
| | | | 1,997,943 | | | | | | 1,859,697 | | |
Add: Application of the Exchange Ratio of 7.5315 to Longevity’s
weighted average common shares outstanding |
| | | | 13,049,564 | | | | | | 12,146,610 | | |
Add: Release of Longevity shares held for possible redemption at
Merger closing at Exchange Ratio |
| | | | 4,736,402 | | | | | | 24,710,384 | | |
Add: Issuance of ordinary shares at the Exchange Ratio for Longevity’s share rights outstanding
|
| | | | 3,253,608 | | | | | | 3,253,608 | | |
Add: Issuance of ordinary shares to Longevity backstop investors
at Merger closing at the Exchange Ratio |
| | | | 5,272,050 | | | | | | 5,272,050 | | |
Add: Issuance of ordinary shares for payment of banker’s fees at Merger Closing
|
| | | | 2,750,000 | | | | | | 2,750,000 | | |
Add: Issuance of ordinary shares in 4D Pharma’s offering after June 30, 2020
|
| | | | 21,898,400 | | | | | | 21,898,400 | | |
Pro forma
|
| | | | 150,605,655 | | | | | | 137,384,591 | | |
| | |
June 30, 2020
|
| |||
Payment of Longevity’s convertible promissory note (B)
|
| | | $ | (1,792) | | |
Record Longevity’s new promissory notes (C)
|
| | | | 2,360 | | |
Record 4D Pharma’s net proceeds from issuance of ordinary shares in July 2020(D)
|
| | | | 9,002 | | |
To reflect the payment of certain transaction costs at Merger closing (H)
|
| | | | (1,389) | | |
Release of marketable securities held in Trust Account to cash (I)
|
| | | | 14,506 | | |
Payment of one of Longevity’s new promissory notes at Merger closing (J)
|
| | | | (1,860) | | |
Total
|
| | | $ | 20,827 | | |
|
| | |
June 30, 2020
|
| |||
4D Pharma’s estimated stock issuance transaction costs (E)
|
| | | $ | 3,856 | | |
Longevity’s estimated transaction costs and reclass of deferred underwriting expenses (F)
|
| | | | 4,008 | | |
Payment of banker’s fee with ordinary shares at Merger closing (G)
|
| | | | (3,690) | | |
To reflect the payment of certain transaction costs at Merger closing (H)
|
| | | | (1,389) | | |
Total
|
| | | $ | 2,785 | | |
| | |
June 30, 2020
|
| |||
Payment of Longevity’s convertible promissory note (B)
|
| | | $ | (1,792) | | |
Record Longevity’s new promissory notes (C)
|
| | | | 2,360 | | |
Payment of one of Longevity’s new promissory notes at Merger closing (H)
|
| | | | (1,860) | | |
Payment of one of Longevity’s new promissory notes with issuance of ordinary shares at Merger closing (I)
|
| | | | (500) | | |
Total
|
| | | $ | (1,792) | | |
| | |
June 30, 2020
|
| |||
Conversion of Longevity’s shares subject to redemption to ordinary shares (A)
|
| | | $ | 6,409 | | |
Record 4D Pharma’s net proceeds from issuance of common stock in July 2020 (D)
|
| | | | 69 | | |
Payment of banker’s fee with ordinary shares at Merger closing (G)
|
| | | | 10 | | |
Eliminate Longevity’s pre-merger ordinary shares (L)
|
| | | | (12,038) | | |
To record the fair value of shares in the stock transaction (M)
|
| | | | 97 | | |
Total
|
| | | $ | (5,453) | | |
| | |
June 30, 2020
|
| |||
Record 4D Pharma’s net proceeds from issuance of ordinary shares in July 2020 (D)
|
| | | $ | 8,933 | | |
4D Pharma’s estimated stock issuance transaction costs (E)
|
| | | | (3,856) | | |
Payment of banker’s fee with ordinary shares at Merger closing (G)
|
| | | | 3,680 | | |
Payment of one of Longevity’s new promissory notes with issuance of ordinary shares at Merger closing (K)
|
| | | | 500 | | |
To record the issuance of shares in the stock transaction (M)
|
| | | | 8,304 | | |
Total
|
| | | $ | 17,561 | | |
| | |
June 30, 2020
|
| |||
Longevity’s estimated transaction costs (F)
|
| | | $ | (3,008) | | |
Eliminate Longevity’s pre-merger accumulated deficit balance (L)
|
| | | | 3,637 | | |
Total
|
| | | $ | 629 | | |
| | |
For the Six Months Ended
June 30, |
| |
For the Year Ended
December 31, |
| ||||||||||||||||||
| | |
2020
|
| |
2019
|
| |
2019
|
| |
2018
|
| ||||||||||||
| | | | | | | | |
(in thousands)
|
| | | | | | | |||||||||
Contractual commitments
|
| | | $ | 7,630 | | | | | $ | 3,790 | | | | | $ | 16,390 | | | | | $ | 10,079 | | |
Staff costs
|
| | | | 3,118 | | | | | | 3,210 | | | | | | 6,414 | | | | | | 5,906 | | |
Depreciation and amortization
|
| | | | 589 | | | | | | 490 | | | | | | 1,171 | | | | | | 1,427 | | |
Other MRx research costs
|
| | | | 893 | | | | | | 1,589 | | | | | | 1,572 | | | | | | 6,675 | | |
Other MDx research costs
|
| | | | 490 | | | | | | 571 | | | | | | 671 | | | | | | 1,251 | | |
Other manufacturing research and development costs
|
| | | | 773 | | | | | | 2,051 | | | | | | 2,975 | | | | | | 2,492 | | |
Total
|
| | | $ | 13,493 | | | | | $ | 11,701 | | | | | $ | 29,193 | | | | | $ | 27,830 | | |
| | |
For the Six Months Ended June 30,
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
| | |
(in thousands)
|
| |||||||||
Revenues
|
| | | $ | 239 | | | | | $ | — | | |
Operating expenses: | | | | | | | | | | | | | |
Research and development
|
| | | | 13,493 | | | | | | 11,701 | | |
General and administrative expenses
|
| | | | 5,509 | | | | | | 5,400 | | |
Foreign currency losses (gains)
|
| | | | (1,491) | | | | | | 148 | | |
Total operating expenses
|
| | | | 17,511 | | | | | | 17,249 | | |
Operating loss
|
| | | | (17,272) | | | | | | (17,249) | | |
Other income (expense), net | | | | | | | | | | | | | |
Interest income
|
| | | | 6 | | | | | | 84 | | |
Interest expense
|
| | | | (1) | | | | | | (1) | | |
Other income
|
| | | | 2,502 | | | | | | 2,720 | | |
Change in fair value of contingent consideration payable
|
| | | | — | | | | | | (252) | | |
Total other income (expense), net
|
| | | | 2,507 | | | | | | 2,551 | | |
Net loss
|
| | | $ | (14,765) | | | | | $ | (14,698) | | |
| | |
For the Year Ended
December 31, |
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
| | |
(in thousands)
|
| |||||||||
Revenues
|
| | | $ | 269 | | | | | $ | — | | |
Operating expenses: | | | | | | | | | | | | | |
Research and development
|
| | | | 29,193 | | | | | | 27,830 | | |
General and administrative expenses
|
| | | | 10,380 | | | | | | 11,294 | | |
Foreign currency losses (gains)
|
| | | | 957 | | | | | | (234) | | |
Total operating expenses
|
| | | | 40,530 | | | | | | 38,890 | | |
Operating loss
|
| | | | (40,261) | | | | | | (38,890) | | |
Other income (expense), net | | | | | | | | | | | | | |
Interest income
|
| | | | 78 | | | | | | 379 | | |
Interest expense
|
| | | | — | | | | | | (3) | | |
Other income
|
| | | | 6,883 | | | | | | 6,378 | | |
Change in fair value of contingent consideration payable
|
| | | | 2,967 | | | | | | (465) | | |
Total other income (Expense), net
|
| | | | 9,928 | | | | | | 6,289 | | |
Net loss
|
| | | $ | (30,333) | | | | | $ | (32,601) | | |
| | |
For the Six Months Ended
June 30, |
| |
For the Year Ended
December 31, |
| ||||||||||||||||||
| | |
2020
|
| |
2019
|
| |
2019
|
| |
2018
|
| ||||||||||||
| | |
(in thousands)
|
| |||||||||||||||||||||
Cash used in operating activities
|
| | | $ | (17,597) | | | | | $ | (17,011) | | | | | $ | (28,683) | | | | | $ | (30,158) | | |
Cash (used in) provided by investing activities
|
| | | | (221) | | | | | | 12,795 | | | | | | 12,283 | | | | | | 35,951 | | |
Cash provided by (used in) financing activities
|
| | | | 26,391 | | | | | | (6) | | | | | | (14) | | | | | | (13) | | |
Effect of exchange rate changes on cash and cash equivalents
|
| | | | (1,191) | | | | | | 147 | | | | | | 1,000 | | | | | | (1,386) | | |
Net increase (decrease) in cash and cash equivalents
|
| | | $ | 7,382 | | | | | | (4,075) | | | | | $ | (15,414) | | | | | $ | 4,394 | | |
| | |
Payments Due by Period
|
| |||||||||||||||||||||
Description
|
| |
Total
|
| |
Less Than
One Year |
| |
1 – 3
Years |
| |
3 – 5
Years |
| ||||||||||||
| | |
(in thousands)
|
| |||||||||||||||||||||
Operating lease obligations
|
| | | $ | 2,108 | | | | | $ | 299 | | | | | $ | 918 | | | | | $ | 891 | | |
Total
|
| | | $ | 2,108 | | | | | $ | 299 | | | | | $ | 918 | | | | | $ | 891 | | |
Name
|
| |
Age
|
| |
Position(s)
|
|
Executive Officers: | | | | | | | |
Duncan Peyton | | |
50
|
| | Chief Executive Officer, and Director | |
Alexander Stevenson | | |
49
|
| | Chief Scientific Officer, and Director | |
Richard Avison | | |
43
|
| | Group Finance Director | |
Non-Executive Directors: | | | | | | | |
Prof. Axel Glasmacher | | |
59
|
| | Non-Executive Director Chairman | |
Dr. Edgardo (Ed) Baracchini | | |
60
|
| | Non-Executive Director | |
Dr. Alexander (Sandy) Macrae | | |
57
|
| | Non-Executive Director | |
Dr. Katrin Rupalla | | |
52
|
| | Non-Executive Director | |
Name
|
| |
Base
Salary |
| |
Taxable
Benefits(1) |
| |
Pension(2)
|
| |
Total
|
| ||||||||||||
| | |
($ in thousands)
|
| |||||||||||||||||||||
Executive Officers: | | | | | | | | | | | | | | | | | | | | | | | | | |
Duncan Peyton(3)
|
| | | $ | 129.0 | | | | | $ | 2.58 | | | | | $ | — | | | | | $ | 131.58 | | |
Alexander Stevenson(4)
|
| | | | 129.0 | | | | | | 2.58 | | | | | | — | | | | | | 131.58 | | |
Non-Executive Directors: | | | | | | | | | | | | | | | | | | | | | | | | | |
Prof. Axel Glasmacher
|
| | | | 64.50 | | | | | | — | | | | | | — | | | | | | 64.50 | | |
Dr. Edgardo (Ed) Baracchini
|
| | | | 64.50 | | | | | | — | | | | | | — | | | | | | 64.50 | | |
Dr. Alexander (Sandy) Macrae
|
| | | | 21.93 | | | | | | — | | | | | | — | | | | | | 21.93 | | |
Dr. Katrin Rupalla(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
David Norwood(6)
|
| | | | 32.25 | | | | | | — | | | | | | — | | | | | | 32.3 | | |
Thomas Engelen(7)
|
| | | | 32.25 | | | | | | — | | | | | | — | | | | | | 32.25 | | |
| | |
Amount and Nature of
Beneficial Ownership |
| |||||||||
Name of Beneficial Owner
|
| |
Number
of Shares |
| |
Percentage
Owned (%) |
| ||||||
Whale Management Corporation(2)(3)
|
| | | | 1,250,000 | | | | | | 47.6% | | |
Matthew Chen(2)(3)
|
| | | | 1,250,000 | | | | | | 47.6% | | |
Teddy Zheng(4)(5)
|
| | | | — | | | | | | *% | | |
Alex Lyamport(6)
|
| | | | — | | | | | | *% | | |
Nicholas H. Adler(7)
|
| | | | — | | | | | | *% | | |
Jerry L Hutter(8)
|
| | | | — | | | | | | *% | | |
Pai Liu(4)(9)
|
| | | | — | | | | | | *% | | |
Jun Liu(4)(10)
|
| | | | — | | | | | | *% | | |
Yukman Lau(4)(11)
|
| | | | — | | | | | | *% | | |
All directors and executive officers as a group
|
| | | | 1,250,000 | | | | | | 47.6% | | |
| | |
Amount and Nature of Beneficial Ownership
|
| |||||||||
Name of Beneficial Owner
|
| |
Number of
Shares |
| |
Percentage Owned (%)
|
| ||||||
Entities affiliated with Steven Olivera(1)
|
| | | | 22,792,370 | | | | | | 16.60% | | |
Hargreaves Lansdown Asset Management
|
| | | | 16,692,909 | | | | | | 12.70% | | |
Merck & Co.
|
| | | | 7,661,000 | | | | | | 5.83% | | |
Interactive Investor Trading(2)
|
| | | | 7,153,800 | | | | | | 5.44% | | |
Duncan Peyton(3)
|
| | | | 9,026,501 | | | | | | 6.83% | | |
Alexander Stevenson(4)
|
| | | | 8,984,562 | | | | | | 6.80% | | |
Axel Glasmacher(5)
|
| | | | 30,000 | | | | | | *% | | |
Richard Avison(6)
|
| | | | 838 | | | | | | *% | | |
Edgardo Baracchini
|
| | | | — | | | | | | *% | | |
Katrin Rupalla
|
| | | | — | | | | | | *% | | |
Sandy Macrae
|
| | | | — | | | | | | *% | | |
All directors and executive officers as a group (7 persons)(7)
|
| | | | 18,041,901 | | | | | | 13.59% | | |
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
| Voting Rights | | |||
| | | | Under English law, a shareholder who is present in person and entitled to vote at a shareholders’ meeting is entitled to one vote on a show of hands regardless of the number of shares he or she holds. Every proxy present who has been duly appointed by a shareholder entitled to vote on the resolution has one vote. | |
| Under Longevity’s memorandum and articles of association, subject to any rights or restrictions attached to any shares, at any meeting of shareholders on a show of hands every shareholder who is present in person (or, in the case of a shareholder being a corporation, by its duly authorized representative) or by proxy shall have one vote and on a poll every shareholder present in person (or, in the case of a shareholder being a corporation, by its duly appointed representative) or by proxy shall have one vote for each share which such shareholder is the holder. Voting at any meeting of the shareholders is by show of hands unless a poll is demanded. A poll may be required if the chairman of the meeting has any doubt as to its outcome or, if the chairman does not so require, a poll may be, demanded by a shareholder present in person or by proxy if the shareholder disputes the outcome of the vote | | |
Under English law, a vote by a poll may generally be demanded by (i) not less than five shareholders having the right to vote on the resolution; or (ii) any shareholder or shareholders representing at least 10% of the total voting rights of all the shareholders having the right to vote on the resolution; or (iii) any shareholder or shareholders, holding shares conferring a right to vote on the resolution, being shares on which the aggregate sum paid up is equal to not less than 10% of the total sum paid up on all the shares.
4D Pharma’s articles of association provide that resolutions put to a vote at a shareholder meeting will be decided on a show of hands, unless a poll is demanded by:
(1)
the chairman of the meeting;
(2)
not less than five members present in person or by proxy and entitled to vote;
(3)
a member or members present in person or by proxy and representing in aggregate not less than one-tenth of the total voting rights of all the members having the right to vote; or
|
|
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
| | | |
(4)
a member or members present in person or by proxy and holding shares in 4D Pharma conferring a right to vote on the resolution, being shares on which an aggregate sum has been paid up equal to not less than one-tenth of the total sum paid up on all the shares.
|
|
| | | | A demand for a poll may be withdrawn with the consent of the chairman of the meeting at any time before the close of the meeting or the taking of the poll, whichever is the earlier. A demand so withdrawn shall not invalidate the result of a show of hands declared before the demand was made. | |
| | | | Under English law an ordinary resolution means a resolution that is passed by a simple majority (i.e. not less than 50%) of those shareholders present at a general meeting in person or by proxy. A resolution passed at a meeting on a show of hands is passed by a simple majority if it is passed by a simple majority of the shareholders present in person or by proxy and entitled to vote on it. A resolution passed on a poll taken at a meeting is passed by a simple majority if it is passed by members representing a simple majority of the total voting rights of members who (being entitled to do so) vote in person or by proxy on the resolution. | |
|
There is no concept under BVI law of a “special resolution” and any resolution of shareholders may be passed by a simple majority of votes cast unless the memorandum and articles of association of a company specify a higher majority.
In relation to resolutions of shareholders, Longevity’s memorandum and articles provide that:
—
prior to the consummation of a business combination in relation to any resolution seeking to amend or vary the rights of the ordinary shares (unless such amendment or variation is for the purposes of approving, or in conjunction with, the consummation of a business combination), a resolution is passed by members holding at least 65% of the votes of the members who (being entitled to do so) vote; or
—
in all other cases, a resolution is passed by the affirmative vote of a majority of the votes of the shares being entitled to vote thereon.
|
| | Under English law a special resolution means a resolution passed by a majority of not less than 75% of those shareholders present at a general meeting in person or by proxy. A resolution passed at a meeting on a show of hands is passed by a majority of not less than 75% if it is passed by not less than 75% of the votes cast by shareholders present in person or by proxy and entitled to vote on it. A resolution passed on a poll taken at a meeting is passed by a majority of not less than 75% if it is passed by members representing not less than 75% of the total voting rights of the members who (being entitled to do so) vote in person or by proxy on the resolution. The resolution is not a special resolution unless the notice of the meeting included the text of the resolution and specified the intention to propose the resolution as a special resolution, and if the notice of the meeting so specified, the resolution may only be passed as a special resolution. | |
| Under BVI law, a shareholder entitled to attend and vote at a meeting is entitled to appoint a proxy to exercise all or any of his rights to attend, speak and vote at a meeting of shareholders of the company. | | | Under English law, any shareholder entitled to attend and vote at a meeting is entitled to appoint a proxy to exercise all or any of his rights to attend, speak and vote at a meeting of shareholders of the company. | |
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
| | ||
| Under BVI law, the quorum for a meeting of shareholders is that fixed by the memorandum and articles of the company or, if no such quorum is fixed, then shareholders (or their proxy) holding at least 50% of the votes constitutes a quorum for a meeting of members. Longevity’s memorandum and articles expressly adopt the basic statutory position such that a meeting of Longevity Shareholders is quorate if at the commencement of the meeting there are present in person or by proxy, shareholders entitled to exercise at least 50% of the votes. | | | Generally, under English law, two shareholders present in person or by proxy constitute a quorum for the purpose of a general meeting of shareholders, unless the company’s articles of association specify otherwise. 4D Pharma’s articles of association specify that two members present in person or by proxy and entitled to vote constitute a quorum for all purposes. | | | ||
| Shareholder Proposals and Shareholder Nominations of Directors | | | | | |||
|
Under BVI law, the directors of a company are required to convene a shareholder meeting upon written request by shareholders entitled to exercise at least 30% of the voting rights in respect of the matter for which the meeting is requested, unless the memorandum and articles of the company specify a lesser percentage.
Longevity’s memorandum and articles follow the basic position and require that the directors of Longevity shall call convene a meeting of shareholders upon the written request of shareholders entitled to exercise 30% or more of the voting rights in respect of the matter for which the meeting is requested.
The directors convening a meeting of members must give not less than 10 and not more than 60 days’ written notice of such meeting to those members who are entitled to vote at the meeting.
|
| |
Under English law, shareholders may require the directors to call a general meeting of shareholders of the company and may specify the text of a resolution be voted on at that meeting if the request is made by either: (i) shareholders holding at least 5% of the total voting rights, or (ii) by at least 100 shareholders who have a relevant right to vote and hold shares in the company on which there has been paid up an average sum, per shareholder, of at least £100.
Shareholders may also require the company to circulate to members of the company entitled to receive notice of a general meeting, a statement of not more than 1,000 words with respect to (i) a matter referred to in a proposed resolution to be dealt with at that meeting, or (ii) other business to be deal with at that meeting. A company is required to circulate such a statement once it has received requests from shareholders (in line with the thresholds outlined above).
Resolutions to appoint directors to a public company such as 4D Pharma must be put to shareholders on the basis of one resolution for each nominated director. A single resolution to appoint two or more directors must not be proposed to be voted upon at a general meeting unless a resolution that it should be so made has first been agreed to by the general meeting without any vote being given against it.
|
| | ||
| Sources and Payment of Dividends | | | |||||
|
Generally speaking, BVI law does not impose:
—
restrictions on the sources from which a company may pay a distribution; or
—
maintenance of capital rules,
similar to those under English law.
Subject to any additional restrictions in the memorandum and articles of a company, BVI law allows the directors of a company such as Longevity
|
| | Generally speaking, and subject to the prior rights of holders of any preferred shares, under English law, a company may pay dividends on its ordinary shares only out of its distributable profits (defined as accumulated, realized profits not previously utilized by distribution or capitalization, less accumulated, realized losses so far as not previously written off in a reduction or reorganization) and not out of share capital, which includes share premiums | | |
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
|
to authorise and pay a dividend or other distribution subject only to them satisfied on reasonable grounds that the company will, immediately after the distribution is made, satisfy the following tests (the Solvency Test):
—
the value of its assets will exceed its liabilities; and
—
it will be able to pay its debts as they fall due.
Any dividend or other distribution paid or made at a time when a company did not, immediately after the dividend or other distribution, satisfy the solvency test may be subject to “claw-back” by the company. However, the company cannot recover such a dividend or other distribution if: (i) the shareholder received it in good faith and without knowledge of the company’s failure to satisfy the solvency test; (ii) the member has altered it position in reliance on the validity of the distributions; and (iii) it would be unfair to require repayment in full or at all.
Longevity’s memorandum and articles authorize the directors of the company to pay out distributions by way of a resolution of directors provided that immediately after the distribution is made, the Company satisfies the Solvency Test.
|
| |
(paid-in surplus).
Amounts credited to the share premium account (representing the excess of the consideration for the issue of shares over the aggregate nominal amount of such shares) may not be used to pay out cash dividends but may be used, among other things, to pay up unissued shares that may then be distributed to shareholders in proportion to their holdings as fully paid bonus shares.
In addition, under English law, 4D Pharma will not be permitted to make a distribution if, at the time, the amount of its net assets is less than the aggregate of its issued and paid-up share capital and undistributable reserves.
|
|
| | | | If recommended by the 4D Pharma Board, 4D shareholders may, by ordinary resolution, declare final dividends, but no dividend may be declared in excess of the amount recommended by the 4D Pharma Board. The 4D Pharma Board has the power under 4D Pharma’s articles of association to pay interim dividends without the approval of shareholders to the extent the financial position of 4D Pharma justifies a dividend in the opinion of the 4D Pharma Board. | |
| Rights of Purchase and Redemption | | |||
|
Under BVI law, a company may issue redeemable shares if specifically authorised to do so by its memorandum and articles, subject to any conditions stated therein. Furthermore, BVI law allows a company to purchase, redeem or otherwise acquire any of the company’s shares subject to the provisions of the memorandum and articles and, to the extent not dis-applied in the BVI Companies Act. Longevity’s memorandum and article confer the company’s ability to purchase or redeem its own ordinary shares from shareholders and the possibility for preferred shares to be issued with rights of redemption.
|
| |
Under English law, a company may issue redeemable shares if specifically authorized to do so by its articles of association, subject to any conditions stated therein. 4D Pharma’s articles of association permit the issuance of redeemable shares; however, 4D Pharma has not issued any redeemable shares.
Under English law, a company may purchase its own shares in certain specific instances, including if the purchase has first been approved by a special resolution of its shareholders. 4D Pharma’s articles of association authorize 4D Pharma to purchase its own shares. A resolution passed at 4D Pharma’s annual general meeting on 30 June 2020 provides the
|
|
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
|
Under BVI law and subject to the company’s memorandum, where a company seeks to purchase, redeem or otherwise acquire its own shares the director’s of the company must be satisfied that the company will pass the Solvency Test immediately after the purchase, redemption or acquisition — unless, amongst other exceptions, the shares are redeemed pursuant to a right of the holder to have his shares redeemed or shares are fully paid and surrendered for nil consideration.
Longevity is permitted by it memorandum and articles to purchase, redeem or otherwise acquire and hold its own shares provided consent from the members whose shares are being purchased, redeemed or otherwise acquired is obtained. In certain cases, Longevity is also positively required under its memorandum and articles to redeem certain of its shares at a set price.
|
| | directors with authority to purchase up to 10% of the ordinary shares of the company in issue at the close of business on 4 June 2020, being the date of publication of the notice convening the annual general meeting. | |
| | | |
Under English law, a company may redeem or repurchase shares only if the shares are fully paid and, in the case of public companies, only out of (i) distributable profits, or (ii) the proceeds of a new issue of shares made for the purpose of the repurchase or redemption.
The U.K. Financial Conduct Authority requires that purchases of 15% or more of any class of a company’s share capital must be by way of a tender offer to all shareholders of that class and unless a tender offer is made to all holders of the class, purchases by a listed company of less than 15% of any class of its share capital pursuant to a general authority granted by its shareholders may only be made if the company complies with certain limits on the price paid for the shares.
|
|
| Meetings of Shareholders | | |||
|
Under BVI law, unless a company’s memorandum and articles prescribe a lower figure, a meeting of shareholders may be requisitioned by shareholders entitled to exercise at least 30% of the voting rights in respect of the matter for which the meeting is to be called.
Longevity’s memorandum and articles prescribe that a meeting of shareholders may be requisitioned by written request of shareholders entitled to exercise 30% or more of the voting rights.
|
| | Under English law, a general meeting of shareholders may be called by the board of directors of a company. Shareholders holding at least 5% of the paid-up capital of the company carrying voting rights at general meetings of the company may require the directors to call a general meeting of the company. The notice requirements for general meetings of the company are as follows: (i) annual general meeting: at least 21 clear days’ notice; (ii) any other general meeting: at least 14 clear days’ notice. | |
| The directors convening a meeting of shareholders must give no less than 10 and no more than 60 days’ written notice of such meeting to those members who are entitled to vote at the meeting. A meeting of shareholders held in contravention of the | | | General meetings may be called upon shorter notice with the agreement of (i) in the case of an annual general meeting, all the shareholders who are permitted to attend and vote, or (ii) in the case of any other general meeting, a majority of the | |
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
| requirement to give notice can still be valid if members holding at least 90% of the total voting rights on all the matters to be considered at the meeting have waived notice of the meeting. | | | shareholders holding at least 95% by nominal value of the shares giving the right to attend and vote at the meeting. | |
| The inadvertent failure of a director who convenes a meeting to give notice of a meeting to a member or another director, or the fact that a member or another director has not received notice, does not invalidate the meeting. | | | “Clear days’ notice” means calendar days and excludes (i) the deemed date of receipt of the notice, and (ii) the date of the meeting itself. 4D Pharma’s articles of association provide that documents sent by first class post are deemed received 24 hours after mailing and, if not sent by first class post, 48 hours after mailing. | |
| Special Meetings of Shareholders | | |||
|
There is no concept of a “special resolution” as such under BVI law and any resolution of shareholders may be passed by a simple majority (subject to limited exceptions) of votes cast unless the company’s memorandum and articles specify a higher majority.
As noted above, in relation to resolutions of shareholders, Longevity’s memorandum and articles provide that:
—
prior to the consummation of a business combination in relation to any resolution seeking to amend or vary the rights of the ordinary shares (unless such amendment or variation is for the purposes of approving, or in conjunction with, the consummation of a business combination), a resolution is passed by members holding at least 65% of the votes of the members who (being entitled to do so) vote; or
—
in all other cases, a resolution is passed by the affirmative vote of a majority of the votes of the shares being entitled to vote thereon.
|
| |
“Special resolutions” generally involve proposals to change the name of the company, alter its capital structure, change or amend the rights of shareholders, permit the company to issue new shares for cash without applying the shareholders’ pre-emptive rights, amend the company’s articles of association, or carry out other matters where either the company’s articles of association or the U.K. Companies Act prescribe that a “special resolution” is required.
Other proposals relating to the ordinary course of the company’s business, such as the election of directors, would generally be proposed as an ordinary resolution.
|
|
| Pre-emptive Rights | | |||
|
BVI law does not confer mandatory pre-emption rights on shareholders in relation to the issue of new shares unless these are expressly adopted by the memorandum and articles of the company.
Longevity’s memorandum and articles of association do not include or adopt pre-emptive rights provisions.
Under BVI law, there is no requirement for a company to hold an annual general meeting (AGM) although an AGM may be required under the company’s M&A.
|
| | Under English law, the issuance for cash of (i) equity securities, being those shares in a company which, with respect to dividends or capital, carry a right to participate beyond a specified amount in a distribution, or (ii) rights to subscribe for or convert into equity securities, must be offered first to the existing equity shareholders in proportion to the respective nominal values of their holdings, unless a special resolution to the contrary has been passed by shareholders in a general meeting. | |
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
|
directors — provided that in no circumstances shall the directors have power to amend the memorandum or articles: (A) to restrict the rights or powers of the shareholders to amend the memorandum or articles; (B) to change the percentage of shareholders required to pass a resolution to amend the memorandum or articles; or (C) in circumstances where the memorandum or articles cannot be amended by the members.
Longevity’s memorandum of association allows amendments to the memorandum and articles to be made by a resolution of shareholders or by a resolution of directors, except that:
(a)
no amendment may be made by a resolution of directors in respect of: (i) any of the matters referred to at (A) through (C) above; (ii) any those provisions of the memorandum in respect of class rights; or (iii) those provisions of the articles of association of the company dealing with the date by which it must consummate its initial business combination and its obligation to redeem certain of the ordinary shares in respect therewith; and
(b)
no amendment at all may be made those provisions of the articles of association of the company dealing with the date by which it must consummate its initial business combination and its obligation to redeem certain of the ordinary shares in respect therewith unless the holders of the ordinary shares issued by Longevity in its initial public offering are given the opportunity to redeem their shares.
|
| |
English law, the board of directors is not authorized to change the articles of association. See “— Share Class Rights” below.
Amendments affecting the rights of the holders of any class of shares may, depending on the rights attached to the class and the nature of the amendments, also require approval by special resolution of the classes affected in separate class meetings. See “— Share Class Rights” below.
|
|
| Preference Shares | | |||
| Longevity’s M&A provide that the directors have the authority and the power by resolution of directors to authorise and create additional classes of shares which such rights as they may determine. Longevity currently holds ordinary and preferred shares. | | | 4D Pharma’s articles of association provide that, subject to any rights attached to existing ordinary shares, any share may be issued with or have attached to it such rights and restrictions as the company may by ordinary resolution decide or, if no such resolution has been passed or so far as the resolution does not make specific provision, as the 4D Pharma Board may decide. 4D Pharma currently has ordinary and deferred shares (which have no rights) in issue. | |
| Share Class Rights | | |||
|
Longevity’s M&A provide that:
(1)
unless the proposed variation of rights is for the purposes of approving, or in conjunction
|
| | 4D Pharma’s articles of association provide that, subject to the provisions of the U.K. Companies Act: | |
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
|
with, the consummation of a business combination, prior to a business combination but subject always to a resolution of shareholders, the rights attached to ordinary shares may only be varied by a resolution passed at a meeting by the holders of at least 65% of the total number of ordinary shares that have voted and are entitled to vote unless otherwise provided by the terms of issue of such class;
(2)
in the case of a proposed variation that (i) is for the purposes of approving or in conjunction with, the consummation of a business combination; or (ii) is after the consummation of a business combination, the rights attached to the ordinary shares may only be varied by a resolution passed at a meeting by the holders of more than 50% of the ordinary shares present at a meeting of members which were present at the meeting and voted; and
(3)
the rights attached to any preferred shares in issue may only be varied by resolution passed at a meeting by the holder of more than 50% of the preferred shares of the same class present at a meeting of members holding preferred shares which were present at the meeting and voted.
|
| |
(1)
all or any rights of any class of shares may only be varied with the consent in writing of holders of 75% of the nominal value of the issued shares of that class or by a special resolution passed at a separate class meeting of the holders of shares of that class;
(2)
the quorum required for the separate class meetings is at least two persons who hold, or act as proxies for, at least one third of the nominal value of the issued shares of that class, except that at any adjourned meeting one shareholder or his proxy constitutes a quorum, regardless of the number of shares that person holds;
(3)
every holder of shares of that class present in person or by proxy and entitled to vote shall be entitled, on a poll, to one vote in respect of each share held; and
(4)
a poll may be demanded at a separate class meeting by any person present in person or by proxy and entitled to vote.
|
|
| | | | Unless otherwise expressly provided by the terms of their issue, the special rights attached to any class of shares are not deemed to be varied by the creation or issue of further shares ranking equally with them. | |
| Shareholders’ Votes on Certain Transactions | | |||
|
Subject to a company’s memorandum and articles, BVI law permits a company to merge with another company provided each BVI company involved in the merger has paid its annual government filing fee and is in good standing with the Registrar of Corporate Affairs in the BVI.
In general, the directors and members of each merging BVI company will need to approve the company’s entry into the merger, unless the merger is between a parent company and its subsidiary.
|
| |
The U.K. Companies Act only permits mergers in specified limited circumstances. However,
the U.K. Companies Act provides for schemes of arrangement which are arrangements or compromises between a company and any class of shareholders or creditors. Schemes of arrangement are used in certain types of restructurings, amalgamations, capital reorganizations and takeovers.
These arrangements require:
•
the approval at a shareholders’ or creditors’ meeting convened by order of the court, of a majority in number of shareholders or creditors representing 75% in value of the capital held by, or debt owed to, the class of shareholders or creditors, or class thereof present and voting, either in person or by proxy; and
|
|
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
| | | |
•
the approval of the court.
Certain other types of extraordinary transactions such as certain capital reorganizations also require approval by shareholders (either by a majority or at least 75% of the votes cast in person or by proxy, depending on the type of transaction), while other types of transactions, including asset sales and tender offers, often do not require shareholder approval.
|
|
| Rights of Inspection | | |||
|
Under BVI law, shareholders have, subject to giving written notice to the company, the right to inspect:
•
the memorandum and articles;
•
the register of members and directors; and
•
minutes of meetings and resolutions of members and those classes of members of which he is a member.
Subject to the memorandum and articles, the directors may, if they are satisfied that it would be contrary the company’s interests to allow a member to inspect any document, or part of a document, refuse to permit the member to inspect the document or limited the inspection of the document, including limiting the making of copies or the taking of extracts from the records.
A company’s memorandum and articles must be registered at the BVI Registry of Corporate Affairs and no amendment thereto or restatement thereof is itself effective unless also so registered.
|
| |
Under the U.K. Companies Act shareholders have rights of inspection, including the right to:
•
inspect and obtain copies (for a fee) of the minutes of all general meetings of the company and all resolutions of members passed other than at a general meeting;
•
inspect copies of the register of members, register of directors, register of secretaries and other statutory registers maintained by the company;
•
receive copies of the company’s annual report and accounts for each financial year; and
•
receive notices of general meetings of the company.
A company’s articles of association must be registered at Companies House and are therefore open to public inspection.
4D Pharma’s shareholders do not have any right to inspect board minutes of the company.
|
|
| Standard of Conduct for Directors | | |||
|
BVI law states a director in exercising his powers or performing his duties shall act honestly and in good faith and in what the director believes to be in the best interests of the company.
However, BVI law also provides that: :
—
a director of a company that is a wholly owned subsidiary may, when exercising powers or performing duties as a director, if expressly permitted to do so by the memorandum or articles of the company, act in a manner which he believes is the interests of its parent even if not in the best interests of the subsidiary; and
—
a director of a joint venture, when exercising powers or performing duties as a director, if expressly permitted to do so by the memorandum or articles of the company, to
|
| |
Under English law, a director has a broad statutory duty to act in the way he or she considers, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole. In addition, there are specific obligations:
(1)
to avoid an actual or potential conflict between his duty to the company and duties to any other person or his or her own personal interests, and to declare any existing interests that may conflict with a proposed transaction or arrangement of the company;
(2)
not to accept a benefit from a third party conferred by reason of his being a director, or his doing (or not doing) anything as a director;
(3)
to act bona fide in what he or she considers is in the interests of the company as a whole, bearing in mind a number of different matters;
|
|
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
|
act in the best interests of a shareholder or shareholders even if not in the best interests of the company.
Although not relevant in its present state, the articles of association of Longevity do permit its directors to regard to the interests of its holding company if it should ever become a wholly owned subsidiary.
BVI law further states that a director, when exercising powers or performing duties as a director, shall exercise the care, diligence and skill that a reasonable director would exercise in the same circumstances, taking into account, but without limitation:
—
the nature of the company;
—
the nature of the decision; and
—
the position of the director and the nature of the responsibilities undertaken by him.
|
| |
(4)
to exercise his or her powers only in accordance with the articles of association of the company;
(5)
to exercise independent judgment; and
(6)
to exercise reasonable care, skill and diligence. This test is both subjective (i.e., was the director’s conduct that of a reasonably diligent person who has the knowledge and experience of the director) and objective (i.e., was the director’s conduct that of a reasonably diligent person having the knowledge and experience that a director holding that position should have).
4D Pharma’s articles of association provide that the 4D Pharma Board may in specified circumstances authorize any matter that would otherwise involve a director breaching his duty under the U.K.
Companies Act to avoid a conflict of interest. The articles of association also provide that, subject to authorization of such conflict, a director may retain any benefit derived by reason of that interest.
|
|
| Removal of Directors | | |||
|
Under BVI law, unless the company’s memorandum and articles state otherwise, the shareholders have the right to remove directors by resolution of shareholders.
Longevity’s M&A provide that a director may be removed from office with or without cause by:
—
(following the consummation of the initial business combination but not at an any time before) a resolution of shareholders passed at a meeting of members called for the purposes of removing the director; or
—
(immediately prior to the consummation of the initial public offering), a resolution of directors.
|
| |
Under the U.K. Companies Act, a company may remove a director without cause by ordinary resolution, irrespective of anything in any agreement between the director and the company, provided that 28 clear days’ notice of the proposed resolution to remove the director is given to the company and certain other procedural requirements under the U.K. Companies Act are followed.
4D Pharma’s articles of association provide that in addition to any power of removal conferred by the U.K. Companies Act, the company may by special resolution (i.e. a resolution approved by 75% of the votes cast in person or by proxy) remove any director before the expiration of his period of office.
|
|
| Vacancies on the Board of Directors | | |||
| Under Longevity’s memorandum and articles of association, Longevity may by a majority of the directors appoint a director to fill in any vacancy. Where the directors appoint a person as director to fill a vacancy, the term shall not exceed the term that remained when the person who ceased to be a director ceased to hold office. | | |
Under 4D Pharma’s articles of association, 4D Pharma may by ordinary resolution of its shareholders appoint a person to be a director:
(i)
to fill a casual vacancy; or
(ii)
to become an additional director,
subject to the requirement of the articles of association that there be no less than two and no more than ten directors at any time.
|
|
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
| Liability of Directors and Officers | | |||
|
No provision in the memorandum or articles or in any agreement entered into by a company may relieve a director for a duty to act in accordance with his duties under the Companies Act, the memorandum and articles or from any personal liability arising from his management of the business and affairs of the company.
The Companies Act and the memorandum of articles of Longevity however allow for a director to be indemnified in respect of costs suffered in connection with proceedings relating to his position, provided that the director was acting honestly, in good faith and in the best interests of the company and, in the case of criminal proceedings, the director has no reasonable cause to believe that his conduct was unlawful.
Longevity’s memorandum and articles also permit the company to purchase and maintain insurance, purchase or furnish similar protection or make other arrangements against any liability asserted against the person and incurred by him in that capacity, whether or not the company has or would have had the power to indemnify him against the liability as provided in the memorandum and articles.
|
| |
Under the U.K. Companies Act, any provision (whether contained in a company’s articles of association or any contract or otherwise) that purports to exempt a director of a company (to any extent) from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company, is void.
Any provision by which a company directly or indirectly provides an indemnity (to any extent) for a director of the company or of an associated company against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he is a director, is also void except as permitted by the U.K. Companies, which provides exceptions for a company to (i) purchase and maintain insurance against such liability; (ii) provide a “qualifying third party indemnity” (being an indemnity against liability incurred by the director to a person other than the company or an associated company as long as he or she is successful in defending the claim or criminal proceedings); and (iii) provide a “qualifying pension scheme indemnity” (being an indemnity against liability incurred in connection with the company’s activities as trustee of an occupational pension plan).
|
|
| | | | The U.K. Companies Act permits companies to purchase and maintain insurance for directors against any liability arising from negligence, default, breach of duty or breach of trust in relation to the company. 4D Pharma maintains directors’ and officers’ liability insurance. | |
| Disclosure of Interests | | |||
|
Under BVI law, a director of a company has a duty to disclose any interest that he may have in a transaction. Failure to do so may render the transaction to be deemed void and the director fined. Having disclosed his interest permits the intended director to attend and vote on the approval of that transaction. A director however is not required to disclose such interest if:
—
the transaction is between the director and the company; and
—
the transaction is to be entered into in the ordinary course of the company’s business and on usual terms and conditions.
|
| | The U.K. Disclosure Guidance and Transparency Rules provide that anyone who acquires a material interest, or becomes aware that he has acquired a material interest, in 3% or more of any class of shares of a public company’s issued share capital carrying rights to vote at general meetings of shareholder must notify that company in writing of his interest within two days. Thereafter, any increase or decrease of a whole percentage point and any decrease that reduces the interest to below 3% must be notified in writing to the company. This requirement applies to all 4D Pharma shareholders. | |
|
Current Rights of Longevity Shareholders
|
| |
Current Rights of 4D Shareholders
|
|
| Longevity’s memorandum and articles provide that so long as a director has disclosed his interest in the transaction, he may vote on a matter relation to the transaction. | | | 4D Pharma is required pursuant to the AIM Rules for Companies to disclose in its annual report and on its website the identity and share interests of its directors and any persons connected with them, as defined in the U.K. Companies Act, and of any person with an interest of 3% or more of 4D Pharma’s ordinary shares. | |
| | | | Pursuant to the Market Abuse Regulation (EU 596/2014), persons discharging managerial responsibilities (being directors and certain senior executives), and their connected persons, must notify a public company such as 4D Pharma in writing of the occurrence of all transactions conducted on their own account in the shares of the company, or derivatives or any other financial instruments relating to those shares within four business days of the day on which the transaction occurred. The notification must contain prescribed information, including the name of the person involved, the type of transaction, the date on which it occurred, and the price and volume of the transaction. The public company must notify a regulatory news service (which will make the information public) of any information notified to it in accordance with these provisions. The notification to a regulatory news service must be made as soon as possible and in any event by no later than the end of the business day following the receipt of the information by the company. | |
| | |
Page
|
| |||
| | | | F-2 | | | |
| | | | F-3 | | | |
| | | | F-4 | | | |
| | | | F-5 | | | |
| | | | F-6 | | | |
| | | | F-7 | | |
| | |
Page
|
| |||
| | | | F-27 | | | |
| | | | F-28 | | | |
| | | | F-29 | | | |
| | | | F-30 | | | |
| | | | F-31 | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
ASSETS | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 5,031 | | | | | $ | 20,445 | | |
Short-term investments and other cash deposits
|
| | | | — | | | | | | 12,958 | | |
Research and development tax credits receivable
|
| | | | 7,049 | | | | | | 5,973 | | |
Prepayments and other current assets
|
| | | | 2,705 | | | | | | 2,854 | | |
Total current assets
|
| | | | 14,785 | | | | | | 42,230 | | |
Property and equipment, net
|
| | | | | | | | | | | | |
Owned assets
|
| | | | 5,596 | | | | | | 6,196 | | |
Right-of-use asset (operating leases)
|
| | | | 1,251 | | | | | | — | | |
Intangible assets, net
|
| | | | 6,296 | | | | | | 6,358 | | |
Goodwill
|
| | | | 12,651 | | | | | | 12,625 | | |
Research and development tax credits receivable, net
|
| | | | 247 | | | | | | 174 | | |
Total assets
|
| | | $ | 40,826 | | | | | $ | 67,583 | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 1,641 | | | | | $ | 2,495 | | |
Accrued expenses and other current liabilities
|
| | | | 4,235 | | | | | | 2,008 | | |
Current portion of operating lease liabilities
|
| | | | 75 | | | | | | — | | |
Contingent consideration, current
|
| | | | — | | | | | | 2,090 | | |
Deferred revenues, current
|
| | | | 538 | | | | | | — | | |
Total current liabilities
|
| | | | 6,489 | | | | | | 6,593 | | |
Long term operating lease liabilities, net
|
| | | | 1,229 | | | | | | — | | |
Contingent consideration, net
|
| | | | — | | | | | | 871 | | |
Deferred revenues, net
|
| | | | 1,720 | | | | | | — | | |
Deferred tax
|
| | | | 31 | | | | | | 33 | | |
Other liabilities
|
| | | | 170 | | | | | | 19 | | |
Total liabilities
|
| | | | 9,639 | | | | | | 7,516 | | |
Commitments and Contingencies (Note 8) | | | | | | | | | | | | | |
Stockholders’ equity: | | | | | | | | | | | | | |
Common Stock, $0.003 par value, 87,325,042 authorized; 65,493,842 shares outstanding at December 31, 2019 and 2018
|
| | | | 266 | | | | | | 266 | | |
Additional paid in capital
|
| | | | 174,376 | | | | | | 174,036 | | |
Accumulated other comprehensive loss
|
| | | | (25,715) | | | | | | (26,828) | | |
Accumulated deficit
|
| | | | (117,740) | | | | | | (87,407) | | |
Total stockholders’ equity
|
| | | $ | 31,187 | | | | | $ | 60,067 | | |
Total liabilities and stockholders’ equity
|
| | | $ | 40,826 | | | | | $ | 67,583 | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Revenues
|
| | | $ | 269 | | | | | $ | — | | |
Operating expenses: | | | | | | | | | | | | | |
Research and development
|
| | | | 29,193 | | | | | | 27,830 | | |
General and administrative expenses
|
| | | | 10,380 | | | | | | 11,294 | | |
Foreign currency losses (gains)
|
| | | | 957 | | | | | | (234) | | |
Total operating expenses
|
| | | | 40,530 | | | | | | 38,890 | | |
Loss from operations
|
| | | | (40,261) | | | | | | (38,890) | | |
Other income (expense), net: | | | | | | | | | | | | | |
Interest income
|
| | | | 78 | | | | | | 379 | | |
Interest expense
|
| | | | — | | | | | | (3) | | |
Other income
|
| | | | 6,883 | | | | | | 6,378 | | |
Change in fair value of contingent consideration payable
|
| | | | 2,967 | | | | | | (465) | | |
Total other income (expense), net
|
| | | | 9,928 | | | | | | 6,289 | | |
Net loss
|
| | | | (30,333) | | | | | | (32,601) | | |
Other comprehensive income (loss) | | | | | | | | | | | | | |
Foreign currency translation adjustment
|
| | | | 1,113 | | | | | | (3,995) | | |
Comprehensive loss
|
| | | $ | (29,220) | | | | | $ | (36,596) | | |
Net loss per common share, basic and diluted
|
| | | $ | (0.46) | | | | | $ | (0.50) | | |
Weighted-average number of common shares used in computing basic and diluted net loss per common share
|
| | | | 65,493,842 | | | | | | 65,493,842 | | |
| | |
Common stock
|
| |
Additional
Paid-In Capital |
| |
Accumulated
Other Comprehensive Loss |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Equity |
| |||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance, December 31, 2017
|
| | | | 65,493,842 | | | | | $ | 266 | | | | | $ | 173,673 | | | | | $ | (22,833) | | | | | $ | (54,806) | | | | | $ | 96,300 | | |
Other comprehensive loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | (3,995) | | | | | | | | | | | | (3,995) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (32,601) | | | | | | (32,601) | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | 363 | | | | | | — | | | | | | — | | | | | | 363 | | |
Balance, December 31, 2018
|
| | | | 65,493,842 | | | | | | 266 | | | | | | 174,036 | | | | | | (26,828) | | | | | | (87,407) | | | | | | 60,067 | | |
Other comprehensive income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 1,113 | | | | | | — | | | | | | 1,113 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (30,333) | | | | | | (30,333) | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | 340 | | | | | | — | | | | | | — | | | | | | 340 | | |
Balance, December 31, 2019
|
| | | | 65,493,842 | | | | | $ | 266 | | | | | $ | 174,376 | | | | | $ | (25,715) | | | | | $ | (117,740) | | | | | $ | 31,187 | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (30,333) | | | | | $ | (32,601) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
Depreciation and amortization
|
| | | | 1,644 | | | | | | 1,614 | | |
Stock based compensation
|
| | | | 340 | | | | | | 363 | | |
Change in fair value of contingent consideration
|
| | | | (2,967) | | | | | | 465 | | |
Other non-cash expenses
|
| | | | 74 | | | | | | 1 | | |
Changes in assets and liabilities: | | | | | | | | | | | | | |
Prepayments and other current assets
|
| | | | 168 | | | | | | 2,735 | | |
Research and development tax credits receivable
|
| | | | (939) | | | | | | (1,678) | | |
Accounts payable
|
| | | | (903) | | | | | | 163 | | |
Deferred revenues
|
| | | | 2,197 | | | | | | — | | |
Operating lease obligations
|
| | | | (148) | | | | | | — | | |
Other liabilities and accrued expenses
|
| | | | 2,184 | | | | | | (1,220) | | |
Net cash used in operating activities
|
| | | | (28,683) | | | | | | (30,158) | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | |
Purchase of software and intangibles
|
| | | | (73) | | | | | | (5) | | |
Purchase of property and equipment
|
| | | | (681) | | | | | | (721) | | |
Acquisition of subsidiary net of cash acquired
|
| | | | — | | | | | | (887) | | |
Proceeds on disposal of assets
|
| | | | 55 | | | | | | — | | |
Maturities of short-term investments
|
| | | | 12,982 | | | | | | 37,564 | | |
Net cash provided by investing activities
|
| | | | 12,283 | | | | | | 35,951 | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | |
Lease liability payments
|
| | | | (14) | | | | | | (13) | | |
Net cash used in financing activities
|
| | | | (14) | | | | | | (13) | | |
Effect of exchange rate changes on cash and cash equivalents
|
| | | | 1,000 | | | | | | (1,386) | | |
Change in cash and cash equivalents
|
| | | | (15,414) | | | | | | 4,394 | | |
Cash and cash equivalents at beginning of year
|
| | | | 20,445 | | | | | | 16,051 | | |
Cash and cash equivalents at end of year
|
| | | $ | 5,031 | | | | | $ | 20,445 | | |
Supplemental disclosures of non-cash investing and financing activities | | | | | | | | | | | | | |
Cash paid for interest
|
| | | $ | 230 | | | | | $ | 1 | | |
Lease liabilities from obtaining right-of-use assets
|
| | | $ | 1,446 | | | | | $ | — | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Prepayments
|
| | | $ | 1,465 | | | | | $ | 1,590 | | |
VAT receivables
|
| | | | 980 | | | | | | 895 | | |
Other assets — goods to be consumed in R&D activities
|
| | | | 260 | | | | | | 369 | | |
| | | | $ | 2,705 | | | | | $ | 2,854 | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Cost
|
| | | | | | | | | | | | |
Property and machinery
|
| | | $ | 7,852 | | | | | $ | 7,361 | | |
Fixtures, fittings and office equipment
|
| | | | 282 | | | | | | 274 | | |
Land and buildings
|
| | | | 2,983 | | | | | | 1,462 | | |
Total cost
|
| | | | 11,117 | | | | | | 9,097 | | |
Accumulated depreciation
|
| | | | 4,270 | | | | | | 2,901 | | |
Total property and equipment, net
|
| | | $ | 6,847 | | | | | $ | 6,196 | | |
|
Balance at January 1, 2018
|
| | | $ | 13,325 | | |
|
Translation differences
|
| | | | (700) | | |
|
Balance at December 31, 2018
|
| | | | 12,625 | | |
|
Translation differences
|
| | | | 26 | | |
|
Balance at December 31, 2019
|
| | | $ | 12,651 | | |
|
| | |
December 31, 2019
|
| |||||||||||||||||||||
| | |
Software
|
| |
Patents
|
| |
Intellectual
Property |
| |
Total
|
| ||||||||||||
Gross amount beginning of period
|
| | | $ | 428 | | | | | $ | 1,377 | | | | | $ | 5,740 | | | | | $ | 7,545 | | |
Additions
|
| | | | 75 | | | | | | — | | | | | | — | | | | | | 75 | | |
Translation differences
|
| | | | 6 | | | | | | 41 | | | | | | 170 | | | | | | 217 | | |
Gross amount end of period
|
| | | | 509 | | | | | | 1,418 | | | | | | 5,910 | | | | | | 7,837 | | |
Disposals
|
| | | | (144) | | | | | | | | | | | | | | | | | | (144) | | |
Accumulated amortization
|
| | | | (232) | | | | | | (1,165) | | | | | | — | | | | | | (1,397) | | |
Net Book value
|
| | | $ | 133 | | | | | $ | 253 | | | | | $ | 5,910 | | | | | $ | 6,296 | | |
|
| | |
December 31, 2018
|
| |||||||||||||||||||||
| | |
Software
|
| |
Patents
|
| |
Intellectual
Property |
| |
Total
|
| ||||||||||||
Gross amount beginning of period
|
| | | $ | 448 | | | | | $ | 1,462 | | | | | $ | 6,097 | | | | | $ | 8,007 | | |
Additions
|
| | | | 5 | | | | | | — | | | | | | — | | | | | | 5 | | |
Translation differences
|
| | | | (25) | | | | | | (85) | | | | | | (357) | | | | | | (467) | | |
Gross amount end of period
|
| | | | 428 | | | | | | 1,377 | | | | | | 5,740 | | | | | | 7,545 | | |
Accumulated amortization
|
| | | | (224) | | | | | | (963) | | | | | | — | | | | | | (1,187) | | |
Net Book value
|
| | | $ | 204 | | | | | $ | 414 | | | | | $ | 5,740 | | | | | $ | 6,358 | | |
Year
|
| | | | | | |
2020
|
| | | $ | 261 | | |
2021
|
| | | | 109 | | |
2022
|
| | | | 16 | | |
Total
|
| | | $ | 386 | | |
| | |
December 31,
2019 |
| |||
Assets | | | | | | | |
Land and Buildings
|
| | | $ | 1,251 | | |
Liabilities
|
| | | | | | |
Current portion of operating lease liabilities
|
| | | | 75 | | |
Long term operating lease liabilities, net
|
| | | | 1,229 | | |
| | | | $ | 1,304 | | |
Weighted-average remaining lease term (years)
|
| | | | 7 | | |
Weighted-average discount rate
|
| | | | 13.6% | | |
| | |
December 31,
2019 |
| |||
2020
|
| | | $ | 299 | | |
2021
|
| | | | 300 | | |
2022
|
| | | | 301 | | |
2023
|
| | | | 317 | | |
2024
|
| | | | 319 | | |
Thereafter
|
| | | | 572 | | |
Total lease payments
|
| | | | 2,108 | | |
Less: Imputed interest
|
| | | | (804) | | |
| | | | $ | 1,304 | | |
|
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Clinical trials accrued expenses
|
| | | $ | 2,561 | | | | | $ | 635 | | |
Patents and other research accruals
|
| | | | 428 | | | | | | 360 | | |
Accrued payroll expenses
|
| | | | 161 | | | | | | 124 | | |
Building and office accruals
|
| | | | 273 | | | | | | 208 | | |
Tax accruals
|
| | | | 334 | | | | | | 354 | | |
Deferred grant income
|
| | | | 52 | | | | | | — | | |
Short-term finance lease
|
| | | | 14 | | | | | | 14 | | |
Other accrued expenses
|
| | | | 412 | | | | | | 313 | | |
| | | | $ | 4,235 | | | | | $ | 2,008 | | |
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Non-Vested
Options |
| |
Weighted
Average Grant date Fair Value |
| | ||||||||||||||
Outstanding at December 31, 2017
|
| | | | 341,462 | | | | | $ | 0.0033 | | | | | | 341,462 | | | | | $ | 6.29 | | | | | |
Granted
|
| | | | 746,779 | | | | | | 0.0033 | | | | | | 746,779 | | | | | | 4.15 | | | | | |
Exercised
|
| | | | — | | | | | | 0.0033 | | | | | | — | | | | | | | | | | | |
Expired/cancelled
|
| | | | (40,909) | | | | | | 0.0033 | | | | | | (40,909) | | | | | | 11.63 | | | | ||
Outstanding at December 31, 2018
|
| | | | 1,047,332 | | | | | | 0.0033 | | | | | | 1,047,332 | | | | | | 2.88 | | | | | |
Granted
|
| | | | 538,596 | | | | | | 0.0033 | | | | | | 538,596 | | | | | | 1.16 | | | | ||
Exercised
|
| | | | — | | | | | | 0.0033 | | | | | | — | | | | | | — | | | | ||
Vested
|
| | | | — | | | | | | 0.0033 | | | | | | (9,686) | | | | | | 11.18 | | | | ||
Expired/cancelled
|
| | | | (660,340) | | | | | | 0.0033 | | | | | | (660,340) | | | | | | 3.01 | | | | ||
Outstanding at December 31, 2019
|
| | | | 925,588 | | | | | $ | 0.0033 | | | | | | 915,902 | | | | | | 1.68 | | | | | |
Options exercisable
|
| | | | 9,686 | | | | | $ | 0.0033 | | | | | | | | | | | | | | | | ||
Options vested
|
| | | | 9,686 | | | | | $ | 0.0033 | | | | | | | | | | | | | | | | | |
Options expected to vest
|
| | | | 73,540 | | | | | $ | 0.0033 | | | | | | | | | | | | | | | | | |
| | |
December 31,
|
| |||
| | |
2019
|
| |
2018
|
|
Risk-free interest rate
|
| |
0.57%
|
| |
0.72%
|
|
Expected volatility
|
| |
69.62%
|
| |
54.95%
|
|
Expected dividend yield
|
| |
0.00%
|
| |
0.00%
|
|
Expected term (in years)
|
| |
3 years
|
| |
3 years
|
|
| | |
Current
Portion |
| |
Long-term
Portion |
| |
Total Contingent
Consideration |
| |||||||||
Balance, January 1, 2018
|
| | | $ | — | | | | | $ | 2,677 | | | | | $ | 2,677 | | |
Change in fair value
|
| | | | 2,205 | | | | | | (1,740) | | | | | | 465 | | |
Translation differences
|
| | | | (115) | | | | | | (66) | | | | | | (181) | | |
Balance, December 31, 2018
|
| | | $ | 2,090 | | | | | $ | 871 | | | | | $ | 2,961 | | |
Change in fair value
|
| | | | (2,094) | | | | | | (873) | | | | | | (2,967) | | |
Translation differences
|
| | | | 4 | | | | | | 2 | | | | | | 6 | | |
Balance, December 31, 2019
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Loss before income taxes arising in UK
|
| | | $ | 27,751 | | | | | $ | 30,364 | | |
Loss before income taxes arising in Ireland
|
| | | | 1,539 | | | | | | 1,693 | | |
Loss/(profit) before income taxes arising in Spain
|
| | | | 1,043 | | | | | | 544 | | |
Loss before income taxes arising in United States
|
| | | | — | | | | | | — | | |
Total loss before income tax
|
| | | $ | 30,333 | | | | | $ | 32,601 | | |
| | |
December 31,
|
| |||||||||||||||||||||
| | |
2019
|
| |
2018
|
| ||||||||||||||||||
Loss before income taxes
|
| | | $ | (30,333) | | | | | | % | | | | | $ | (32,601) | | | | | | % | | |
Expected tax benefit
|
| | | | (5,785) | | | | | | (19.1)% | | | | | | (6,087) | | | | | | (18.7)% | | |
Foreign tax differential
|
| | | | (69) | | | | | | (0.2)% | | | | | | 4 | | | | | | 0.0% | | |
Change in valuation allowance
|
| | | | 5,784 | | | | | | 19.1% | | | | | | 6,057 | | | | | | 18.6% | | |
Other
|
| | | | 70 | | | | | | 0.2% | | | | | | 26 | | | | | | 0.1% | | |
Actual income tax benefit
|
| | | $ | — | | | | | | 0% | | | | | $ | — | | | | | | 0% | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Net operating tax loss carried forwards
|
| | | $ | 59,566 | | | | | $ | 40,711 | | |
Fair value adjustment on acquisitions
|
| | | | (119) | | | | | | (116) | | |
Valuation allowance
|
| | | | (59,478) | | | | | | (40,628) | | |
Net deferred tax liability
|
| | | $ | (31) | | | | | $ | (33) | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
UK research and development tax credits
|
| | | $ | 6,565 | | | | | $ | 6,173 | | |
Irish research and development tax credits
|
| | | | 373 | | | | | | 306 | | |
Translation differences
|
| | | | 358 | | | | | | (332) | | |
Total
|
| | | | 7,296 | | | | | | 6,147 | | |
Less: current portion
|
| | | | (7,049) | | | | | | (5,973) | | |
Research and development tax credits receivable, net
|
| | | $ | 247 | | | | | $ | 174 | | |
|
| | |
June 30, 2020
|
| |
December 31, 2019
|
| ||||||
| | |
(unaudited)
|
| | | | | | | |||
ASSETS | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 12,413 | | | | | $ | 5,031 | | |
Research and development tax credits receivable
|
| | | | 8,999 | | | | | | 7,049 | | |
Prepayments and other current assets
|
| | | | 4,208 | | | | | | 2,705 | | |
Total current assets
|
| | | | 25,620 | | | | | | 14,785 | | |
Property and equipment, net
|
| | | | | | | | | | | | |
Owned assets
|
| | | | 5,219 | | | | | | 5,596 | | |
Right-of-use asset (operating leases)
|
| | | | 1,117 | | | | | | 1,251 | | |
Intangible assets, net
|
| | | | 5,826 | | | | | | 6,296 | | |
Goodwill
|
| | | | 12,300 | | | | | | 12,651 | | |
Research and development tax credits receivable, net
|
| | | | 236 | | | | | | 247 | | |
Total assets
|
| | | $ | 50,318 | | | | | $ | 40,826 | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 4,012 | | | | | $ | 1,641 | | |
Accrued expenses and other current liabilities
|
| | | | 2,160 | | | | | | 4,235 | | |
Current portion of operating lease liabilities
|
| | | | 79 | | | | | | 75 | | |
Deferred revenues, current
|
| | | | 1,252 | | | | | | 538 | | |
Total current liabilities
|
| | | | 7,503 | | | | | | 6,489 | | |
Long term operating lease liabilities, net
|
| | | | 1,088 | | | | | | 1,229 | | |
Deferred revenues, net
|
| | | | 644 | | | | | | 1,720 | | |
Deferred tax
|
| | | | 32 | | | | | | 31 | | |
Other liabilities
|
| | | | 172 | | | | | | 170 | | |
Total liabilities
|
| | | | 9,439 | | | | | | 9,639 | | |
Commitments and Contingencies (Note 8) | | | | | | | | | | | | | |
Stockholders’ equity: | | | | | | | | | | | | | |
Common Stock, $0.003 par value, 167,991,442 authorized; 109,493,842 and
65,493,842 shares outstanding at June 30, 2020 and December 31, 2019, respectively |
| | | | 405 | | | | | | 266 | | |
Additional paid in capital
|
| | | | 200,775 | | | | | | 174,376 | | |
Accumulated other comprehensive loss
|
| | | | (27,796) | | | | | | (25,715) | | |
Accumulated deficit
|
| | | | (132,505) | | | | | | (117,740) | | |
Total stockholders’ equity
|
| | | $ | 40,879 | | | | | $ | 31,187 | | |
Total liabilities and stockholders’ equity
|
| | | $ | 50,318 | | | | | $ | 40,826 | | |
|
| | |
For the Six Months Ended June 30,
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Revenues
|
| | | $ | 239 | | | | | $ | — | | |
Operating expenses: | | | | | | | | | | | | | |
Research and development
|
| | | | 13,493 | | | | | | 11,701 | | |
General and administrative expenses
|
| | | | 5,509 | | | | | | 5,400 | | |
Foreign currency losses (gains)
|
| | | | (1,491) | | | | | | 148 | | |
Total operating expenses
|
| | | | 17,511 | | | | | | 17,249 | | |
Loss from operations
|
| | | | (17,272) | | | | | | (17,249) | | |
Other income (expense), net: | | | | | | | | | | | | | |
Interest income
|
| | | | 6 | | | | | | 84 | | |
Interest expense
|
| | | | (1) | | | | | | (1) | | |
Other income
|
| | | | 2,502 | | | | | | 2,720 | | |
Change in fair value of contingent consideration payable
|
| | | | — | | | | | | (252) | | |
Total other income (expense), net
|
| | | | 2,507 | | | | | | 2,551 | | |
Net loss
|
| | | | (14,765) | | | | | | (14,698) | | |
Other comprehensive income (loss) | | | | | | | | | | | | | |
Foreign currency translation adjustment
|
| | | | (2,081) | | | | | | 111 | | |
Comprehensive loss
|
| | | $ | (16,846) | | | | | $ | (14,587) | | |
Net loss per common share, basic and diluted
|
| | | $ | (0.15) | | | | | $ | (0.22) | | |
Weighted-average number of common shares used in computing basic and diluted net loss per common share
|
| | | | 97,647,688 | | | | | | 65,493,842 | | |
| | |
Common stock
|
| |
Additional
Paid-In Capital |
| |
Accumulated
Other Comprehensive Loss |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Equity |
| |||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance, January 1, 2020
|
| | | | 65,493,842 | | | | | $ | 266 | | | | | $ | 174,376 | | | | | $ | (25,715) | | | | | $ | (117,740) | | | | | $ | 31,187 | | |
Issuance of common stock, net
|
| | | | 44,000,000 | | | | | | 139 | | | | | | 22,990 | | | | | | — | | | | | | — | | | | | | 23,129 | | |
Issuance of warrants
|
| | | | — | | | | | | — | | | | | | 3,270 | | | | | | — | | | | | | — | | | | | | 3,270 | | |
Other comprehensive loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | (2,081) | | | | | | — | | | | | | (2,081) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (14,765) | | | | | | (14,765) | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | 139 | | | | | | — | | | | | | — | | | | | | 139 | | |
Balance, June 30, 2020
|
| | | | 109,493,842 | | | | | $ | 405 | | | | | $ | 200,775 | | | | | $ | (27,796) | | | | | $ | (132,505) | | | | | $ | 40,879 | | |
|
| | |
Common stock
|
| |
Additional
Paid-In Capital |
| |
Accumulated
Other Comprehensive Loss |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Equity |
| |||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance, January 1, 2019
|
| | | | 65,493,842 | | | | | $ | 266 | | | | | $ | 174,036 | | | | | $ | (26,828) | | | | | $ | (87,407) | | | | | $ | 60,067 | | |
Other comprehensive loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | 111 | | | | | | — | | | | | | 111 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (14,698) | | | | | | (14,698) | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | 696 | | | | | | — | | | | | | — | | | | | | 696 | | |
Balance, June 30, 2019
|
| | | | 65,493,842 | | | | | $ | 266 | | | | | $ | 174,732 | | | | | $ | (26,717) | | | | | $ | (102,105) | | | | | $ | 46,176 | | |
| | |
For the Six Months Ended June 30,
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (14,765) | | | | | $ | (14,698) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
Depreciation and amortization
|
| | | | 784 | | | | | | 879 | | |
Stock based compensation
|
| | | | 139 | | | | | | 696 | | |
Change in fair value of contingent consideration
|
| | | | — | | | | | | 252 | | |
Other non-cash expenses
|
| | | | 15 | | | | | | 88 | | |
Changes in assets and liabilities: | | | | | | | | | | | | | |
Prepayments and other current assets
|
| | | | (1,685) | | | | | | (789) | | |
Research and development tax credits receivable
|
| | | | (2,392) | | | | | | (2,699) | | |
Accounts payable
|
| | | | 2,509 | | | | | | (519) | | |
Deferred revenues
|
| | | | (240) | | | | | | — | | |
Operating lease obligations
|
| | | | (91) | | | | | | (61) | | |
Other liabilities and accrued expenses
|
| | | | (1,871) | | | | | | (160) | | |
Net cash used in operating activities
|
| | | | (17,597) | | | | | | (17,011) | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | |
Purchase of software and intangibles
|
| | | | (19) | | | | | | (23) | | |
Purchase of property and equipment
|
| | | | (202) | | | | | | (345) | | |
Maturities of short-term investments
|
| | | | — | | | | | | 13,163 | | |
Net cash (used in) provided by investing activities
|
| | | | (221) | | | | | | 12,795 | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | |
Net proceeds from issuance of common stock
|
| | | | 23,129 | | | | | | — | | |
Issuance of warrants
|
| | | | 3,270 | | | | | | — | | |
Lease liability payments
|
| | | | (8) | | | | | | (6) | | |
Net cash provided by (used in) financing activities
|
| | | | 26,391 | | | | | | (6) | | |
Effect of exchange rate changes on cash and cash equivalents
|
| | | | (1,191) | | | | | | 147 | | |
Change in cash and cash equivalents
|
| | | | 7,382 | | | | | | (4,075) | | |
Cash and cash equivalents at beginning of year
|
| | | | 5,031 | | | | | | 20,445 | | |
Cash and cash equivalents at end of year
|
| | | $ | 12,413 | | | | | $ | 16,370 | | |
Supplemental disclosures of non-cash investing and financing activities | | | | | | | | | | | | | |
Cash paid for interest
|
| | | $ | 110 | | | | | $ | 117 | | |
Lease liabilities from obtaining right-of-use assets
|
| | | $ | — | | | | | $ | 1,466 | | |
| | |
June 30,
2020 |
| |
December 31,
2019 |
| ||||||
Prepayments
|
| | | $ | 2,533 | | | | | $ | 1,465 | | |
VAT receivables
|
| | | | 1,187 | | | | | | 980 | | |
Other assets — goods to be consumed in R&D activities
|
| | | | 488 | | | | | | 260 | | |
| | | | $ | 4,208 | | | | | $ | 2,705 | | |
| | |
June 30,
2020 |
| |
December 31,
2019 |
| ||||||
Cost
|
| | | | | | | | | | | | |
Property and machinery
|
| | | $ | 7,990 | | | | | $ | 7,852 | | |
Fixtures, fittings and office equipment
|
| | | | 267 | | | | | | 282 | | |
Land and buildings
|
| | | | 2,919 | | | | | | 2,983 | | |
Total cost
|
| | | | 11,176 | | | | | | 11,117 | | |
Accumulated depreciation
|
| | | | 4,840 | | | | | | 4,270 | | |
Total property and equipment, net
|
| | | $ | 6,336 | | | | | $ | 6,847 | | |
|
|
Balance at January 1, 2019
|
| | | $ | 12,625 | | |
|
Translation differences
|
| | | | 26 | | |
|
Balance at December 31, 2019
|
| | | | 12,651 | | |
|
Translation differences
|
| | | | (351) | | |
|
Balance at June 30, 2020
|
| | | $ | 12,300 | | |
| | |
June 30, 2020
|
| |||||||||||||||||||||
| | |
Software
|
| |
Patents
|
| |
Intellectual
Property |
| |
Total
|
| ||||||||||||
Gross Amount beginning of period
|
| | | $ | 365 | | | | | $ | 1,418 | | | | | $ | 5,910 | | | | | $ | 7,693 | | |
Additions
|
| | | | 18 | | | | | | — | | | | | | — | | | | | | 18 | | |
Translation differences
|
| | | | (20) | | | | | | (80) | | | | | | (330) | | | | | | (430) | | |
Gross Amount end of period
|
| | | | 363 | | | | | | 1,338 | | | | | | 5,580 | | | | | | 7,281 | | |
Accumulated amortization
|
| | | | (274) | | | | | | (1,181) | | | | | | — | | | | | | (1,455) | | |
Net Book value
|
| | | $ | 89 | | | | | $ | 157 | | | | | $ | 5,580 | | | | | $ | 5,826 | | |
|
| | |
December 31, 2019
|
| |||||||||||||||||||||
| | |
Software
|
| |
Patents
|
| |
Intellectual
Property |
| |
Total
|
| ||||||||||||
Gross Amount beginning of period
|
| | | $ | 428 | | | | | $ | 1,377 | | | | | $ | 5,740 | | | | | $ | 7,545 | | |
Additions
|
| | | | 75 | | | | | | — | | | | | | — | | | | | | 75 | | |
Translation differences
|
| | | | 6 | | | | | | 41 | | | | | | 170 | | | | | | 217 | | |
Gross Amount end of period
|
| | | | 509 | | | | | | 1,418 | | | | | | 5,910 | | | | | | 7,837 | | |
Disposals
|
| | | | (144) | | | | | | — | | | | | | — | | | | | | (144) | | |
Accumulated amortization
|
| | | | (232) | | | | | | (1,165) | | | | | | — | | | | | | (1,397) | | |
Net Book value
|
| | | $ | 133 | | | | | $ | 253 | | | | | $ | 5,910 | | | | | $ | 6,296 | | |
Year
|
| | | | | | |
Remaining 2020
|
| | | $ | 121 | | |
2021
|
| | | | 109 | | |
2022
|
| | | | 16 | | |
Total
|
| | | $ | 246 | | |
| | |
June 30,
2020 |
| |
December 31,
2019 |
| ||||||
UK research and development tax credits
|
| | | $ | 8,855 | | | | | $ | 6,565 | | |
Irish research and development tax credits
|
| | | | 409 | | | | | | 373 | | |
Translation differences
|
| | | | (29) | | | | | | 358 | | |
Total
|
| | | | 9,235 | | | | | | 7,296 | | |
Less: current portion
|
| | | | (8,999) | | | | | | (7,049) | | |
Research and development tax credits receivable, net
|
| | | $ | 236 | | | | | $ | 247 | | |
| | |
June 30,
2020 |
| |
December 31,
2019 |
| ||||||
Clinical trials accrued expenses
|
| | | $ | 749 | | | | | $ | 2,561 | | |
Patents and other research accruals
|
| | | | 212 | | | | | | 428 | | |
Accrued payroll expenses
|
| | | | 247 | | | | | | 161 | | |
Building and office accruals
|
| | | | 358 | | | | | | 273 | | |
Tax accruals
|
| | | | 298 | | | | | | 334 | | |
Deferred grant income
|
| | | | 32 | | | | | | 52 | | |
Short-term finance lease
|
| | | | 11 | | | | | | 14 | | |
Other accrued expenses
|
| | | | 253 | | | | | | 412 | | |
| | | | $ | 2,160 | | | | | $ | 4,235 | | |
| | |
Amount
|
| |||
Remaining 2020
|
| | | $ | 144 | | |
2021
|
| | | | 290 | | |
2022
|
| | | | 291 | | |
2023
|
| | | | 306 | | |
2024
|
| | | | 308 | | |
Thereafter
|
| | | | 547 | | |
Total remaining lease payments
|
| | | | 1,886 | | |
Less: Imputed interest
|
| | | | (719) | | |
Total lease liabilities
|
| | | $ | 1,167 | | |
| | |
Current
Portion |
| |
Long-term
Portion |
| |
Total Contingent
Consideration |
| |||||||||
Balance, January 1, 2019
|
| | | $ | 2,090 | | | | | $ | 871 | | | | | $ | 2,961 | | |
Change in fair value
|
| | | | 178 | | | | | | 74 | | | | | | 252 | | |
Translation differences
|
| | | | (10) | | | | | | (4) | | | | | | (14) | | |
Balance, June 30, 2019
|
| | | $ | 2,258 | | | | | $ | 941 | | | | | $ | 3,199 | | |
Change in fair value
|
| | | | (2,271) | | | | | | (948) | | | | | | (3,219) | | |
Translation differences
|
| | | | 13 | | | | | | 7 | | | | | | 20 | | |
Balance, December 31, 2019
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
| Financial Statements: | | | | | | | |
| | | | | F-44 | | | |
| | | | | F-45 | | | |
| | | | | F-47 | | | |
| | | | | F-48 | | |
| | |
August 31,
2020 |
| |
February 29,
2020 |
| ||||||
| | |
(unaudited)
|
| | | | | | | |||
ASSETS | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | |
Cash
|
| | | $ | 6,607 | | | | | $ | 26,294 | | |
Prepaid expenses and other current assets
|
| | | | 25,695 | | | | | | 112,195 | | |
Total Current Assets
|
| | | | 32,302 | | | | | | 138,489 | | |
Marketable securities held in Trust Account
|
| | | | 14,505,510 | | | | | | 42,412,991 | | |
Total Assets
|
| | | $ | 14,537,812 | | | | | $ | 42,551,480 | | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | |
Account payable and accrued expenses
|
| | | $ | 337,007 | | | | | $ | 262,877 | | |
Total Current Liabilities
|
| | | | 337,007 | | | | | | 262,877 | | |
Convertible promissory note – related party
|
| | | | 1,791,972 | | | | | | 1,500,000 | | |
Deferred underwriting fee payable
|
| | | | 1,000,000 | | | | | | 1,000,000 | | |
Total Liabilities
|
| | | | 3,128,979 | | | | | | 2,762,877 | | |
Commitments | | | | | | | | | | | | | |
Ordinary shares subject to possible redemption, 599,471 and 3,280,938 shares at redemption value at August 31, 2020 and February 29, 2020, respectively
|
| | | | 6,408,823 | | | | | | 34,788,598 | | |
Shareholders’ Equity | | | | | | | | | | | | | |
Preferred shares, no par value; unlimited shares authorized, none issued and outstanding
|
| | | | — | | | | | | — | | |
Ordinary shares, no par value; unlimited shares authorized; 2,027,351 and 1,989,062 shares issued and outstanding (excluding 599,471 and 3,280,938 shares subject to possible redemption) at August 31, 2020 and February 29, 2020, respectively
|
| | | | 5,629,317 | | | | | | 5,305,335 | | |
Accumulated deficit
|
| | | | (629,307) | | | | | | (305,330) | | |
Total Shareholders’ Equity
|
| | | | 5,000,010 | | | | | | 5,000,005 | | |
Total Liabilities and Shareholders’ Equity
|
| | | $ | 14,537,812 | | | | | $ | 42,551,480 | | |
| | |
Three Months Ended August 31,
|
| |
Six Months Ended August 31,
|
| ||||||||||||||||||
| | |
2020
|
| |
2019
|
| |
2020
|
| |
2019
|
| ||||||||||||
Operating costs
|
| | | $ | 201,425 | | | | | $ | 327,835 | | | | | $ | 370,317 | | | | | $ | 570,558 | | |
Loss from operations
|
| | | | (201,425) | | | | | | (327,835) | | | | | | (370,317) | | | | | | (570,558) | | |
Other income: | | | | | | | | | | | | | | | | | | | | | | | | | |
Interest income
|
| | | | 1,287 | | | | | | 209,002 | | | | | | 46,340 | | | | | | 454,998 | | |
Unrealized gain
|
| | | | — | | | | | | 76 | | | | | | — | | | | | | 6,374 | | |
Other income
|
| | | | 1,287 | | | | | | 209,078 | | | | | | 46,340 | | | | | | 461,372 | | |
Net Loss
|
| | | $ | (200,138) | | | | | $ | (118,757) | | | | | $ | (323,977) | | | | | $ | (109,186) | | |
Weighted average ordinary shares outstanding, basic
and diluted(1) |
| | | | 2,006,824 | | | | | | 1,819,533 | | | | | | 1,997,943 | | | | | | 1,809,240 | | |
Basic and diluted net loss per ordinary share(2)
|
| | | $ | (0.10) | | | | | $ | (0.16) | | | | | $ | (0.17) | | | | | $ | (0.28) | | |
| | |
Ordinary Shares
|
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity |
| |||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||
Balance – March 1, 2020
|
| | | | 1,989,062 | | | | | $ | 5,305,335 | | | | | $ | (305,330) | | | | | $ | 5,000,005 | | |
Change in value of ordinary shares subject to possible redemption
|
| | | | 17,762 | | | | | | 123,843 | | | | | | — | | | | | | 123,843 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | (123,839) | | | | | | (123,839) | | |
Balance – May 31, 2020
|
| | | | 2,006,824 | | | | | | 5,429,178 | | | | | | (429,169) | | | | | | 5,000,009 | | |
Change in value of ordinary shares subject to possible redemption
|
| | | | 20,527 | | | | | | 200,139 | | | | | | — | | | | | | 200,139 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | (200,138) | | | | | | (200,138) | | |
Balance – August 31, 2020
|
| | | | 2,027,351 | | | | | $ | 5,629,317 | | | | | $ | (629,307) | | | | | $ | 5,000,010 | | |
| | |
Ordinary Shares
|
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity |
| |||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||
Balance – March 1, 2019
|
| | | | 1,798,946 | | | | | $ | 5,014,272 | | | | | $ | (14,269) | | | | | $ | 5,000,003 | | |
Change in value of ordinary shares subject to possible redemption
|
| | | | 20,587 | | | | | | (9,573) | | | | | | — | | | | | | (9,573) | | |
Net income
|
| | | | — | | | | | | — | | | | | | 9,571 | | | | | | 9,571 | | |
Balance – May 31, 2019
|
| | | | 1,819,533 | | | | | | 5,004,699 | | | | | | (4,698) | | | | | | 5,000,001 | | |
Change in value of ordinary shares subject to possible redemption
|
| | | | 62,409 | | | | | | 118,765 | | | | | | — | | | | | | 118,765 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | (118,757) | | | | | | (118,757) | | |
Balance – August 31, 2019
|
| | | | 1,881,942 | | | | | $ | 5,123,464 | | | | | $ | (123,455) | | | | | $ | 5,000,009 | | |
| | |
Six Months Ended August 31,
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (323,977) | | | | | $ | (109,186) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
Interest earned on securities held in Trust Account
|
| | | | (46,340) | | | | | | (454,998) | | |
Unrealized gain on securities held in Trust Account
|
| | | | — | | | | | | (6,374) | | |
Changes in operating assets and liabilities:
|
| | | | | | | | | | | | |
Prepaid expenses and other current assets
|
| | | | 86,500 | | | | | | 49,551 | | |
Accounts payable and accrued expenses
|
| | | | 74,130 | | | | | | 21,660 | | |
Net cash used in operating activities
|
| | | | (209,687) | | | | | | (499,347) | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | |
Investment of cash into Trust Account
|
| | | | (101,972) | | | | | | (400,000) | | |
Cash withdrawn from Trust Account for redemption
|
| | | | 28,055,793 | | | | | | — | | |
Net cash provided by (used in) investing activities
|
| | | | 27,953,821 | | | | | | (400,000) | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | |
Proceeds from promissory notes – related party
|
| | | | — | | | | | | 400,000 | | |
Proceeds from convertible promissory notes – related party
|
| | | | 291,972 | | | | | | — | | |
Redemption of ordinary shares
|
| | | | (28,055,793) | | | | | | — | | |
Net cash (used in) provided by financing activities
|
| | | | (27,763,821) | | | | | | 400,000 | | |
Net Change in Cash
|
| | | | (19,687) | | | | | | (499,347) | | |
Cash – Beginning
|
| | | | 26,294 | | | | | | 639,102 | | |
Cash – Ending | | | | $ | 6,607 | | | | | $ | 139,755 | | |
Non-Cash investing and financing activities: | | | | | | | | | | | | | |
Change in value of ordinary shares subject to possible redemption
|
| | | $ | (323,982) | | | | | $ | (109,192) | | |
| | |
Three Months Ended
August 31, |
| |
Six Months Ended
August 31, |
| ||||||||||||||||||
| | |
2020
|
| |
2019
|
| |
2020
|
| |
2019
|
| ||||||||||||
Net loss
|
| | | $ | (200,138) | | | | | $ | (118,757) | | | | | $ | (323,977) | | | | | $ | (109,186) | | |
Less: Income attributable to ordinary shares subject to possible redemption
|
| | | | (474) | | | | | | (177,089) | | | | | | (17,076) | | | | | | (390,782) | | |
Adjusted net loss
|
| | | $ | (200,612) | | | | | $ | (295,846) | | | | | $ | (341,053) | | | | | $ | (499,968) | | |
Weighted average shares outstanding, basic and diluted
|
| | | | 2,006,824 | | | | | | 1,819,533 | | | | | | 1,997,943 | | | | | | 1,809,240 | | |
Basic and diluted net loss per ordinary share
|
| | | $ | (0.10) | | | | | $ | (0.16) | | | | | $ | (0.17) | | | | | $ | (0.28) | | |
Description
|
| |
Level
|
| |
August 31,
2020 |
| |
February 29,
2020 |
| |||||||||
Assets: | | | | | | | | | | | | | | | | | | | |
Marketable securities held in Trust Account
|
| | | | 1 | | | | | $ | 14,505,510 | | | | | $ | 42,412,991 | | |
| | | | | F-63 | | | |
| Financial Statements: | | | | | | | |
| | | | | F-64 | | | |
| | | | | F-65 | | | |
| | | | | F-66 | | | |
| | | | | F-67 | | | |
| | | | | F-68 | | |
| | |
February 29,
2020 |
| |
February 28,
2019 |
| ||||||
ASSETS | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | |
Cash
|
| | | $ | 26,294 | | | | | $ | 639,102 | | |
Prepaid expenses and other current assets
|
| | | | 112,195 | | | | | | 64,079 | | |
Total Current Assets
|
| | | | 138,489 | | | | | | 703,181 | | |
Marketable securities held in Trust Account
|
| | | | 42,412,991 | | | | | | 40,425,370 | | |
Total Assets
|
| | | $ | 42,551,480 | | | | | $ | 41,128,551 | | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | |
Account payable and accrued expenses
|
| | | $ | 262,877 | | | | | $ | 48,887 | | |
Total Current Liabilities
|
| | | | 262,877 | | | | | | 48,887 | | |
Convertible promissory notes – related party
|
| | | | 1,500,000 | | | | | | — | | |
Deferred underwriting fee payable
|
| | | | 1,000,000 | | | | | | 1,000,000 | | |
Total Liabilities
|
| | | | 2,762,877 | | | | | | 1,048,887 | | |
Commitments | | | | | | | | | | | | | |
Ordinary shares subject to possible redemption, 3,280,938 and 3,471,054 shares at redemption value at February 29, 2020 and February 28, 2019, respectively
|
| | | | 34,788,598 | | | | | | 35,079,661 | | |
Shareholders’ Equity | | | | | | | | | | | | | |
Preferred shares, no par value; unlimited shares authorized, none issued and outstanding
|
| | | | — | | | | | | — | | |
Ordinary shares, no par value; unlimited shares authorized; 1,989,062 and 1,798,946 shares issued and outstanding (excluding 3,280,938 and 3,471,054 shares subject to possible redemption) at February 29, 2020 and February 28, 2019, respectively
|
| | | | 5,305,335 | | | | | | 5,014,272 | | |
Accumulated deficit
|
| | | | (305,330) | | | | | | (14,269) | | |
Total Shareholders’ Equity
|
| | | | 5,000,005 | | | | | | 5,000,003 | | |
Total Liabilities and Shareholders’ Equity
|
| | | $ | 42,551,480 | | | | | $ | 41,128,551 | | |
| | |
Year Ended
February 29, 2020 |
| |
For the Period from
March 9, 2018 (inception) through February 28, 2019 |
| ||||||
Operating and formation costs
|
| | | $ | 1,078,682 | | | | | $ | 439,639 | | |
Loss from operations
|
| | | | (1,078,682) | | | | | | (439,639) | | |
Other income: | | | | | | | | | | | | | |
Interest income
|
| | | | 787,621 | | | | | | 430,130 | | |
Unrealized loss
|
| | | | — | | | | | | (4,760) | | |
Other income, net
|
| | | | 787,621 | | | | | | 425,370 | | |
Net Loss
|
| | | $ | (291,061) | | | | | $ | (14,269) | | |
Weighted average ordinary shares outstanding, basic and diluted(1)
|
| | | | 1,859,697 | | | | | | 1,522,527 | | |
Basic and diluted net loss per ordinary share(2)
|
| | | $ | (0.50) | | | | | $ | (0.25) | | |
| | |
Ordinary Shares
|
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity |
| |||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||
Balance – March 9, 2018 (inception)
|
| | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Issuance of founder shares to Sponsor
|
| | | | 1,150,000 | | | | | | 25,000 | | | | | | — | | | | | | 25,000 | | |
Forfeiture of founder shares
|
| | | | (150,000) | | | | | | — | | | | | | — | | | | | | — | | |
Sale of 4,000,000 Units, net of underwriting discounts and offering expenses
|
| | | | 4,000,000 | | | | | | 37,368,833 | | | | | | — | | | | | | 37,368,833 | | |
Sale of 270,000 Private Units
|
| | | | 270,000 | | | | | | 2,700,000 | | | | | | — | | | | | | 2,700,000 | | |
Proceeds from the sale of unit purchase option
|
| | | | — | | | | | | 100 | | | | | | — | | | | | | 100 | | |
Ordinary shares subject to possible
redemption |
| | | | (3,471,054) | | | | | | (35,079,661) | | | | | | — | | | | | | (35,079,661) | | |
Net loss
|
| | |
|
—
|
| | | |
|
—
|
| | | | | (14,269) | | | | | | (14,269) | | |
Balance – February 28, 2019
|
| | | | 1,798,946 | | | | | | 5,014,272 | | | | | | (14,269) | | | | | | 5,000,003 | | |
Change in value of ordinary shares subject to possible redemption
|
| | | | 190,116 | | | | | | 291,063 | | | | | | — | | | | | | 291,063 | | |
Net loss
|
| | |
|
—
|
| | | |
|
—
|
| | | | | (291,061) | | | | | | (291,061) | | |
Balance – February 29, 2020
|
| | | | 1,989,062 | | | | | $ | 5,305,335 | | | | | $ | (305,330) | | | | | $ | 5,000,005 | | |
| | |
Year Ended
February 29, 2020 |
| |
For the Period from
March 9, 2018 (Inception) Through February 28, 2019 |
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (291,061) | | | | | $ | (14,269) | | |
Adjustments to reconcile net loss to net cash used in operating activities:
|
| | | | | | | | | | | | |
Interest earned on securities held in Trust Account
|
| | | | (787,621) | | | | | | (430,130) | | |
Unrealized loss on securities held in Trust Account
|
| | | | — | | | | | | 4,760 | | |
Changes in operating assets and liabilities:
|
| | | | | | | | | | | | |
Prepaid expenses and other current assets
|
| | | | (48,116) | | | | | | (64,079) | | |
Accounts payable and accrued expenses
|
| | | | 213,990 | | | | | | 48,887 | | |
Net cash used in operating activities
|
| | | | (912,808) | | | | | | (454,831) | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | |
Investment of cash into Trust Account
|
| | | | (1,200,000) | | | | | | (40,000,000) | | |
Net cash used in investing activities
|
| | | | (1,200,000) | | | | | | (40,000,000) | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | |
Proceeds from issuance of founder shares to Sponsor
|
| | | | — | | | | | | 25,000 | | |
Proceeds from sale of Units, net of underwriting discounts paid
|
| | | | — | | | | | | 38,800,000 | | |
Proceeds from sale of Private Units
|
| | | | — | | | | | | 2,700,000 | | |
Proceeds from sale of unit purchase option
|
| | | | — | | | | | | 100 | | |
Payment of offering costs
|
| | | | — | | | | | | (431,167) | | |
Proceeds from convertible promissory notes – related party
|
| | | | 1,500,000 | | | | | | 202,415 | | |
Repayment of promissory note – related party
|
| | | | — | | | | | | (202,415) | | |
Net cash provided by financing activities
|
| | | | 1,500,000 | | | | | | 41,093,933 | | |
Net Change in Cash
|
| | | | (612,808) | | | | | | 639,102 | | |
Cash – Beginning
|
| | | | 639,102 | | | | | | — | | |
Cash – Ending | | | | $ | 26,294 | | | | | $ | 639,102 | | |
Non-Cash investing and financing activities: | | | | | | | | | | | | | |
Initial classification of ordinary shares subject to possible redemption
|
| | | $ | — | | | | | $ | 35,086,980 | | |
Change in value of ordinary shares subject to possible redemption
|
| | | $ | (291,063) | | | | | $ | (7,319) | | |
Deferred underwriting fee payable
|
| | | $ | — | | | | | $ | 1,000,000 | | |
| | |
Year Ended
February 29, 2020 |
| |
For the Period
from March 9, 2018 (inception) through February 28, 2019 |
| ||||||
Net loss
|
| | | $ | (291,061) | | | | | $ | (14,269) | | |
Less: Income attributable to ordinary shares subject to possible redemption
|
| | | | (646,007) | | | | | | (369,136) | | |
Adjusted net loss
|
| | | $ | (937,068) | | | | | $ | (383,405) | | |
Weighted average shares outstanding, basic and diluted
|
| | | | 1,859,697 | | | | | | 1,522,527 | | |
Basic and diluted net loss per ordinary share
|
| | | $ | (0.50) | | | | | $ | (0.25) | | |
Description
|
| |
Level
|
| |
February 29,
2020 |
| |
February 28,
2019 |
| |||||||||
Assets: | | | | | | | | | | | | | | | | | | | |
Marketable securities held in Trust Account
|
| | | | 1 | | | | | $ | 42,412,991 | | | | | $ | 40,425,370 | | |
| | | | | A-2 | | | |
| | | | | A-2 | | | |
| | | | | A-2 | | | |
| | | | | A-3 | | | |
| | | | | A-3 | | | |
| | | | | A-3 | | | |
| | | | | A-3 | | | |
| | | | | A-4 | | | |
| | | | | A-5 | | | |
| | | | | A-5 | | | |
| | | | | A-5 | | | |
| | | | | A-5 | | | |
| | | | | A-5 | | | |
| | | | | A-6 | | | |
| | | | | A-6 | | | |
| | | | | A-6 | | | |
| | | | | A-7 | | | |
| | | | | A-7 | | | |
| | | | | A-8 | | | |
| | | | | A-9 | | | |
| | | | | A-9 | | | |
| | | | | A-9 | | | |
| | | | | A-9 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-12 | | |
| | | | | A-12 | | | |
| | | | | A-12 | | | |
| | | | | A-12 | | | |
| | | | | A-12 | | | |
| | | | | A-13 | | | |
| | | | | A-13 | | | |
| | | | | A-13 | | | |
| | | | | A-13 | | | |
| | | | | A-14 | | | |
| | | | | A-15 | | | |
| | | | | A-15 | | | |
| | | | | A-16 | | | |
| | | | | A-16 | | | |
| | | | | A-17 | | | |
| | | | | A-17 | | | |
| | | | | A-18 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-20 | | | |
| | | | | A-20 | | | |
| | | | | A-20 | | | |
| | | | | A-20 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-22 | | | |
| | | | | A-23 | | | |
| | | | | A-23 | | | |
| | | | | A-23 | | | |
| | | | | A-24 | | | |
| | | | | A-24 | | | |
| | | | | A-24 | | |
| | | | | A-24 | | | |
| | | | | A-25 | | | |
| | | | | A-25 | | | |
| | | | | A-26 | | | |
| | | | | A-26 | | | |
| | | | | A-27 | | | |
| | | | | A-27 | | | |
| | | | | A-27 | | | |
| | | | | A-27 | | | |
| | | | | A-28 | | | |
| | | | | A-28 | | | |
| | | | | A-29 | | | |
| | | | | A-30 | | | |
| | | | | A-30 | | | |
| | | | | A-31 | | | |
| | | | | A-31 | | | |
| | | | | A-32 | | | |
| | | | | A-32 | | | |
| | | | | A-32 | | | |
| | | | | A-33 | | | |
| | | | | A-33 | | | |
| | | | | A-33 | | | |
| | | | | A-34 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-36 | | | |
| | | | | A-36 | | | |
| | | | | A-37 | | | |
| | | | | A-37 | | | |
| | | | | A-37 | | | |
| | | | | A-46 | | | |
| | | | | A-46 | | | |
| | | | | A-46 | | |
| | | | | A-46 | | | |
| | | | | A-46 | | | |
| | | | | A-46 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-49 | | | |
| | | | | A-49 | | | |
| | | | | A-49 | | |
| Parent: | | |
4D PHARMA PLC
|
|
| | | |
By:
/s/ Duncan Peyton
Name: Duncan Peyton
Title: Chief Executive Officer |
|
| Merger Sub: | | |
DOLPHIN MERGER SUB LIMITED
|
|
| | | |
By:
/s/ Duncan Peyton
Name: Duncan Peyton
Title: Director |
|
| the Company: | | |
LONGEVITY ACQUISITION CORPORATION
|
|
| | | |
By:
/s/ Matthew Chen
Name: Matthew Chen
Title: Chairman and Chief Executive Officer |
|
| | | | 4D PHARMA PLC | |
| | | |
By:
/s/ Duncan Peyton
Name: Duncan Peyton
Title: Chief Executive Officer |
|
| | | | WHALE MANAGEMENT CORPORATION | |
| | | |
By:
/s/ Matthew Chen
Name: Matthew Chen
Title: Managing Member |
|
| | | | 4D PHARMA PLC | |
| | | |
By:
Name:
Title: |
|
| | | | LONGEVITY ACQUISITION CORPORATION | |
| | | |
By:
Name:
Title: |
|
| | | | WHALE MANAGEMENT CORPORATION | |
| | | |
By:
Name:
Title: |
|
| | | | [BUYER] | |
| | | |
By:
Name:
Title: |
|
|
SIGNED on behalf of
|
| | ) | |
|
LONGEVITY ACQUISITION CORPORATION
|
| | ) | |
| | | | ) | |
| Surviving Company | | | ||
|
SIGNED on behalf of
|
| | ) | |
|
DOLPHIN MERGER SUB LIMITED
|
| | ) | |
| | | | ) | |
Exhibit
Number |
| |
Exhibit Description
|
| |
Included
herein |
| |
Form
|
| |
Filing
Date |
| ||||
| | 2 | .1 | | | | Agreement and Plan of Merger by and among Longevity Acquisition Corporation, 4D pharma plc and Dolphin Merger Sub Limited, dated October 21, 2020 | | |
x
|
| | | | | | |
| | 2 | .2 | | | | BVI Plan of Merger | | |
x
|
| | | | | | |
| | 3 | .1* | | | | Memorandum of Association of 4D pharma plc | | | | | | | | | | |
| | 3 | .2* | | | | Articles of Association of 4D pharma plc | | | | | | | | | | |
| | 4 | .1* | | | | Form of share certificate of 4D pharma plc ordinary share | | | | | | | | | | |
| | 4 | .2* | | | | Form of Deposit Agreement among 4D pharma plc., JPMorgan Chase Bank, N.A., as depositary thereunder, and all Holders and Beneficial Owners from time to time of American Depositary Receipts issued thereunder evidencing American Depositary Shares representing deposited Shares | | | | | | | | | | |
| | 5 | .1* | | | | Opinion of Pinsent Masons regarding legality of the ordinary shares underlying the 4D pharma ADSs | | | | | | | | | | |
| | 9 | .1 | | | | Voting and Support Agreement between 4D pharma plc and the shareholder listed on Schedule A thereto, dated October 21, 2020 | | |
x
|
| | | | | | |
| | 10 | .1# | | | | Strategic Collaboration Agreement by and between The University of Texas M.D. Anderson Cancer Center and 4D pharma plc, dated November 10, 2017 | | |
x
|
| | | | | | |
| | 10 | .2# | | | | Research Collaboration and Option to License Agreement by and between Merck Sharp & Dohme Corp. and 4D pharma plc, dated October 7, 2019 | | |
x
|
| | | | | | |
| | 10 | .3* | | | | Lease Agreement between University Court of the University of Aberdeen and 4D Pharma Research Limited dated August 1, 2013 | | | | | | | | | | |
| | 10 | .4* | | | | Lease Agreement by and among Bishopsgate Long Term Property Fund Nominees No. 1 Limited and Bishopsgate Long Term Property Fund Nominees No. 2 Limited and 4D pharma plc, dated May 3, 2017 | | | | | | | | | | |
| | 10 | .5* | | | | Lease Agreement between Istituto Biomar and 4D Pharma Leon SLU, dated April 7, 2016 | | | | | | | | | | |
| | 10 | .6+* | | | | Service Agreement between Duncan Peyton and 4D pharma plc, dated February 10, 2014 | | | | | | | | | | |
| | 10 | .7+* | | | | Service Agreement between Alexander Stevenson and 4D pharma plc, dated February 10, 2014 | | | | | | | | | | |
| | 10 | .8+* | | | | Service Agreement between Richard Avison and 4D pharma plc | | | | | | | | | | |
| | 10 | .9+* | | | | Form of Director Service Agreement | | | | | | | | | | |
| | 10 | .10+* | | | | 4D pharma plc 2015 Long Term Incentive Plan and related forms | | | | | | | | | | |
| | 10 | .11 | | | | Form of lock-up agreement by and among 4D pharma plc and certain of 4D pharma’s shareholders | | | | | | | | | | |
| | 21 | .1* | | | | Subsidiaries of 4D pharma plc | | | | | | | | | | |
| | 23 | .1 | | | | | |
x
|
| | | | | | | |
| | 23 | .2 | | | | Consent of Marcum LLP, Independent Registered Public Accounting Firm | | |
x
|
| | | | | | |
| | 23 | .3* | | | | Consent of Pinsent Masons (included in Exhibit 5.1 and incorporated herein by reference) | | | | | | | | | | |
| | 24 | .1 | | | | Powers of Attorney for 4D pharma plc (included on the signature page to this registration statement) | | |
x
|
| | | | | | |
| | 99 | .1* | | | | Form of Proxy for Longevity Corporation | | | | | | | | | | |
|
Name
|
| |
Title(s)
|
| |
Date
|
|
|
/s/ Duncan Peyton
Duncan Peyton
|
| | Chief Executive Officer and Director | | | November 25, 2020 | |
|
/s/ Alexander Stevenson
Alexander Stevenson
|
| | Director and Chief Scientific Officer | | | November 25, 2020 | |
|
/
s/ Richard Avison
Richard Avison
|
| | Group Finance Director | | | November 25, 2020 | |
|
/
s/ Axel Glasmacher
Axel Glasmacher
|
| | Chairman (non-executive) of the Board of Directors | | | November 25, 2020 | |
|
/s/ Alexander Macrea
Alexander (Sandy) Macrae
|
| | Director | | | November 25, 2020 | |
|
/
s/ Edgardo Baracchini
Edgardo (Ed) Baracchini
|
| | Director | | | November 25, 2020 | |
|
/
s/ Katrin Rupalla
Katrin Rupalla
|
| | Director | | | November 25, 2020 | |
| | | | | A-2 | | | |
| | | | | A-2 | | | |
| | | | | A-2 | | | |
| | | | | A-3 | | | |
| | | | | A-3 | | | |
| | | | | A-3 | | | |
| | | | | A-3 | | | |
| | | | | A-4 | | | |
| | | | | A-5 | | | |
| | | | | A-5 | | | |
| | | | | A-5 | | | |
| | | | | A-5 | | | |
| | | | | A-5 | | | |
| | | | | A-6 | | | |
| | | | | A-6 | | | |
| | | | | A-6 | | | |
| | | | | A-7 | | | |
| | | | | A-7 | | | |
| | | | | A-8 | | | |
| | | | | A-9 | | | |
| | | | | A-9 | | | |
| | | | | A-9 | | | |
| | | | | A-9 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-10 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-11 | | | |
| | | | | A-12 | | |
| | | | | A-12 | | | |
| | | | | A-12 | | | |
| | | | | A-12 | | | |
| | | | | A-12 | | | |
| | | | | A-13 | | | |
| | | | | A-13 | | | |
| | | | | A-13 | | | |
| | | | | A-13 | | | |
| | | | | A-14 | | | |
| | | | | A-15 | | | |
| | | | | A-15 | | | |
| | | | | A-16 | | | |
| | | | | A-16 | | | |
| | | | | A-17 | | | |
| | | | | A-17 | | | |
| | | | | A-18 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-19 | | | |
| | | | | A-20 | | | |
| | | | | A-20 | | | |
| | | | | A-20 | | | |
| | | | | A-20 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-21 | | | |
| | | | | A-22 | | | |
| | | | | A-23 | | | |
| | | | | A-23 | | | |
| | | | | A-23 | | | |
| | | | | A-24 | | | |
| | | | | A-24 | | | |
| | | | | A-24 | | |
| | | | | A-24 | | | |
| | | | | A-25 | | | |
| | | | | A-25 | | | |
| | | | | A-26 | | | |
| | | | | A-26 | | | |
| | | | | A-27 | | | |
| | | | | A-27 | | | |
| | | | | A-27 | | | |
| | | | | A-27 | | | |
| | | | | A-28 | | | |
| | | | | A-28 | | | |
| | | | | A-29 | | | |
| | | | | A-30 | | | |
| | | | | A-30 | | | |
| | | | | A-31 | | | |
| | | | | A-31 | | | |
| | | | | A-32 | | | |
| | | | | A-32 | | | |
| | | | | A-32 | | | |
| | | | | A-33 | | | |
| | | | | A-33 | | | |
| | | | | A-33 | | | |
| | | | | A-34 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-35 | | | |
| | | | | A-36 | | | |
| | | | | A-36 | | | |
| | | | | A-37 | | | |
| | | | | A-37 | | | |
| | | | | A-37 | | | |
| | | | | A-46 | | | |
| | | | | A-46 | | | |
| | | | | A-46 | | |
| | | | | A-46 | | | |
| | | | | A-46 | | | |
| | | | | A-46 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-47 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-48 | | | |
| | | | | A-49 | | | |
| | | | | A-49 | | | |
| | | | | A-49 | | |
| Parent: | | |
4D PHARMA PLC
|
|
| | | |
By:
/s/ Duncan Peyton
Name: Duncan Peyton
Title: Chief Executive Officer |
|
| Merger Sub: | | |
DOLPHIN MERGER SUB LIMITED
|
|
| | | |
By:
/s/ Duncan Peyton
Name: Duncan Peyton
Title: Director |
|
| the Company: | | |
LONGEVITY ACQUISITION CORPORATION
|
|
| | | |
By:
/s/ Matthew Chen
Name: Matthew Chen
Title: Chairman and Chief Executive Officer |
|
| | | | 4D PHARMA PLC | |
| | | |
By:
/s/ Duncan Peyton
Name: Duncan Peyton
Title: Chief Executive Officer |
|
| | | | WHALE MANAGEMENT CORPORATION | |
| | | |
By:
/s/ Matthew Chen
Name: Matthew Chen
Title: Managing Member |
|
| | | | Very truly yours, | |
| | | |
Printed Name of Holder
|
|
| | | |
By:
Signature
|
|
| | | |
Printed Name of Person Signing
|
|
| | | | (and indicate capacity of person signing if signing as officer, manager, director, custodian, trustee, or on behalf of an entity) | |
| | | | 4D PHARMA PLC | |
| | | |
By:
Name:
Title: |
|
| | | | LONGEVITY ACQUISITION CORPORATION | |
| | | |
By:
Name:
Title: |
|
| | | | WHALE MANAGEMENT CORPORATION | |
| | | |
By:
Name:
Title: |
|
| | | | [BUYER] | |
| | | |
By:
Name:
Title: |
|
Exhibit 10.1
*** | Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
STRATEGIC COLLABORATION AGREEMENT
This Strategic Collaboration Agreement ("Agreement"), effective as of the 10th day of November, 2017 ("Effective Date"), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA ("MD Anderson"), a member institution of The University of Texas System ("System") and 4D pharma plc with a place of business located at 9 Bond Court Leeds LS1 2JZ, United Kingdom ("Company") (MD Anderson and Company each a "Party" and collectively the "Parties").
WITNESSETH
Whereas Company is a pharmaceutical development company involved in the field of research, development and marketing of pharmaceutical products, including the sponsorship of clinical trials.
Whereas MD Anderson is a comprehensive cancer research, treatment, and prevention center, with scientists and technicians in substantive fields relating to cancer research.
Whereas the Parties hereby wish to establish a strategic collaboration, as further described herein, ("Collaboration") whereby Company will provide funding and in-kind support for (a) one or more preclinical studies ("Pre-clinical Studies"); and (b) one or more clinical studies ("Clinical Studies") to be conducted by MD Anderson pursuant to this Agreement (each such Clinical Study or Pre-clinical Study, a "Study," and all such Clinical Studies and Pre-clinical Studies, the "Studies.").
Now therefore, in consideration of the premises and the mutual covenants and conditions hereinafter recited, the Parties do hereby agree as follows:
1. | Subject and Scope of Agreement |
1.1 The initial scope of the Collaboration will consist of clinical studies and preclinical studies in Solid Tumours and Radiation Oncology, the details of which are to be mutually agreed upon by the JSC. The Studies and/or the scope of the Collaboration may be supplemented, replaced and/or changed as agreed upon by the JSC. Responsibility for IND filing and monitoring will be agreed upon by the JSC and may vary by Study. The final design for each Study will be agreed upon by the JSC.
1.2 MD Anderson shall be responsible for the conduct of each Study in accordance with the relevant protocol and/or workscope. The Agreement shall govern the performance of Studies by MD Anderson and one or more Principal Investigator(s) on basis of Study specific documents ("Study Orders") as agreed upon by the Parties. This Agreement shall apply to all Studies performed by MD Anderson and the MD Anderson principal investigator(s) responsible for the performance of such Studies ("Principal Investigators)") upon execution of Study Orders during the term of this Agreement. Each Study Order shall be substantially in the form attached as Exhibit I to this Agreement and shall detail the specifics of the Study to be performed under such Study Order including, without limitation, (i) the detailed Protocol or workscope, (ii) the Principal Investigator and (iii) identify any project-specific resources or support provided by Company. In the event of any conflict of terms of this Agreement and the terms of a Study Order, the terms of this Agreement shall govern, unless the Study Order specifically and expressly supersedes this Agreement with respect to a specific term, and then only with respect to the particular Study Order and specific term. If there is any discrepancy or conflict between the terms contained in a Protocol or workscope and this Agreement and/or the relevant Study Order, the terms of the Protocol or works cope shall govern and control with respect to clinical/scientific matters and the terms of the Agreement and/or the relevant Study Order shall govern and control with respect to all other matters, e.g., legal and financial matters.
1 |
1.3 Company agrees to commit funding in an amount of [***] for the performance of the Studies during the term ("Collaboration Funding"). The JSC may allocate and/or re-allocate funds to Studies as necessary. If the Parties extend the term by mutual agreement as set forth herein, the Parties shall negotiate in good faith the amount of future Study funding commitments by Company applicable to such extended term. In the event a Study is terminated early or does not initiate, the Parties shall promptly replace that Study with a new study similar in scope that is of mutual scientific interest to the Parties and that is approved by the JSC, and that will be funded by the Collaboration Funding. [***].
The Parties understand that the compensation being paid to MD Anderson under this Agreement constitutes the fair market value of the services to be provided hereunder. Neither MD Anderson nor Principal Investigator shall seek or accept reimbursement from any third-party payor for any Study items or procedures supplied by or paid for by Company under this Agreement. MD Anderson acknowledges that Company may be obligated to disclose all payments made hereunder, including the provision of non-monetary items of value, as may be required under applicable law, including the Physician Payments Sunshine Act, passed as Section 6002 of the 2010 Patient Protection and Affordable Care Act.
No amounts paid under this Agreement are intended to be for, nor shall they be construed as, an offer or payment made in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, or provide a favorable formulary status, for any Company product or service. Any such compensation will be consistent with fair market value in arms-length transactions and will not be determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the Parties for which payment may be made in whole or in part under Medicare, Medicaid or other Federal health care programs.
1.4 The [***] US dollars of Collaboration Funding for the Studies shall be due and payable to MD Anderson according to the schedule below. The JSC retains the right to prioritize and replace Studies as necessary.
[***]
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
2 |
Or if payment is made by wire transfer, wired to the following:
[***]
1.5 The Parties will establish a Joint Steering Committee ("JSC") of equal representation, comprised of three (3) representatives (employees, directors or consultants who are subject to appropriate confidentiality obligations) from each Party, with the representatives of each Party collectively having one vote on all matters to be decided upon by the JSC. Each Party can appoint and replace its representatives in the JSC at its own discretion through timely written notice to the other Party. Each Party shall bear all of its own travel related costs, in connection with its attendance at JSC meetings. Company will be invoiced for JSC members travel that is required or requested by or on behalf of Company.
1.6 The JSC will have meetings (either in person, by teleconference or via electronic means) at least quarterly. At least one meeting per year will be conducted in person or videoconference (including the kick-off meeting). The JSC will decide on matters by unanimous vote with each of MD Anderson and Company exercising one vote each provided, however, that no action may lawfully be taken at any meeting unless at least two representatives of each Party (including for this purpose any proxy representative appointed as provided below) are present at the meeting. If a member of the JSC is unable to attend a meeting, he or she may appoint, in writing, a proxy to participate and vote in his or her stead.
1.7 The main task of the JSC will be to oversee the Collaboration. In order to achieve the objectives of the Collaboration, the JSC will oversee each Study under the Collaboration. The JSC will provide technical, scientific, clinical, and regulatory guidance to the Studies and will be responsible for monitoring progress of these Studies. Each Party may invite guests at each JSC meeting in order to provide expertise as needed, provided that such guests will be subject to an obligation of confidentiality and non-use at least as strict as Section 5 below. In the event a Study is terminated early or does not initiate, the Parties shall promptly replace that Study with a new study similar in scope that is of mutual scientific interest to the Parties and that is approved by the JSC, to be funded by the Collaboration Funding. If there is any Collaboration Funding remaining at the expiration of this Agreement, they will be allocated to studies or tests deemed appropriate by the JSC.
1.8 In addition the JSC will be responsible for coordinating resolution of problems arising in the Studies or in the Collaboration as a whole. In the event of any matter to which the JSC cannot reach resolution, or in the event of any dispute arising as to any matter subject to JSC responsibility, such matter or dispute will be escalated to executive management of MD Anderson and Company for good faith resolution. In the event that any such issue is in relation to the allocation or spending of the Collaboration Funding, or any third party funding for the Collaboration in addition to the Collaboration Funding committed herein , the Company shall, in good faith, determine the dispute having reasonable regard for MD Anderson's views, provided that such Company determination shall not require either party to violate applicable law or regulation and shall not require MD Anderson (and MD Anderson shall not be required) to changes its policies or procedures or be in violation of the same.
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
3 |
2. | Responsibilities and Compliance |
2.1 Each Clinical Study shall be subject to review and approval of the Study protocol ("Protocol") as required by MD Anderson's Institutional Review Board ("Institutional Review Board" or "IRB") and/or any relevant authorities prior to commencement of the Study.
2.2 The scope of the Study to be performed shall be set forth in the Protocol(s) or workscope referenced in the Study Order, which shall be incorporated by reference into such Study Order. These Protocol(s)/workscope shall be considered final after being agreed to by MI) Anderson and Company and, for Clinical Studies, including approval by MD Anderson's IRE. The Principal Investigator for a Clinical Study shall submit the Protocol and reports of the ongoing conduct of the Clinical Study to the IRB as required by the IRB, obtain written approval from the IRB, and inform the IRB of Study closure.
2.3 MD Anderson represents that each Principal Investigator shall use reasonable efforts to conduct a Study in accordance with (a) the terms and conditions of this Agreement and the relevant Study Order, (b) the provisions of the Protocol or workscope, as applicable, (c) applicable Good Clinical Practice requirements as incorporated by FDA regulations ("GCP"), (d) the ethical principles of the Declaration of Helsinki, as applicable, and (e) any and all applicable orders and mandates of relevant authorities and IRB and applicable MD Anderson policies.
2.4 MD Anderson and Company shall comply with all federal, state, and local laws and regulations as well as ethical codes applicable to the conduct of each such Study.
2.5 MD Anderson and/or Principal Investigator shall forward to Company evidence of approval of each Clinical Study by MD Anderson's IRB, and with respect to Studies for which MD Anderson serves as "sponsor" within the meaning of such term under applicable laws and regulations, evidence of approval of the Study by relevant regulatory authorities (or exemption from such regulatory authority/ies review and approval).
2.6 If, in the course of any Clinical Study at MD Anderson, a Study subject is injured by such Study subject's participation in the Study, MD Anderson and/or Principal Investigator shall inform Company of any such injury by fax or email in case of serious and unexpected adverse reactions and/or serious and unexpected adverse events arising from the use of Study Drug, and/or, if applicable, pregnancies, within the timelines stipulated in the Protocol, or if such is not stipulated in the Protocol, within [***] following MD Anderson or Principal Investigator becoming aware of such event.
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
4 |
2.7 MD Anderson represents that (a) it has not been debarred by the FDA pursuant to its authority under Sections 306(a) and (b) of the U.S. Food, Drug, and Cosmetic Act (21 U.S.C. § 335(a) and (b)) and is not the subject of any investigation or proceeding which may result in debarment by the FDA, and to the extent applicable, it shall not use any Principal Investigator or Study team member in the performance of a Study that has been so debarred or subject to any such investigation or proceeding, and; (b) it is not included in the List of Excluded Individuals/Entities (maintained by the U.S. Department of Health and Human Services Office of Inspector General) or the List of Parties Excluded from Federal Procurement and Non-procurement maintained by the U.S. General Services Administration, and is not the subject of any investigation or proceeding which may result in inclusion in any such list, and to the extent applicable, it shall not use any Principal Investigator or Study team member in the performance of a Study that is so included or the subject of any such investigation or proceeding. MD Anderson agrees to promptly notify Company in writing if it becomes aware of any such debarment, exclusion, investigation or proceeding of MD Anderson or, to the extent applicable, any Principal Investigator.
2.8 MD Anderson and Company shall comply with all applicable federal, state and local laws pertaining to confidentiality and disclosure of all information or records obtained and reviewed in the course of the Study, and shall permit access to such information or records only as authorized by a relevant Study subject, the IRB, and as authorized by law. Each Party agrees to comply with all provisions of the Health Insurance Portability and Accountability Act ("HIPAA") regulations (45 C.F.R. Parts 160 and 164) as to the protection and security of Protected Health Information ("PHI"). Prior to participation of each subject in a Clinical Study, MD Anderson will ensure that (a) it has obtained a signed written informed consent document from the subject ("Consent") and (b) it has obtained a signed, written, HIPAA authorization that adequately discloses the circumstances under which the subject's personal data might be disclosed, as applicable, and documents the subject's express written authorization for use and disclosure of the subject's PHI for Study purposes, as applicable, pursuant to the HIPAA regulations ("Authorization"). Company will only obtain access, use and disclose the individually identifiable health information of each Study Subject in accordance with and to the extent permitted by the IRB, Consent and the Authorization document and in accordance with this Agreement and applicable laws.
2.9 MD Anderson and Company will promptly notify each other upon identifying any aspect of a Protocol, including information discovered during site monitoring visits, or Study results that may adversely affect the safety, well-being, or medical care of the Study subjects, or that may affect the willingness of Study subjects to continue participation in a Study, influence the conduct of the Study, or that may alter the IRB's approval to continue the Study. MD Anderson will promptly notify the IRB of any such events. When Study subject safety or medical care could be directly affected by Study results, then notwithstanding any other provision of this Agreement, MD Anderson will send Study subjects a written communication about such results.
3. | Personnel, Materials and Equipment |
3.1 Except as set forth in this Agreement, MD Anderson shall provide all reasonable necessary personnel, facilities, and resources to accomplish their responsibilities under this Agreement and the relevant Study Order.
3.2 Company agrees to promptly provide MD Anderson with the required quantities of the drug under a Study Order that will be utilized in accordance with the provisions of the Protocol or workscope applicable to the Study ("Study Drug"), Collaboration Funding applicable to the Study, and/or support services to the extent required for the conduct of a Study as specified in the Protocol or workscope. Any Study Drug provided by Company will be used solely in accordance with the applicable Study. MD Anderson will not use such Study Drug outside of the scope of the Study. MD Anderson will not transfer the Study Drug to any third party for any purpose, without the prior written consent of Company.
5 |
3.3 Use of Proprietary Materials. From time to time during the term, either Party (the "Transferring Party") may supply the other Party (the "Receiving Party") with proprietary materials of the Transferring Party (other than Study Drug) ("Proprietary Materials") for use in the Study as may be further listed in the Study Order. In connection therewith, each Receiving Party hereby agrees that: (a) the Receiving Party will not use the Proprietary Materials for any purpose other than exercising its rights or performing its obligations hereunder; (b) it will use such Proprietary Materials only in compliance with all applicable laws; (c) it will not transfer any such Proprietary Materials to any third party without the prior written consent of the Transferring Party; (d) it will not acquire any rights of ownership, or title in or to such Proprietary Materials as a result of such supply by the Transferring Party; and (e) upon the expiration or termination of this Agreement or a Study Order, if requested by the Transferring Party, it will destroy or return any such Proprietary Materials that are not the subject of the grant of a continuing license hereunder.
3.4 Nothing in this Agreement shall be construed to limit the freedom of MD Anderson or of any Principal Investigator or Study team member to engage in similar clinical trials or research performed independently under other grants, contracts, or agreements with parties other than Company.
4. | Payments |
4.1 | [***]. |
5. | Confidential Information |
5.1 In conjunction with each Study, the Parties may wish to disclose confidential information to each other. For purposes of this Agreement, "Confidential Information" means confidential, non-public information, know-how and data (technical or non-technical) that is disclosed in writing, orally, graphically, in machine readable form, or in any other manner by or on behalf of a disclosing Party to a receiving Party or its Affiliates for purposes of this Agreement or any Study Order ("Purpose"). Confidential Information may be disclosed in any form (e.g. oral, written, graphic, electronic or sample) by or on behalf of disclosing Party or its Affiliates, or may be otherwise accessible to receiving Party or its Affiliates. Exchanges of Confidential Information directly between the Affiliates are also covered by this Agreement "Affiliates" means any individual, company, partnership or other entity which directly or indirectly, at present or in the future, controls, is controlled by or is under common control of a Party, and "control" will mean direct or indirect beneficial ownership of at least fifty per cent (50%) of the voting share capital in such company or other business entity, or to hold the effective power to appoint or dismiss members of the management.
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
6 |
5.2 Without disclosing Party's prior written consent, receiving Party will: (a) not use any part of or the whole of the Confidential Information for any purpose other than the Purpose; (b) restrict the dissemination of Confidential Information to individuals within its own organization and disclose the Confidential Information only to those of its officers, employees, advisers and Affiliates who have a legitimate need to have access to the Confidential Information, who will be bound by confidentiality and non-use commitments no less restrictive than those of this Agreement, and who will have been made aware of the confidential nature of the Confidential Information; (c) protect the Confidential Information by using the same degree of care, but not less than a reasonable degree of care, to prevent the unauthorized use, dissemination, or publication of the Confidential Information as receiving Party uses to protect its own confidential information of a like nature; (d) preserve the confidentiality of the Confidential Information, not disclose it to any third party, and take all necessary and reasonable precautions to prevent such information from being accessible to any third party; (e) not combine any part of or the whole of the Confidential Information with any other information; and (f) promptly notify the disclosing Party upon becoming aware of evidence or suspicion of any unauthorized use or disclosure of the Confidential Information. The foregoing obligations will exist for a period of five (5) years from the date of completion of the last Study in relation to which the Confidential Information is disclosed or used.
5.3 The obligations of confidentiality and non-use listed in this Section 5 will not apply to information: (a) which is in the public domain or public knowledge at the time of disclosure, or which subsequently enters the public domain through no fault of receiving Party; (b) which was rightfully in the possession of receiving Party at the time of disclosure by disclosing Party; (c) which is independently developed by receiving Party without use of disclosing Party's Confidential Information; (d) which the receiving Party receives legally from any third party and which is not subject to an obligation of confidentiality; (e) receiving Party is required to disclose pursuant to applicable law, by any applicable governmental or other regulatory authority, or by a court or other authority of competent jurisdiction; provided, however, that receiving Party will make reasonable efforts, if legally permissible, to notify disclosing Party prior to the disclosure of any part of or the whole of the Confidential Information and allow disclosing Party the opportunity to contest and avoid such disclosure, and provided, further, that receiving Party will disclose only that portion of such Confidential Information that it is legally required to disclose; (f) is communicated to the receiving party's IRB or other scientific committee; (g) is required to be disclosed in order to obtain informed consent from patients or subjects who may wish to enroll in the Study, provided, however, that the information will be disclosed only to the extent necessary and will not be provided in answer to unsolicited inquiries by telephone or to individuals who are not eligible to be Study subjects; or (h) is disclosed to a Study subject for the safety or well-being of the Study subject.
5.4 For the purposes of this Section 5, any combination of features disclosed to the receiving Party wil not be deemed to be within the foregoing exceptions merely because individual features are. Moreover, specific disclosures made to the receiving Party will not be deemed to be within the foregoing exceptions merely because they are embraced by general disclosures.
5.5 All Confidential Information disclosed to receiving Party pursuant to this Agreement will be and remain the disclosing Party's property. Nothing contained herein will be construed as granting to receiving Party any proprietary right on or in relation to any part of or the whole of the Confidential Information, or any right to use any of the Confidential Information except for purposes of this Agreement and the Collaboration. Receiving Party will return to disclosing Party all documents and other materials which constitute Confidential Information, as well as all copies thereof, promptly upon request or upon termination of this Agreement (whichever is earlier); provided, however, that receiving Party may keep one copy of the Confidential Information received under this Agreement in its secure files in accordance with the terms of this Agreement for the sole purpose of maintaining a record of the Confidential Information received hereunder and for compliance with this Agreement and/or applicable laws.
7 |
5.6 Company will not require MD Anderson to disclose any Protected Health Information. Notwithstanding the foregoing, if Company comes into knowledge or possession of any "Protected Health Information" (as such term is defined under HIPAA) by or through MD Anderson or any information that could be used to identify any Study subject or other MD Anderson patients or research subjects, Company will maintain any such Protected Health Information or other information confidential in accordance with laws and regulations as applicable to MD Anderson, including without limitation HIPAA, will use any such Protected Health Information solely to the extent permitted by applicable laws, the IRB and the Consent/Authorization of the patient/research subject, and will not use or disclose any such Protected Health Information or other information in any manner that would constitute a violation of any applicable laws or regulation if such use or disclosure was made by MD Anderson. It is intended that MD Anderson will not disclose any Protected Health Information to Company under this Agreement.
5.7 Improper use or disclosure of the Confidential Information by receiving Party is likely to cause substantial harm to disclosing Party. Therefore, in the event of a breach, threatened breach, or intended breach of this Agreement by receiving Party, in addition to any other rights and remedies available to it at law or in equity, disclosing Party will be entitled to seek preliminary and final injunctions enjoining and restraining such breach, threatened breach, or intended breach.
6. | Clinical Data / Monitoring |
6.1 Oral reports and interim written status reports of the progress of the Studies will be provided by the Principal Investigator to Company no less than once per [***] during the course of a Study. Significant developments arising out of Studies will be communicated promptly to Company.
6.2 As applicable to and appropriate for a Clinical Study, Company may monitor the conduct of a Clinical Study in accordance with Good Clinical Practice requirements of FDA Regulations, and may visit MD Anderson for the purpose of such monitoring. Any such monitoring visits shall be scheduled in coordination with MD Anderson and/or Principal Investigator during normal administrative business hours, and shall be subject to compliance with MD Anderson's reasonable measures for confidentiality, safety and security, and shall also be subject to compliance with generally applicable premises rules at MD Anderson.
6.3 MD Anderson and Principal Investigator shall, during a Study, permit inspections by responsible legal and regulatory authorities with respect to such Clinical Study. To the extent permitted by law and to the extent practicable, MD Anderson shall notify Company of such inspection and provide a summary of the results of such inspection to the extent applicable to the Studies.
6.4 Notwithstanding any provision of this Section 6, to the extent that MD) Anderson is the holder of an Investigational New Drug Application ("IND") or other applicable regulatory application or approval for a Study, the provisions of Section 6.2 and 6.3 shall not apply, and MD Anderson shall have the sole responsibility for monitoring, auditing, and reporting for such Study, provided that MD Anderson agrees to reasonably negotiate access to Study documentation and records relevant to the applicable Study Drug and documentation and facilities applicable to the Study upon the request of Company and provided that Company shall be subject to compliance with MD Anderson's reasonable measures for confidentiality, safety and security, and shall also be subject to compliance with generally applicable premises rules at MD Anderson.
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
8 |
7. | Data & Inventions. |
7.1 Each Party will retain all right, title and interest in and to its own Background IP and no license to use such Background IP is granted to the other party except for MD Anderson's use of Study Drug in a Study as set forth in the Protocol. "Background IP" means all intellectual property of a Party that: (a) was generated by such Party before the Effective Date; (b) is generated by such Party outside the scope of this Agreement or any Study under this Agreement; and in each such case; (c) is owned by such Party, either partially or wholly, or is licensed to, or otherwise controlled by such Party, and which is not an Invention under this Agreement.
7.2 | [***]. |
7.3 | [***]. |
7.4 | [***]. |
7.5 | [***]. |
7.6 | [***]. |
7.7 | [***]. |
7.8 | [***]. |
8. | Term and Termination |
8.1 The term of this Agreement shall be six (6) years following the Effective Date or until the Studies are completed, whichever is later, unless terminated earlier in accordance with the provisions hereof.
8.2 [***]. Any expiration or termination of this Agreement will not affect any then existing Study Orders, and any then outstanding Study Orders will continue after the expiration or earlier termination of this Agreement in accordance with their respective provisions. Upon any expiration or termination of this Agreement, provisions of this Agreement that are incorporated by reference into any then outstanding Study Orders will survive termination of this Agreement and will continue to apply to such Study Orders until termination or expiration of each such Study Orders in effect at the time this Agreement expires or is terminated.
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
9 |
8.3 A Party may terminate a Study Order: (a) if the other Party commits a material breach of this Agreement or the Study Order and fails to cure such breach within [***] of receiving notice from the non-breaching Party of such breach; or (b) due to health and safety concerns related to the Study Drug or procedures in the Study (including regulatory holds due to the health and safety of the Study Subjects). The Parties agree that any termination of a Study Order shall allow for (i) the wind down of the Study to ensure the safety of Study Subjects; and (ii) Company's final reconciliation of Data related to the Study in addition to Company's final monitoring visit. All reasonable fees associated with the wind-down activities and final monitoring visit shall be paid by Company. Termination of one or more Study Orders will not automatically result in the termination of this Agreement or termination of any other Study Orders. Upon termination of a Study Order, MD Anderson will immediately return (at Company's cost) any Study Drugs provided by Company for such Study as directed by Company.
8.4 In case any regulatory or legal authorization necessary for the conduct of the Study is (i) finally rejected or (ii) withdrawn, the relevant Study Order shall terminate automatically at the date of receipt of such final rejection. Termination or cancellation of this Agreement or a Study Order will not affect the rights and obligations of the Parties that have accrued prior to termination, and any provisions of this Agreement or a particular Study Order that by their nature extend beyond expiration or termination will survive the expiration or termination of this Agreement and/or that particular Study Order. In particular, the provisions of Sections 2-13, 15.1(a), 15.1(b), 15.2, 15.3, 15.6, 15.7 and 15.12 as applicable will survive any expiration or termination of this Agreement.
8.5 In the event the Parties cannot reach agreement on a new Principal Investigator pursuant to Section 14.1 or such new Principal Investigator does not agree to the terms of this Agreement and the relevant Study Order, either Party may terminate such Study Order upon notice to the other Party.
8.6 In addition, in order to accommodate the review and approval of this Agreement by the Office of General Counsel of UT System (the "OGC"), for a period of sixty (60) days following the Effective Date (the "Limited Unilateral Termination Period"), MD Anderson will have the right to terminate this Agreement without cause upon ten (10) days' notice to Company ; provided, however, that (i) a termination by MD Anderson will be effective if notice of termination is sent by MD Anderson any time within the Limited Unilateral Termination Period even if the ten day notice period extends beyond the Limited Unilateral Termination Period and (ii) the Limited Unilateral Termination Period will expire on the earlier to occur of (x) the end of the sixty days, or (y) written notice to Company from MD Anderson that the Agreement has been approved by the OGC.
9. | Indemnification |
9.1 Company agrees to defend, indemnify, and hold harmless MD Anderson, System, each Principal Investigator and its/their Regents, trustees, directors, officers, staff, employees, students, faculty members, and its/their affiliates and contracted clients and other parties as may be listed on a Study Order ("Indemnified Party/ies"): (a) from and against any and all liability, claims, lawsuits, losses, demands, damages, costs, and expenses ("Indemnified Losses") resulting from (i) the design or manufacture of the Study Drug, and (ii) the use of the Data or results of the Study and (iii) Company' negligence in connection with a Study or this Agreement; (b) from and against any Indemnified Losses arising from an injury to a Study subject caused by the Study Drug or any procedure required by the Protocol. The completion or termination of a Study shall not affect Company's obligation to indemnify with respect to any claim or suit based upon the aforementioned Indemnified Losses. Notwithstanding the foregoing, Company will not be responsible for any Indemnified Losses to the extent that they arise from the negligence, intentional misconduct, or malpractice of the Indemnified Parties, it being understood that the proper administration of the Study Drug in accordance with the Protocol (including permitted deviations) shall not constitute negligence, intentional misconduct, or malpractice for the purposes of this Agreement.
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
10 |
9.2 To the extent authorized by the constitution and laws of the State of Texas, MD Anderson, agrees indemnify, and hold harmless Company (also hereinafter an "Indemnified Party"): (a) from and against any and all Indemnified Losses resulting from any negligent or intentional act or omission of MD Anderson in conducting a Study hereunder. The completion or termination of a Study shall not affect MD Anderson's obligation to indemnify with respect to any claim or suit based upon the aforementioned Indemnified Losses. Notwithstanding the foregoing, MD Anderson will not be responsible for any Indemnified Losses to the extent that they arise from the negligence, intentional misconduct, or malpractice of Company.
9.3 Subject to the statutory duties of the Texas State Attorney General, any Indemnified Party shall: (a) notify the indemnifying Party in writing as soon as is reasonably possible after receipt of notice of any and all claims, lawsuits, and demands, or any action, suit, or proceeding giving rise to the right of indemnification; (b) permit the indemnifying Party to retain counsel to represent the named Indemnified Party; and (c) permit the indemnifying Party to retain control of any such claims, lawsuits, and demands, including the right to make any settlement, except that the indemnifying Party shall not make any settlement or take any other action which would be deemed to confess wrongdoing by any of the Indemnified Parties without the prior written consent of the applicable Indemnified Party.
10. | Subject Injury Medical Costs |
10.1 Company shall assume responsibility for reasonable medical expenses incurred by a Study subject for reasonable and necessary treatment if the Study subject experiences an illness, adverse event or injury that is a result of the Study Drug or any procedure required by the Protocol that the subject would not have undergone were it not for such Study subject's participation in the Study. Company shall not be responsible for expenses to the extent that they are due to pre-existing medical conditions, underlying disease, or the negligence or intentional misconduct of MD Anderson or Principal Investigator.
11. | Insurance |
11.1 During the term of any Study Order under this Agreement, Company shall maintain in full force and effect insurance for its liabilities arising from the Study with limits of not less than $[***] per loss and $[***] annual aggregate. Company shall provide MD Anderson with evidence of such insurance upon request.
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
11 |
11.2 MD Anderson is self-insured pursuant to The University of Texas Professional Medical Liability Benefit Plan under the authority of Chapter 59, Texas Education Code. MD Anderson has and will maintain in force during the term of this Agreement adequate insurance or financial resources to cover its obligations pursuant to this Agreement.
12. | Publications |
12.1 MD Anderson and/or Principal Investigator shall have the first right to publish or publicly disclose, either in writing or orally, the Data and results of the Study/ies, provided that MD Anderson or Principal Investigator, as applicable, shall provide Company with a copy of any such proposed publication or disclosure at least [***] prior to submission for publication or proposed disclosure. Within such [***] period, Company shall review such proposed publication or disclosure for any Confidential Information of Company provided hereunder or potentially patentable subject matter. MD Anderson and/or Principal Investigator shall remove Confidential Information of Company that has been so identified (other than Data or Study results) , provided that Company agrees to act in good faith when requiring the deletion of Company Confidential Information. If the proposed publication or disclosure could reasonably be deemed to have an adverse effect on the ability to obtain patent or similar protection for any potentially patentable subject matter, Company may request a delay of the publication or disclosure for a period not exceeding [***] in order to permit the filing of a patent application. Notwithstanding the foregoing, Company shall have the right to disclose or publish Study Data to the extent it is required to do so under any applicable laws, regulations or rules (including any stock market rules and obligations),
12.2 MD Anderson and/or Principal Investigator shall give Company acknowledgment for its sponsorship of a Study in all applicable Study publications. Authorship and acknowledgements for scientific publications shall be consistent with the principles embodied in the International Committee of Medical Journal Editors ("ICMJE") Uniform Requirements for Manuscripts.
12.3 The "sponsor" of a Study, within the regulatory meaning of such term, shall register the Study if required by, and in accordance with, Section 801 of the Food and Drug Administration Amendments Act of 2007 on www.clinicaltrials.gov and on any other database required by laws or regulations in accordance with applicable standards regarding scope, form and content and in accordance with ICMJE guidelines such that the Study will be eligible for publication in those publications.
13. | Use of Name/Public Statements/ Press Release/ Disclosure |
13.1 Except as expressly set forth in this Agreement, each Party agrees that it will not at any time during the term of this Agreement or following termination of this Agreement use any name of the other Party or any other names, insignia, mark(s), symbol(s), or logotypes associated with the other Party or any variant or variants thereof in any advertising, or promotional materials without the prior written consent of the other Party.
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
12 |
13.2 Except as expressly set forth in this Agreement, to the extent required by law or regulation, or to the extent necessary for MD Anderson for the recruitment of subjects to any Study hereunder, the Parties agree to make no public presentations about any Study Drug or any Study conducted under this Agreement, and to issue no news releases about any Study Drug or any Study, without the prior written consent of the other Party. Any advertisements directed at recruitment of study subjects for a Study must comply with al applicable laws, rules and regulations (including the need for IRB review), the confidentiality obligations herein, and shall not include the trademarked insignia, symbol(s), or logotypes, or any variant or variants thereof, of the other Party. Except as required by law or for regulatory purposes, neither Party will use the name (including trademark or other identifier) of the other Party or such other Party's employee or staff member (except in an acknowledgment of sponsorship) in publications, advertising, press releases (except as permitted below in Section 13.3) or for any other commercial purpose without the written approval of the other Party. Company will not state or imply in any publication, advertisement, or other medium that any product or service bearing any of Company's names or trademarks and/or manufactured, sold or distributed by Company has been tested, approved, or endorsed by MD Anderson. Notwithstanding any other provision of this Agreement, MD Anderson and its researchers and employees will have the right, without Company's approval, to acknowledge Company and Company's involvement with a Study in scientific or academic publications and communications describing the Study or reporting the results of the Study.
13.3 Any press release by either Party relating to this Agreement, the Collaboration, or any Study shall require the prior review and written approval of the other Party.
13.4 Either Party may use the name of the other Party in any document filed with any governmental authority or regulatory agency applicable to a Study, and to comply with any applicable legal or regulatory requirements. Further, each Party is permitted to disclose the other Party's name, the title of the Study, the name of the Principal Investigator, and an overall Study budget amount projected to be paid/actual total amount paid for conducting the Study, provided that this information is presented together as part of mandatory disclosure in accordance with and to the extent required applicable law.
14. | Principal Investigator |
14.1 If a designated Principal Investigator is terminated from a Study, or in the event of the death or other non-availability of the Principal Investigator, MD Anderson shall use reasonable efforts to designate a duly qualified person to act as new Principal Investigator, subject to the reasonable agreement of Company. If the Parties are unable to agree on a new Principal Investigator or if the new Principal Investigator is unwilling to agree to the terms and conditions of this Agreement and the relevant Study Order, either Party shall be entitled to terminate the respective Study Order in accordance with Section 8.5.
15. | General Provisions |
15.1 Warranties. EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPL1H1), CONCERNING THE RESULTS OF ANY STUDY OR THE STUDY DRUG, OR OF THE MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH DATA, RESULTS OR STUDY DRUG. NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT OR CONSEQUENTIAL DAMAGES SUFFERED BY THE OTHER PARTY AS A RESULT OF PERFORMANCE OF ANY STUDY UNDER THIS AGREEMENT. NOTWITHSTANDING THE FOREGOING, COMPANY REPRESENTS AND WARRANTS THAT EACH STUDY DRUG HEREUNDER SHALL HAVE BEEN MANUFACTURED IN ACCORDANCE WITH CURRENT GOOD MANUFACTURING PRACTICES IN THE UNITED STATES AND THAT IT HAS NOT RECEIVED AND SHALL NOT HAVE RECEIVED ANY CLAIM THAT USE OF ANY STUDY DRUG IN THE PERFORMANCE OF A STUDY WOULD INFRINGE THE RIGHTS OF ANY THIRD PARTY. COMPANY REPRESENTS THAT THERE ARE NO KNOWN DEFECTS IN ANY STUDY DRUG; COMPANY UNDERSTANDS AND ACKNOWLEDGES THAT THE DEVELOPMENT AND DISSEMINATION OF SCIENTIFIC KNOWLEDGE IS A FUNDAMENTAL COMPONENT OF MD ANDERSON'S MISSION, AND THAT MD ANDERSON MAKES NO REPRESENTATIONS, WARRANTIES, OR GUARANTEES WITH RESPECT TO ANY SPECIFIC RESULTS OF 1HE STUDIES.
13 |
15.2 Assignment. This Agreement and/or any Study Order may not be assigned by either Party except as agreed upon in writing by the other Party, except that each Party may assign this Agreement and/or any Study Order to an Affiliate and/or any third party taking over all or substantially all of its business provided such Affiliate or third party agrees to be bound by the terms and conditions hereof. Any assignment or attempt to assign, or any delegation or attempt to delegate, not in accordance with this Section shall be void and without effect. For any permitted assignment, the rights and obligations of the Parties hereunder will inure to the benefit of and be binding upon their permitted successors and assigns.
15.3 Further Assurance. Each Party shall (at its own expense) promptly execute and deliver all such reasonable documents, and do all such reasonable things, or procure the execution and delivery of all reasonable documents and doing of all such reasonable things as are required to give full effect to this Agreement and the transactions contemplated by it.
15.4 Independent Contractors. MD Anderson and Company shall be independent parties and nothing contained in this Agreement shall be construed or implied to create an agency or partnership. No Party shall have the authority to agree to or incur expenses on behalf of another except as may be expressly authorized by this Agreement or a Study Order.
15.5 Notices. Any notice or communication required or permitted to be given or made under this Agreement by one of the Parties hereto to the other shall be in writing and shall be deemed to have been sufficiently given or made for all purposes on the date of mailing by certified mail, postage prepaid, overnight courier service, and/or fax to be followed by mailed original addressed to such other Party at its respective address as referenced in the Study Order.
15.6 Severability. If any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby.
15.7 Entirety. This Agreement represents the entire agreement of the Parties with respect to the subject matter hereof and it expressly supersedes all previous written and oral communications between the Parties. No amendment, alteration, or modification of this Agreement or any Study Orders attached hereto shall be valid unless executed in writing by authorized signatories of all Parties.
15.8 Waiver. The failure of any Party hereto to insist upon strict performance of any provision of this Agreement or to exercise any right hereunder will not constitute a waiver of that provision or right.
14 |
15.9 Force Majeure. In the event that performance of the obligations of a Party hereunder are prevented by events beyond their reasonable control, including, but not limited to, acts of God, regulations or acts of any governmental authority, war, civil commotion, strikes, or other labor disturbances, epidemics, fire, earthquakes, storms or other catastrophes of a similar nature, the affected Party will promptly notify the other Party of such event using the procedure defined herein, and the Parties shall be relieved of their respective obligations hereunder to the extent that the performance of such obligations is actually prevented thereby. During the existence of any such condition, the affected Party shall, nevertheless, use its best efforts to remove the cause thereof and resume performance of its obligations hereunder. The period of performance shall be extended for the Party who is unable to perform due to Force Majeure reasons by a period of time equal to the length of the period during which the Force Majeure reason exists or for a longer period if required to meet the requirements of the Study Protocol.
15.10 Counterparts. It is understood that this Agreement may be executed in one or more counterpart copies, each of equal dignity, which when joined, shall together constitute one Agreement. In the event of execution by exchange of facsimile or electronic signed copies, the Parties agree that, upon being signed by both Parties, this Agreement shall become effective and binding and that facsimile or .pdf signed copies will constitute evidence of this Agreement.
15.11 Export Control. Notwithstanding any other provision of this Agreement, it is understood that the Parties are subject to, and shall comply with, applicable United States laws, regulations, and governmental requirements and restrictions controlling the export of technology, technical data, computer software, laboratory prototypes, and other commodities, information and items (individually and collectively, "Technology and Items"), including without limitation, the Arms Export Control Act, the Export Administration Act of 1979, relevant executive orders, and United States Treasury Department embargo and sanctions regulations, all as amended from time to time ("Restrictions") and that the Parties' obligations hereunder are contingent on compliance with applicable Restrictions.
15.12 Choice of Law. Any disputes or claims arising under this Agreement shall be governed by the laws of the State of Texas. MD Anderson is an agency of the State of Texas and under the constitution and the laws of the State of Texas possesses certain rights and privileges, is subject to certain limitations and restrictions, and only has such authority as is granted to it under the constitution and laws of the State of Texas. Notwithstanding any provision hereof, nothing in this Agreement is intended to be, nor will it be construed to be, a waiver of the sovereign immunity of the State of Texas or a prospective waiver or restriction of any of the rights, remedies,, claims, and privileges of the State of Texas. Moreover, notwithstanding the generality or specificity of any provision hereof, the provisions of this Agreement as they pertain to MD Anderson are enforceable only to the extent authorized by the constitution and laws of the State of Texas; accordingly, to the extent any provision hereof conflicts with the constitution or laws of the State of Texas or exceeds the right, power or authority of MD Anderson to agree to such provision, then that provision will not be enforceable against MD Anderson or the State of Texas.
[Signatures of Following Page]
15 |
In witness whereof, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives to be effective as of the Effective Date.
The University of Texas M. D. Anderson Cancer Center | 4D pharma plc | ||
Date: 11/13/17 | Date: | 11/28/2017 | |
/s/ Ben Melson | /s/ Alex Stevenson | ||
Name Ben Melson | Name: Alex Stevenson | ||
Title: Sr. Vice President and Chief Financial Officer | Title: Director |
16 |
Exhibit I
STRATEGIC COLLABORATION AGREEMENT - STUDY ORDER
This Study Order ("Study Order"), effective as of the ____ day of 2017 ("Effective Date"), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA ("MD Anderson"), a member institution of The University of Texas System ("System") and 4D pharma plc, with a place of business located at Third Floor, 9 Bond Court Leeds LS1 2JZ, United Kingdom ("Company") (MD Anderson and Company each a "Party" and collectively the "Parties"). This Study Order is a part of, and is subject to, the terms and conditions of the Strategic Collaboration Agreement entered into between MD Anderson and Company dated ____ 2017 (“Agreement").
1. The Parties enter into this Study Order in connection with:
the [Pre-Clinical or Clinical]] Study entitled_____________________, to be conducted pursuant
for Clinical: to Protocol No. [Insert Protocol number] as attached hereto and incorporated herein.
for Preclinical: to the workscope attached as Appendix A
2. ______is the Principal Investigator (as defined in the Agreement) for the Study which will be conducted at MD Anderson.
3. Study Drug for the above referenced Study is__________________.
4. The parties may further exchange the following Proprietary Materials (other than Study Drug) with each other in connection with the Study:
_______being provided by [Insert name of Transferring party]
_______being provided by [Insert name of Transferring party]
5. Term: This Study Order will continue until the Study is completed, which is expected to be ( _ ) months after the Effective Date, or until terminated early as provided in the Agreement.
6. Notices.
Any notice or other formal communication related to this Agreement must be in writing and will be deemed given only if: (a) delivered in person; or (b) sent by internationally recognized overnight delivery service or air courier guaranteeing next day delivery. Until a change of address is communicated, as provided below, all notices and other communications must be sent to the Parties at the following addresses or facsimile numbers:
17 |
If to MD Anderson:
[***]
With a copy to:
[***]
And to:
[insert investigator information]
If to Company:
[***]
With a copy to:
[To Be Added]
All notices will be effective and will be deemed delivered: (a) if by personal delivery, delivery service or courier, on the date of delivery; and (b) if by electronic facsimile communication, on the date of transmission of the communication. Either Party may change its notice address by sending notice of the change to the other Party in the manner set forth above.
7. Specific superseding terms: N/A.
In witness whereof, the Parties hereto have caused this Study Order to be executed by their duly authorized representatives to be effective as of the Effective Date.
The University of Texas M. D. Anderson Cancer Center | 4D pharma plc | ||
Date: | Date: | ||
Name | Name | ||
Title: | Title: |
***Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
18 |
READ AND UNDERSTOOD:
I confirm that I have received a copy of the Agreement under which this Study Order is issued, and that I have read and understand the Agreement and this Study Order.
Principal Investigator | ||
Date: | ||
Name |
Appendix A
19 |
Exhibit 10.2
EXECUTION COPY
RESEARCH COLLABORATION AND OPTION TO
LICENSE AGREEMENT
by and between
4D PHARMA PLC
and
MERCK SHARP & DOHME CORP.
*** | Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
EXECUTION COPY |
RESEARCH COLLABORATION AND OPTION TO LICENSE AGREEMENT
This Agreement (this “Agreement”) is effective as of October 7, 2019, (the “Effective Date”) and is entered into by and between 4D Pharma plc, having an address of 9 Bond Court, Leeds LS l 2JZ, United Kingdom (organized and existing under the laws of England and Wales (“Company”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“MSD”).
RECITALS:
WHEREAS, Company has developed and is the owner of a library of certain proprietary LBPs (as defined below);
WHEREAS, MSD has developed and owns or controls the Selected Antigens (as defined below);
WHEREAS, MSD is interested in working with the Company to discover, design and develop, as part of the Research Program (as defined below), mucosal vaccines derived from Selected LBPs (as defined below) when used in conjunction with Selected Antigens (as defined below);
WHEREAS, through the Research Program, the Parties will endeavor to discover, design and develop up to [***] combinations of Selected LBPs and Selected Antigens for use in up to three (3) Indications (as defined below);
WHEREAS, during the Option Exercise Period (as defined below), and with respect to each Indication, MSD shall have an exclusive option to exercise an Exclusive License (as defined below) under the Company’s rights to certain intellectual property in order to conduct internal research, commercialize and otherwise exploit Licensed Compounds (as defined below) and Licensed Products (as defined below), all as more fully set forth herein;
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, Company and MSD hereby agree as follows:
ARTICLE 1 DEFINITIONS.
Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below.
1.1 | “AAALAC” shall mean the Association for Assessment and Accreditation of Laboratory Animal Care International. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
1 |
EXECUTION COPY |
1.2 | “Act” shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 et seq., and/or the Public Health Service Act, 42 U.S.C. §§ 262 et seq., as amended from time to time. |
1.3 | “Affiliate” shall mean (i) any corporation or business entity of which, now or hereafter, fifty percent (50%) or more of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by MSD or Company; or (ii) any corporation or business entity which, now or hereafter, directly or indirectly, owns, controls or holds fifty percent (50%) (or the maximum ownership interest permitted by law) or more of the securities or other ownership interests representing the equity, the voting stock or, if applicable, the general partnership interest, of MSD or Company; or (iii) any corporation or business entity of which, now or hereafter, fifty percent (50%) or more of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a corporation or business entity described in (i) or (ii). |
1.4 | “Agreement” shall have the meaning given such term in the preamble to this document. |
1.5 | “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. |
1.6 | “Calendar Year” shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31. |
1.7 | “Change of Control” shall mean with respect to a Party: (1) the sale of all or substantially all of such Party’s assets or business relating to this Agreement; (2) a merger, reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (3) a person or entity, or group of persons or entities, acting in concert acquire more than fifty percent (50%) of the voting equity securities or management control of such Party. |
1.8 | “Clinical Trial” shall mean a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, and/or Post-approval Clinical Trial. |
1.9 | “Combination Product” shall mean a Licensed Product that includes one or more other clinically active components that produce a specific immune response in combination with a Licensed Compound, excluding a product containing a Licensed Compound in combination with a Licensed Compound with no other clinically active components. |
1.10 | “Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a Party with respect to any objective, such reasonable and diligent, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances. [***] |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
2 |
EXECUTION COPY |
1.11 | “Committee” shall mean the joint research committee established to facilitate the Research Program as more fully described in Section 2.4. |
1.12 | “Company” shall have the meaning given such term in the preamble to this Agreement. |
1.13 | “Company Competitor” shall mean any Person engaged in a business primarily focused on the development of therapeutic live biotherapeutics. |
1.14 | “Company Information and Inventions” shall mean all protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, created or conceived during the Research Program Term and resulting from the Research Program developed or invented solely by employee(s) of Company and/or its Affiliates, and/or a Third Party acting on behalf of Company and/or its Affiliates, and not employed by MSD and/or its Affiliates. |
1.15 | “Company Know-How” shall mean all information and materials (other than MSD Know-How), including but not limited to discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including without limitation Company Information and Inventions and Company’s rights in Joint Information and Inventions), know-how and trade secrets, patentable or otherwise, which during the Term of this Agreement (i) are in the possession or control of Company or its Affiliates, (ii) are not generally known and (iii) are necessary or useful to MSD in the Field, including, without limitation, in connection with the Research Program and the research, development, manufacture, marketing, use or sale of Licensed Compound or Licensed Product in the Territory. |
1.16 | “Company Patent Rights” shall mean Patent Rights that during the Term of this Agreement are in the possession or control of Company or its Affiliates which: (i) claim or cover Licensed Compound and/or Licensed Product, or a composition, method of use or process of manufacture thereof, including without limitation any improvements; or (ii) claim or cover Company Information and Inventions. |
1.17 | “Exclusive License” shall mean (individually or collectively) the exclusive licenses granted to MSD in accordance with Section 3.3. |
1.18 | “Field” shall mean the treatment, prevention and/or amelioration of an Indication in humans and animals. |
1.19 | “Filing” of an NDA shall mean the acceptance by a Regulatory Authority of an NDA for filing. |
1.20 | “First Commercial Sale” shall mean, with respect to any Licensed Product, the first sale for end use or consumption of such Licensed Product in a country, excluding, however, any sale or other distribution for use in a Clinical Trial. |
1.21 | “GLP” or “Good Laboratory Practice” shall mean the applicable then-current standards for laboratory activities for pharmaceuticals or biologicals, as set forth in the Act and any regulations or guidance documents promulgated thereunder, as amended from time to time, together with any similar standards of good laboratory practice as are required by any Regulatory Authority in the Territory. |
3 |
EXECUTION COPY |
1.22 | “IND” shall mean an Investigational New Drug application, Clinical Study Application, Clinical Trial Exemption, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. |
1.23 | “Indication” shall mean an infection or disease affecting humans and/or animals caused by an Infectious Agent. |
1.24 | “Infectious Agent” shall mean [***] . |
1.25 | “Information” shall mean any and all information and data, including without limitation all MSD Know-How, all Company Know-How, and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection with this Agreement. |
1.26 | “Initiates”, “Initiated” or “Initiation” shall mean, with respect to a Clinical Trial, the administration of the first dose to a patient in such Clinical Trial. |
1.27 | “Insolvency Event” shall mean any one of the following: |
1.27.1 | A petition is filed, a notice is given, a resolution is passed or any order is made for or in connection with the winding up of that Party, other than those for the sole purposes of (i) a resolution for the solvent reconstruction or reorganization of that Party, or (ii) the inclusion of any part of the share capital of that Party in the Official List of the London Stock Exchange or in the list of the New York Stock Exchange, American Stock Exchange or quotation of the same on the National Association of Securities Dealers Automated Quotation System in relation to an initial public offering; or |
1.27.2 | a receiver, administrative receiver, receiver and manager, interim receiver, custodian, sequestrator or similar officer is appointed in respect of that Party or over a substantial part of its assets or any Third Party takes steps to appoint such an officer in respect of that Party or an encumbrancer takes steps to enforce or enforces its security; or |
1.27.3 | a proposal for a voluntary arrangement shall have been made in relation to that Party under the United Kingdom Part I Insolvency Act 1986; or |
1.27.4 | a step or event shall have been taken or arisen outside the United Kingdom which is similar or analogous to any of the steps or events listed in Sections 1.27.1 through 1.27.3; or |
1.27.5 | that Party takes any step (including without limitation starting negotiations) with a view to readjustment, rescheduling or deferral of any part of that Party’s indebtedness, or proposes or makes any general assignment, composition or arrangement with or for the benefit of al or some of that Party’s creditors or makes or suspends or threatens to suspend making payments to all or some of that Party’s creditors or the Party submits to any type of voluntary arrangement; or |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
4 |
EXECUTION COPY |
1.27.6 | where (i) that Party is resident in the United Kingdom it is deemed to be unable to pay its debts within the meaning of Section 123 Insolvency Act 1986 or (ii) where that Party is resident in the United States, it is deemed unable to pay its debts within the meaning of the United States Bankruptcy Code. |
1.28 | “Invention” shall mean any process, method, composition of matter, article of manufacture, discovery or finding that is conceived and/or reduced to practice as a result of the Research Program. |
1.29 | “Joint Information and Inventions” shall mean all protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, created or conceived during the Research Program Term and resulting from the Research Program developed or invented jointly by employee(s) of MSD and/or its Affiliates, and/or a Third Party acting on behalf of MSD and/or its Affiliates, and by employee(s) of Company and/or its Affiliates, and/or a Third Party acting on behalf of Company and/or its Affiliates. |
1.30 | “Joint Patent Rights” shall mean Patent Rights that during the Term of this Agreement are jointly owned by MSD (and/or its Affiliates) and Company (and/or its Affiliates) that claim or cover (i) Joint Information and Inventions; or (ii) Licensed Compound and/or Licensed Product, or a composition, method of use or process of manufacture thereof of the Licensed Compound and/or Licensed Product, including without limitation any improvements thereon. |
1.31 | “LBPs” shall mean gut microbiome derived commensal bacteria selected from within the Company culture collection; provided, however, that Schedule 1.31 sets forth a list of LBPs which are included within such Company culture collection but specifically excluded from this Agreement. |
1.32 | “Licensed Compound” shall mean [***]. |
1.33 | “Licensed Product(s)” shall mean any pharmaceutical or biological preparation in final form containing Licensed Compound (i) for sale by prescription, over-the-counter or any other method; or (ii) for administration to human or animal patients in a clinical trial, for any and all uses in the Field, including without limitation any Combination Product. |
1.34 | “Major Market” shall mean any one of the following countries: [***]. |
1.35 | “Marketing Authorization” shall mean all approvals from the relevant Regulatory Authority necessary to market and sell a Licensed Product in any country (including without limitation all applicable pricing and governmental reimbursement approvals even if not legally required to sell Licensed Product in a country). |
1.36 | “Materials” means any tangible chemical or biological material, including any compounds, LBPs (with or without engineered or conjugated antigens), Selected LBPs, Selected Antigens, DNA, RNA, polypeptides, clones, cells, elementary bodies, constructs, vectors, receptors and other nucleic acids, proteins, peptides and any expression product, progeny, derivative or improvement thereto, along with any tangible chemical or biological material embodying any know-how. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
5 |
EXECUTION COPY |
1.37 | “MSD” shall have the meaning given such term in the preamble to this Agreement. |
1.38 | “MSD Information and Inventions” shall mean all protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, created or conceived during the Research Program Term and resulting from the Research Program developed or invented solely by employee(s) of MSD and/or its Affiliates, and/or a Third Party acting on behalf of MSD and/or its Affiliates, and not employed by Company and/or its Affiliates. |
1.39 | “MSD Know-How” shall mean all information and materials (other than Company Know-How), including but not limited to discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including without limitation MSD Information and Inventions and MSD’s rights in Joint Information and Inventions), know-how and trade secrets, patentable or otherwise, which during the Term of this Agreement (i) are in MSD’s possession or control, (ii) are not generally known and (iii) are in MSD’s opinion necessary to Company in the performance of its obligations under the Research Program. |
1.40 | “MSD Patent Rights” shall mean Patent Rights that during the Term of this Agreement are owned by MSD or any of its Affiliates, or to which MSD or any of its Affiliates, through license or otherwise, acquires rights, which: (i) claim or cover Licensed Compound and/or Licensed Product, or a composition, method of use or process of manufacture thereof, including without limitation any improvements; or (ii) claim or cover MSD Information and Inventions. |
1.41 | “NDA” shall mean a New Drug Application, Biologics License Application, Marketing Authorization Application, filing pursuant to Section 510(k) of the Act, or similar application or submission for Marketing Authorization of a Product filed with a Regulatory Authority to obtain marketing approval for a biological, pharmaceutical or diagnostic product in that country or in that group of countries. |
1.42 | “Net Sales” shall mean [***] |
1.42.1 [***]
1.42.2 [***]
1.42.3 [***]
1.42.4 [***]
1.42.5 [***]
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
6 |
EXECUTION COPY |
1.42.6 [***]
1.42.7 [***].
[***].
1.43 | “Party” shall mean MSD or Company, individually, and “Parties” shall mean MSD and Company, collectively. |
1.44 | “Patent Rights” shall mean any and all patents and patent applications in the Territory (which for the purpose of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention), including divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates, and the like of any such patents and patent applications, and foreign equivalents of the foregoing. |
1.45 | “Person” means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. |
1.46 | “Phase I Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(a). |
1.47 | “Phase II Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(b). |
1.48 | “Phase III Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(c). |
1.49 | “Qualifying Phase II Clinical Trial” shall mean a human clinical trial, in any country, the principal purpose of which is confirmation of immunogenicity, efficacy and safety (each as applicable), and consistent with that observed in previous Clinical Trial(s) of the relevant Licensed Product, in a target population, at the intended clinical dose or doses or range of doses, on a sufficient number of subjects and for a sufficient period of time to determine the optimal manner of use of the Licensed Product (dose and dose regimen) prior to the Initiation of a Phase III Clinical Trial of such Licensed Product. For clarity, the Parties’ expectation is that a Qualifying Phase II Clinical Trial will be a phase II proof of concept Clinical Trial which is intended to confirm the immunogenicity, efficacy and safety demonstrated in a prior phase II/IIa Clinical Trial or phase I/Ib Clinical Trial. |
1.50 | “Regulatory Authority” shall mean any applicable government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of a Licensed Product in the Territory, including, in the United States, the United States Food and Drug Administration and any successor governmental authority having substantially the same function. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
7 |
EXECUTION COPY |
1.51 | “Related Party” shall mean each of MSD, its Affiliates, and their respective sublicensees (which term does not include distributors), as applicable. |
1.52 | “Research Program” shall mean the research activities undertaken by the Parties as set forth in Article 2 and the Work Plan. |
1.53 | “Research Program Term” shall have the meaning set forth in Section 2.9. |
1.54 | “Response Outcome(s)” shall mean, individually and collectively (as applicable), each of the definitions and criteria for Response Outcome 1, Response Outcome 2 and Response Outcome 3, and the associated decision making process to be applied on a program-by-program basis, all as more fully set forth on Schedule 1.54. |
1.55 | “Selected Antigens” shall mean one or more antigens of an Infectious Agent associated with an Indication. |
1.56 | “Selected LBPs” shall mean the three (3) LBPs mutually agreed to by the Parties at the conclusion of Stage 1 of the Work Plan. |
1.57 | “Stock Purchase Agreements” means that certain (i) put option agreement between Company and MSD entered into as of the Effective Date and (ii) subscription agreement to be entered into between Company and MSD in the form appended to the aforementioned put option agreement, which together provide for MSD’s purchase of ordinary shares in the share capital of the Company. |
1.58 | “Territory” shall mean [***]. |
1.59 | “Third Party” shall mean an entity other than MSD and its Related Parties, and Company and its Affiliates. |
1.60 | “Vaccine Product” shall mean a live biotherapeutic in combination with one or more exogenous antigens targeted to elicit a specific immune response against such antigen(s). |
1.61 | “Valid Patent Claim” shall mean a claim of an issued, unexpired and in-force patent included within the Company Patent Rights or Joint Patent Rights that claims Licensed Compound as a composition of matter, which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction (which decision is not appealable or has not been appealed within the time allowed for appeal), and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, reexamination, supplemental examination or disclaimer or otherwise. |
1.62 | “Work Plan” shall have the meaning set forth in Section 2.1. |
1.63 | Additional Definitions. Each of the following terms has the meaning described in the corresponding Section of this Agreement indicated below: |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
8 |
EXECUTION COPY |
Definition: | Section: |
“AAA” | 9.7.2 |
“Agreement Payments” | 5.9 |
“Alliance Manager” | 2.5 |
“Approved Activity(ies)” | 3.5 |
“Biosimilar Application” | 7.3.5 |
“Collaboration Materials” | 2.10.2 |
“Company Product Related Inventions” | 7.1.1(a) |
“Company Product Related Patent Rights” | 7.1.1(b) |
“Company Restriction” | 3.5 |
“Dispute” | 9.7.1 |
“Excluded Claim” | 9.7.9 |
“Expert” | 9.7.11(a) |
“License Option” | 3.1 |
“Licensed Indication” | 3.1 |
“MSD Agent” | 3.5.4 |
“MSD Approval Process” | 2.2 |
“Officials” | 2.11.3 |
“Option Exercise Period” | 3.1 |
“Patent Committee” | 7.4.1 |
“Payment” | 2.11.3 |
“Response Outcome 3 Option Payment” | 5.3 |
“Royalty Period” | 5.5.1(c) |
“Taxes” | 5.9 |
“Technology Transfer Plan” | 3.12.1 |
“Term” | 8.1 |
“Termination of the Company Restriction” | 3.5 |
“Third Party Licenses” | 5.5.5 |
ARTICLE 2 RESEARCH PROGRAM
2.1 | General. Company and MSD shall engage in the Research Program upon the terms and conditions set forth in this Agreement. The activities to be undertaken in the course of the Research Program are set forth in Schedule 2.1 (the “Work Plan”). For clarity, the Research Program will evaluate up to [***] combinations of Selected LBPs and Selected Antigens for use in up to three (3) Indications. |
2.2 | Performance of Research Program. Each Party shall be responsible for its costs and expenses in connection with the Research Program. Each Party shall proceed diligently and in good faith with the work set out in the Work Plan by using its reasonable efforts to allocate sufficient time, effort, equipment and facilities to the Research Program and to use personnel with sufficient skills and experience as are required to accomplish its activities under the Research Program in accordance with the terms of this Agreement and the Work Plan. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
9 |
EXECUTION COPY |
MSD shall be entitled to utilize the services (by sublicense through multiple tiers or otherwise) of its Affiliates and Third Parties to perform its Research Program activities. Company may utilize the services (by sublicense through multiple tiers or otherwise) of Third Parties to perform certain of its activities under the Work Plan as specifically set forth in the Work Plan or on Schedule 2.2 attached hereto, or upon MSD’s prior written consent (such approval processes, the “MSD Approval Process”); provided, that any such activities to be undertaken and the identity of any such Third Parties shall be set forth in reasonable detail. Notwithstanding the foregoing, each Party shall remain at all times fully liable for its respective responsibilities under the Research Program.
2.3 | License Grants for Research Program. |
2.3.1 | Company License Grant to MSD. Company hereby grants to MSD during the Research Program Term a non-exclusive, non-transferable, sublicensable (in accordance with Section 2.2) license in the Territory under Company Patent Rights and Company Know-How solely to perform MSD’s activities under the Research Program in accordance with this Agreement and the Work Plan. |
2.3.2 | MSD License Grant to Company. MSD hereby grants to Company during the Research Program Term a non-exclusive, non-transferable, sublicensable (in accordance with Section 2.2) license under the MSD Patent Rights and MSD Know-How, as applicable, solely to perform Company’s activities under the Research Program in accordance with this Agreement and the Work Plan. |
2.4 | Joint Research Committee. The Parties hereby establish a committee to facilitate the Research Program as follows: |
2.4.1 | Composition of the Joint Research Committee. The Research Program shall be conducted under the direction of a joint research committee (the “Committee”) comprised of two (2) representatives of MSD (who shall be employees of MSD or its Affiliate, as applicable) and two (2) representatives of Company (who shall be employees of Company or its Affiliate, as applicable). Each Party may change its representatives to the Committee from time to time in its sole discretion, effective upon notice to the other Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research Program. Additional representative(s) or consultant(s) may, from time to time by mutual consent of the Parties, be invited to attend Committee meetings, subject to such representative’s or consultant’s written agreement to comply with the requirements of Section 4.1. The Committee shall be chaired by a representative of MSD. Decisions of the Committee shall be made unanimously by the representatives, with each Party having one (1) vote. In the event that the Committee cannot or does not, after reasonable good faith efforts, reach agreement on an issue, the resolution and/or course of conduct shall be determined by MSD (except for the matter set forth in Section 9.7.11, which shall be governed by the procedures set forth therein), in its sole discretion. |
10 |
EXECUTION COPY |
2.4.2 | Scope of Committee Oversight. The Committee shall be responsible for overseeing the Research Program, including to (i) review and amend the Research Program activities set forth in the Work Plan from time to time, (ii) review and coordinate the Parties’ activities under the Research Program, (iii) confer regarding the status of the Research Program and the progress under the Research Program and to make determinations and decisions in connection with the activities under the Work Plan (including issues of priority), (iv) review relevant data and results under the Research Program, (v) consider and advise on any technical issues that arise under the Research Program, (vi) assigning Response Outcomes, as per the criteria and decision tree outlined in Schedule 1.54, (vii) agree on a specific, single percentage between [***] and [***] that will be applied (in accordance with the processes set forth in Sections 5.3 and 5.4.2, as applicable) to all future upfront payments (as set forth in Section 5.3), development and regulatory milestone payments, and sales milestones payments associated with each of the three (3) individual programs to be undertaken under the Work Plan which may be assigned a Response Outcome 2 as per the process outlined in Schedule 1.54, (viii) and to determine such other matters as allocated to the Committee hereunder and (ix) agreeing on which of the LBPs will be deselected and discontinued from further work during the performance of the Work Plan, including establishing a reasonable process for formally documenting same. The Committee shall not have the authority to: (w) modify or amend the terms and conditions of this Agreement; (x) waive either Party’s compliance with the terms and conditions of this Agreement; (y) determine any issue in a manner that would conflict with the express terms and conditions of this Agreement or (z) amend the Work Plan in a manner that would result in an increase in a Party’s obligations, costs or expenses under the Research Program or this Agreement. For clarity, other than amendments outlined above, all other changes to the Work Plan may only be amended upon mutual written agreement by authorized representative(s) of the Parties. |
2.4.3 | Meetings. During the Research Program Term, the Committee shall meet in accordance with a schedule established by mutual written agreement of the Parties, but no less frequently than once per Calendar Quarter, by means of teleconference, videoconference or other similar communications equipment. Subject to and in accordance with Section 2.4.2, the Committee shall confer regarding the status of the Research Program, review relevant data, consider and advise on any technical issues that arise, consider issues of priority, and review and advise on any budgetary and economic matters relating to the Research Program which may be referred to the Committee. Each Party shall bear its own expenses related to the attendance of such meetings by its representatives. |
2.4.4 | Disbandment of Committee. Upon completion (or earlier termination) of the Research Program, the Committee shall have a final meeting to review the results of the Research Program, shall then be disbanded with no further action by the Committee or the Parties and shall have no further authority with respect to the activities under this Agreement. |
2.5 | Alliance Managers. Each Party shall have the right to appoint an employee who shall oversee interactions between the Parties for all matters related to this Agreement (each an “Alliance Manager”). Such persons shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and may serve as a single point of contact for any matters arising under this Agreement. The Alliance Managers shall have the right to attend all Committee meetings as non-voting participants and may bring to the attention of the Committee any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. The Alliance Managers shall keep accurate records and meeting minutes for all Committee meetings. All such meeting minutes shall be prepared, agreed to and distributed to the Committee members promptly following each Committee meeting but in no event more than [***] thereafter. Each Party may designate different Alliance Managers by notice in writing to the other Party. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
11 |
EXECUTION COPY |
2.6 | Exchange of Information. Upon execution of this Agreement, and on an ongoing basis during the Option Exercise Period, Company shall disclose to MSD in English and in writing or in an electronic format all results generated by or on behalf of Company under the Research Program and all Company Know-How reasonably necessary for MSD to determine whether to exercise a License Option. If MSD exercises a License Option, Company shall disclose to MSD all Company Know-How, including any such know-how requested by, or required to be disclosed to, a Regulatory Authority in connection with the development or commercialization of a Licensed Compound or Licensed Product. Company shall make itself reasonably available to MSD and such Regulatory Authority in connection with the foregoing. |
2.7 | Records and Reports. |
2.7.1 | Records. Each Party shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of the Research Program by or on behalf of such Party. |
2.7.2 | Copies and Inspection of Records. MSD shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such records of Company referred to in Section 2.7.1. MSD shall maintain such records and the information disclosed therein in confidence in accordance with Section 4.1. MSD shall have the right to arrange for its employee(s) and/or consultant(s) involved in the activities contemplated hereunder to visit the offices and laboratories of Company and any of its Third Party contractors as permitted under Section 2.2 during normal business hours and upon reasonable notice, and to discuss the Research Program work and its results in detail with the technical personnel and consultant(s) of Company. Upon request, Company shall provide copies of the records described in Section 2.7.1. |
2.7.3 | Annual and Quarterly Reports. |
(a) | Within [***] following the end of each Calendar Quarter during the Research Program Term, or as part of the Committee meeting, the Parties shall provide to each other a written progress report in English which shall describe the work performed to date on the Work Plan, evaluate the work performed in relation to the goals of the Research Program and provide such other information as may be required by the Work Plan relating to the progress of the goals or performance of the Research Program. |
(b) | To the extent MSD exercises a License Option, if at all, until the First Commercial Sale of such Licensed Product, MSD shall provide an annual summary written progress report in English which shall describe the work performed to date under the Agreement. All subsequent reports following the initial report, shall summarize the activities conducted since the last report. For clarity, all such reports shall be considered the Confidential Information of MSD. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
12 |
EXECUTION COPY |
2.8 | Research Information and Inventions; Perpetual Research Licenses. Subject to the terms and conditions of this Agreement, the entire right, title and interest in: |
2.8.1 | Company Information and Inventions, Company Know-How and Company Patent Rights shall be owned solely by Company; |
2.8.2 | MSD Information and Inventions, MSD Know-How and MSD Patent Rights shall be owned solely by MSD; and |
2.8.3 | Joint Information and Inventions and Joint Patents Rights shall be owned jointly by Company and MSD. |
Each Party shall promptly disclose to the other Party in writing the development, making, conception, or reduction to practice of Joint Information and Inventions. MSD shall promptly disclose to Company in writing the development, making, conception or reduction to practice of MSD Information and Inventions. Company shall promptly disclose to MSD in writing the development, making, conception or reduction to practice of Company Information and Inventions. For the purposes of determining ownership under this Section 2.8, inventorship shall be determined in accordance with United States patent laws (regardless of where the applicable activities occurred). Subject to the licenses granted to the other Party under this Agreement and the other terms and conditions of this Agreement (including, for clarity, those licences provided in Sections 3.7.1 and 3.7.2), (i) MSD hereby grants to Company a non-exclusive, perpetual, irrevocable, royalty-free, sublicensable license in the Territory under the MSD Information and Inventions for internal research purposes only and (ii) Company hereby grants to MSD a non-exclusive, perpetual, irrevocable, royalty-free, sublicensable license in the Territory under the Company Information and Inventions for internal research purposes only. Subject to the licenses granted to the other Party under this Agreement and the other terms and conditions of this Agreement, each Party shall have the non-exclusive right to exploit its interest in Joint Information and Inventions and Joint Patent Rights, and to grant licenses under its interest in Joint Information and Inventions and Joint Patent Rights for internal research purposes only; provided, however, that for clarity, the foregoing joint ownership rights shall not be construed as granting, conveying or creating any license or other rights to the other Party’s intellectual property, unless otherwise expressly set forth in this Agreement.
13 |
EXECUTION COPY |
2.9 | Research Program Term. Except as otherwise provided herein, the term of the Research Program shall commence on the [***] (the “Research Program Term”). The Parties may extend the Research Program Term by mutual written agreement of the authorized representatives of the Parties, and shall, in such case, amend the Work Plan as applicable. Furthermore if, following bona fide, good faith discussions, the Parties agree that it is likely that additional research would be mutually beneficial, the Parties will agree on the scope of the additional research work to be performed (and amend the Work Plan to incorporate same), and the Company shall provide such additional research during the period up to expiration of the Option Exercise Period. For clarity, in the circumstances provided for in the immediately preceding sentence, unless otherwise mutually agreed to by the Parties, the additional research shall not result in an extension of the Research Program Term and the Option Exercise Period. Notwithstanding anything herein to the contrary, unless otherwise mutually agreed to by the Parties, Company shall provide MSD with the results of all research conducted pursuant to the Work Plan on a rolling basis but in no event later than [***] prior to the expiration of the Option Exercise Period; provided, however, that in the event the results of any such research conducted is provided to MSD within the [***] period immediately preceding the expiration date of the Option Exercise Period, MSD shall have [***] from the date of receipt thereof to evaluate same and exercise a License Option with respect thereto. |
2.10 | Materials. During the Research Program Term, each Party shall provide the other Party (at no cost to such other Party) with sufficient quantities of Materials solely for the purpose of enabling each Party to perform its activities under the Work Plan in accordance with the terms of this Agreement. For the avoidance of doubt, Materials may not be re-engineered by the receiving Party in any way. The Materials are not to be used in humans, nor shall any of the Materials, or any derivatives, analogs, modifications or components thereof be transferred, delivered or disclosed to any Third Party without the prior written approval of the other Party. |
2.10.1 | Unless otherwise agreed to in writing by the Parties, any unused Materials which were in existence as of the Effective Date of this Agreement shall be, at the providing Party’s option, either returned to such Party, or destroyed in accordance with instructions by such Party within [***] of the conclusion of the Research Program Term. |
2.10.2 | All Materials created as a direct result of the conduct of the Research Program (the “Collaboration Materials”) shall be discussed between the Parties in good faith following expiration or termination of this Agreement in order for each Party to exercise its rights under this Agreement. In the event that MSD has not exercised a License Option, Collaboration Materials may be used by both Parties beyond the Option Exercise Period for internal research purposes only; provided, that any Collaboration Materials created by MSD will not be provided to Company where such provision would violate the terms of any agreement MSD or an Affiliate of MSD has with a third party. |
2.11 | Compliance with Law and Ethical Business Practices. |
2.11.1 | Each Party shall conduct the Research Program in accordance with all applicable laws, rules and regulations including, without limitation, all current governmental regulatory requirements concerning Good Laboratory Practices. Each Party shall notify the other Party in writing of any deviations from applicable regulatory or legal requirements. Each Party hereby certifies that it has not and will not employ or otherwise use in any capacity the services of any person or entity debarred under Section 21 USC 335a in performing any services hereunder. Each Party shall notify the other Party in writing immediately if any such debarment occurs or comes to its attention, and shall promptly remove any person or entity so disbarred from performing any activities under the Research Program, or function or capacity related to the Research Program. MSD shall have the right, in its sole discretion, to terminate this Agreement immediately in the event of any such debarment by or on behalf of Company. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
14 |
EXECUTION COPY |
2.11.2 | Company acknowledges that MSD’s corporate policy requires that MSD’s business must be conducted within the letter and spirit of the law. By signing this Agreement, each Party agrees to conduct the services contemplated herein in a manner which is consistent with both law and good business ethics. |
2.11.3 | Each Party warrants that none of its employees, agents, officers or other members of its management are officials, officers, agents or representatives of any government or public international organization (as such term is defined in the Foreign Corrupt Practices Act). Neither Party shall make any payment, either directly or indirectly, of money or other assets, including but not limited to the compensation such Party derives from this Agreement (hereinafter collectively referred as a “Payment”), to government or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing (hereinafter collectively referred as “Officials”) where such Payment would constitute violation of any law. In addition, regardless of legality, neither Party shall make Payment either directly or indirectly to Officials if such Payment is for the purpose of influencing decisions or actions with respect to the subject matter of this Agreement or any other aspect of the other Party’s business. |
2.11.4 | Company acknowledges that no employee of MSD or its Affiliates shall have authority to give any direction, either written or oral, relating to the making of any commitment by Company or its agents to any Third Party in violation of terms of this or any other provisions of this Agreement. |
2.11.5 | Any failure to abide by the provisions of this Section 2.11 shall be deemed a material breach of this Agreement. |
2.12 | Animal Research. |
2.12.1 | If animals are used in research hereunder, each Party will comply with the Animal Welfare Act or any other applicable local, state, national and international laws and regulations relating to the care and use of laboratory animals. Each Party’s care and use of animals will at all times meet or exceed all applicable requirements or standards for the humane handling, care, and treatment of research animals established by the AAALAC, the Guide for the Care and Use of Laboratory Animals (NRC, 2011) and the Guide for the Care and Use of Agricultural Animals in Research and Teaching published by the Federation of Animal Science Societies, 2010, even if such standards exceed those required under applicable laws. Proposed animal work must be reviewed by a site Institutional Animal Care and Use Committee (IACUC) or Animal Ethical Review Committee prior to initiation of any animal work under the Research Program and Work Plan. Company hereby certifies that it has and shall maintain current and valid accreditation from AAALAC during the Research Program Term. Any animals which are used in the course of the Research Program, or products derived from those animals, such as eggs or milk, will not be used for food purposes, nor will these animals be used for commercial breeding purposes; |
15 |
EXECUTION COPY |
2.12.2 | Each Party will comply with all applicable laws relating to animals in connection with the performance of the Research Program, including but not limited to the Animal Welfare Act (United States), Directive 2010/63/EU (European Union), Canadian Council on Animal Care (Canada), and any other applicable laws. Prior to the performance under the Research Program and Work Plan, each Party will obtain any and all licenses and permits required for the performance thereunder at such Party’s facilities and will comply with all such licenses and permits in connection with the performance thereof. |
2.12.3 | Each Party shall provide adequate veterinary care and health monitoring for the animals. Health and care records for all animals shall be maintained by each Party in accordance with any and all applicable laws and standards for the period required by applicable law. Each Party will make such health and care records available to the other Party in paper or electronic format upon request. |
ARTICLE 3 OPTION TO LICENSE; LICENSE; DEVELOPMENT AND COMMERCIALIZATION.
3.1 | License Option. Company hereby grants to MSD, with respect to each Indication, an exclusive option to obtain the exclusive licenses set forth in Section 3.3 pursuant to the terms of this Agreement (each such option, a “License Option”). MSD may exercise each License Option, in its sole discretion, at any point [***] thereafter (the “Option Exercise Period”), by (i) sending Company written notice of such exercise, with such notice containing the Indication (each, a “Licensed Indication”) and Licensed Compounds that are the subject of such License Option being exercised and (ii) making the applicable payment in accordance with Section 5.3. Upon exercise of a License Option, Company shall exclude the Selected LBPs from Company’s library of gut microbiome derived commensal bacteria and no longer use the Selected LBPs in any way. The Option Exercise Period may be extended by mutual written agreement of the Parties. |
3.2 | Certain Company Restrictions. |
3.2.1 | Subject to the terms and conditions of this Agreement, during the Option Exercise Period, Company shall not (directly or indirectly) research, develop or commercialize any Vaccine Product. |
3.2.2 | During the Term of this Agreement, and provided that MSD has exercised at least one License Option, Company shall not use (i) any Licensed Compound or Licensed Product for any use; or (ii) any Company Information and Inventions, including Company Patent Rights, MSD Information and Inventions or Joint Information and Inventions to research, develop or commercialize a Vaccine Product; or (iii) any LBPs (including Selected LBPs or any other gut microbiome derived commensal bacterial of Company or any Third Party) in the research, development or commercialization of a compound or product that could reasonably be expected to compete with a Licensed Compound or Licensed Product. |
3.3 | Exclusive License Grants to MSD. Upon exercise by MSD of a License Option in accordance with Section 3.1: |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
16 |
EXECUTION COPY |
3.3.1 | Company hereby grants to MSD an exclusive license (even as to Company) in the Territory under Company Patent Rights, Company Know-How and the Company's rights in and to the Joint Patent Rights to the extent they relate to the Licensed Compounds and/or Licensed Products, with the right to grant and authorize sublicenses, to (i) conduct internal research on Licensed Compounds for any and all uses; and (ii) make, have made, use, import, sell, offer to sell and otherwise exploit the Licensed Compounds and Licensed Products in the Field in the Territory. |
3.3.2 | Company hereby grants to MSD an exclusive license (even as to Company) in the Territory under Company’s rights in and to the Joint Information and Inventions, with the right to grant and authorize sublicenses, to (i) conduct internal research on Licensed Compounds for any and all uses; and (ii) make, have made, use, import, sell, offer to sell and otherwise exploit the Licensed Compounds and Licensed Products in the Field in the Territory. |
3.4 | Effects of an Unexercised License Option; Restrictions on use of Information beyond Research Program Term. For the avoidance of doubt, (i) in the event that MSD does not exercise a License Option with respect to any Indication (x) there will be no milestones or royalties payable by MSD to Company under this Agreement and (y) each Party will be permitted to exercise its respective background rights to any LBPs and Selected Antigens that were the subject of such License Option for any and all purposes. |
3.4.1 | Following expiration of the Option Exercise Period, provided MSD does not exercise a License Option, both Parties agree to use Information created in the course of the Research Program and Collaboration Materials for internal research purposes only. |
3.5 | Restrictions during Option Exercise Period. During the Option Exercise Period, Company shall not by itself or with others, directly or indirectly, research, develop or commercialize any Vaccine Product (the “Company Restriction”). In the event that, during the Option Exercise Period, MSD (directly or indirectly) researches, develops or commercializes any Vaccine Product (excluding any Licensed Compound or Licensed Product) for an Indication in the Field (excluding Selected LBPs), the Company Restriction shall cease and have no further force or effect (the “Termination of the Company Restriction”). Notwithstanding the foregoing sentence, the Termination of the Company Restriction shall not apply in any of the following events (each, an “Approved Activity”, and collectively, the “Approved Activities”): |
3.5.1 | [***] |
3.5.2 | [***] |
3.5.3 | [***] |
3.5.4 | [***] |
3.5.5 | [***]. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
17 |
EXECUTION COPY |
3.6 | Non-Exclusive License Grant. In the event that the making, having made, use, import, offer for sale and/or sale by MSD or its Related Parties of Licensed Compound or Licensed Product in the Field would infringe during the Term of this Agreement a claim of an issued letters patent that Company (or its Affiliate) owns or has the rights to license and which patents are not covered by the grant in Section 3.3, Company hereby grants to MSD, to the extent Company is legally able to do so, a non-exclusive, sublicensable, royalty-free license in the Territory under such issued letters patent for MSD and its Related Parties to research internally, make, have made, use, import, sell, offer to sell and otherwise exploit the Licensed Compounds and Licensed Products in the Field in the Territory (all in accordance with the licenses granted to MSD in Section 3.3) or to sell and otherwise exploit the Licensed Compounds and Licensed Products in the Field in the Territory (all in accordance with the licenses granted to MSD in Section 3.3). |
3.7 | Additional Perpetual Licenses. |
3.7.1 | MSD hereby grants to Company a non-exclusive, sublicensable, non-royalty bearing, perpetual, irrevocable, worldwide license under MSD Patent Rights, MSD’s interest in any Joint Patent Rights that specifically and solely claim or cover LBPs other than the Selected LBPs, and MSD Know-How that is specifically and solely related to LBPs other than the Selected LBPs for any and all purposes other than the research, development or commercialization of a Vaccine Product. In addition, MSD agrees not to sublicense its interest in any of the Patent Rights set forth in this Section 3.7.1 to a Company Competitor. |
3.7.2 | Company hereby grants to MSD an exclusive, sublicensable, non-royalty bearing, perpetual, irrevocable, worldwide license under Company Patent Rights, Company’s interest in any Joint Patent Rights that specifically and solely claim or cover the Selected Antigens, and Company Know-How that is specifically and solely related to the Selected Antigens for any and all purposes, including the research, development and commercialization of any vaccine. |
3.8 | No Implied Licenses. Except as specifically set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, in any Information disclosed to it under this Agreement or under any patents or patent applications owned or controlled by the other Party or its Affiliates. |
3.9 | No Grant of Inconsistent Rights by Company. Company (and its Affiliates) shall not assign, transfer, convey or otherwise grant to any Person or otherwise encumber (including through lien, charge, security interest, mortgage, encumbrance or otherwise) (i) any rights to any Company Know-How, Company Patent Rights or Joint Patent Rights (or any rights to any intellectual property that would otherwise be included in the Company Know-How, Company Patent Rights or Joint Patent Rights), in any manner that is inconsistent with or would interfere with the grant of the rights or licenses to MSD hereunder, or (ii) any rights to any Licensed Compounds or Licensed Products (other than as set forth herein). Without limiting the foregoing, during the Term, Company (and its Affiliates) shall not use (and shall not grant to any Third Party the right to use) any Licensed Compounds or Licensed Products for any purposes (including the development, manufacturing or commercialization thereof). |
18 |
EXECUTION COPY |
3.10 | Sublicenses. Subject to Section 2.2, each Party shall have the right to sublicense (through multiple tiers of sublicenses) any or all of the licenses granted to such Party hereunder. Each Party shall be responsible for ensuring that the performance by any of its sublicensees hereunder that are exercising rights under a sublicense hereunder is in accordance with the applicable terms of this Agreement, and the grant of any such sublicense shall not relieve the sublicensor Party of its obligations under this Agreement (except to the extent they are performed by any such sublicensee(s) in accordance with this Agreement). |
3.11 | Development and Commercialization. Following exercise of a License Option, if at all, MSD shall use Commercially Reasonable Efforts, at its own expense, to develop and commercialize a Licensed Product. MSD shall be solely responsible for the development and commercialization of Licensed Product in the Field in the Territory. Upon request from MSD, Company shall use Commercially Reasonable Efforts to assist MSD in securing regulatory approval from Regulatory Authorities for the Licensed Products in the Field in the Territory. |
3.12 | Manufacturing. |
3.12.1 | No later than [***], MSD will have the right to require Company, at Company’s sole cost and expense, to provide MSD (or an Affiliate of MSD) with a suitably detailed plan outlining a technology transfer process of Company’s manufacturing and CMC processes related to the Selected LBPs and/or Licensed Compound(s) and/or Licensed Product(s) (“Technology Transfer Plan”); any Technology Transfer Plan will take into account the timing required to complete such transfer process to MSD (or an Affiliate of MSD or a CMO acting on MSD’s behalf) in order to ensure continuity of supply of the Selected LBPs and/or Licensed Compound(s) and/or Licensed Product(s). The Parties will (i) cooperate with each other and work in good faith towards the implementation and achievement of the Technology Transfer Plan and (ii) discuss in good faith the sharing of any reasonable actual direct costs thereof, provided that any costs must be pre-agreed by MSD. |
3.12.2 | In addition to the Technology Transfer Plan, if requested by MSD, during the same period provided in Section 3.12.1, Company will use Commercially Reasonable Efforts to ensure it has sufficient stocks of Selected LBPs, Licensed Compound(s), or Licensed Product(s) (based on reasonable, good faith estimates provided by MSD) to ensure a continuous supply of such material in the event MSD exercises a License Option. In the event MSD does not exercise a License Option as described hereunder, MSD shall reimburse Company for pre-agreed actual direct and documented costs incurred, provided that the material manufactured under this section shall be divided equally between the Parties in order for each Party to exercise its research rights described hereunder. |
3.12.3 | For the avoidance of doubt, should MSD exercise a License Option hereunder, all decisions with respect to manufacturing and/or supply chain shall be at the sole discretion of MSD. |
3.13 | Excused Performance. In addition to the provisions of Section 9.1, the obligations of MSD with respect to any Licensed Product under Section 3.11 are expressly conditioned upon the continuing absence of any adverse condition or event relating to the safety or efficacy of the Licensed Product, and the obligation of MSD to develop or commercialize any such Licensed Product shall be delayed or suspended so long as in MSD’s opinion any such condition or event exists. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
19 |
EXECUTION COPY |
ARTICLE 4 CONFIDENTIALITY AND PUBLICATION.
4.1 | Nondisclosure Obligation. All Information disclosed by one Party to the other Party hereunder shall be maintained in confidence by the receiving Party and shall not be disclosed to any Third Party or used for any purpose except as set forth herein without the prior written consent of the disclosing Party, except to the extent that such Information: |
4.1.1 | is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records; |
4.1.2 | is in the public domain by use and/or publication before its receipt from the disclosing Party, or thereafter enters the public domain through no fault of the receiving Party; |
4.1.3 | is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the disclosing Party; |
4.1.4 | is developed by the receiving Party independently of Information received from the disclosing Party, as documented by the receiving Party’s business records; |
4.1.5 | is disclosed to governmental or other regulatory agencies in order to obtain patents or to gain or maintain approval to conduct clinical trials or to market Product, but such disclosure may be only to the extent reasonably necessary to obtain patents or authorizations; |
4.1.6 | is deemed necessary by MSD to be disclosed to Related Parties, agent(s), consultant(s), and/or other Third Parties for any and all purposes MSD and its Affiliates deem necessary or advisable in the ordinary course of business in exercising its rights or performing its obligations under this Agreement on the condition that such Third Parties agree to be bound by confidentiality and non-use obligations that substantially are no less stringent than those confidentiality and non-use provisions contained in this Agreement; or |
4.1.7 | is deemed necessary by counsel to the receiving Party to be disclosed to such Party’s attorneys, independent accountants or financial advisors for the sole purpose of enabling such attorneys, independent accountants or financial advisors to provide advice to the receiving Party, on the condition that such attorneys, independent accountants and financial advisors agree to be bound by the confidentiality and non-use obligations contained in this Agreement. |
Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party.
If a Party is required by judicial or administrative process (including a request for discovery received in an arbitration or litigation proceeding) to disclose Information that is subject to the nondisclosure provisions of this Section 4.1 or Section 4.2, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 4.1 and Section 4.2, and the Party disclosing Information pursuant to law or court order shall take all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such Information.
20 |
EXECUTION COPY |
4.2 | Company Know-How. During the Term, Company agrees to keep all Company Know-How created or conceived during the Research Program Term and resulting from the Research Program confidential. |
4.3 | Publication. |
4.3.1 | Neither Party shall publish results of the Research Program, if any, without the other Party’s prior written consent. Notwithstanding the foregoing, the Parties acknowledge and agree that (i) patent applications may be published by patent offices in which such filing is made, before the earlier of (x) MSD’s exercise of a License Option (if at all) and (y) expiration of the term of the Option Exercise Period, and (ii) all such applications and related disclosures will be conducted by the Parties in accordance with Article 7. |
4.3.2 | If MSD exercises a License Option, Company shall have no right to publish results of the Research Program and MSD shall have the right to publish results of such Research Program. Prior to a written publication or oral presentation of any such results, MSD shall deliver to Company a copy of the proposed written publication or an outline of an oral disclosure at least [***] prior to submission for publication or presentation. Company shall have the right to: (a) propose modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) request a reasonable delay in publication or presentation in order to protect patentable information for which MSD does not have filing rights in accordance with Article 7. If Company requests such a delay, MSD shall delay submission or presentation for a period of up to [***] as necessary to enable patent applications protecting Company’s rights in such information to be filed in accordance with Article 7. Upon expiration of such [***], MSD shall be free to proceed with the publication or presentation; provided, that if Company requests modifications to the publication or presentation, MSD shall edit such publication to prevent disclosure of trade secret or proprietary business information prior to submission of the publication or presentation. Provisions governing the filing of patent applications by the Parties, which may be published by patent offices in which such filing is made, if MSD exercises a License Option, are provided under Article 7 of this Agreement. |
4.4 | Publicity/Use of Names. No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except (a) as may be required by law including securities laws in connection with any registration of Company securities (provided, that, the disclosing party shall seek confidential treatment, or a protective order, as applicable, for the terms of the Agreement to the extent permitted by applicable laws and regulations as determined by such Party), (b) in confidence to its legal and financial advisors to the extent such disclosure is reasonably necessary in connection with such Party's activities in connection with this Agreement and (c) to any bona fide potential or actual financial investor or lender (but not including any corporate pharmaceutical venture groups), acquirer or merger partner for the sole purpose of evaluating an actual or potential investment, acquisition, merger or loan; provided, that, in each case, such disclosees are bound by written obligations of confidentiality consistent with the confidentiality obligations of this Agreement, and the disclosing Party shall be responsible for any breach by any such disclosee of the confidentiality obligations of this Agreement. Notwithstanding the foregoing, (i) to the extent Company is required by law in connection with the registration of any of its securities to make a disclosure, Company shall provide MSD with reasonable opportunity to review and comment on any such disclosure and shall consider such comments in good faith, in each case, prior to any such disclosure in connection with such registration and (ii) on or about the Effective Date, Company will issue a press release in the form attached hereto as Schedule 4.4 to announce the execution of this Agreement. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
21 |
EXECUTION COPY |
ARTICLE 5 PAYMENTS; ROYALTIES AND REPORTS
5.1 | Upfront Fee. In consideration for Company's performance of its obligations under the Research Program and the licenses granted to MSD hereunder, upon the terms and conditions contained herein, MSD shall pay Company a one-time, non-refundable upfront payment equal to two million five hundred thousand dollars ($2,500,000.00), payable within thirty (30) days after the Effective Date. |
5.2 | Equity Investment in Company Securities. Subject to the terms and conditions of the Stock Purchase Agreements, Company shall have the right to require MSD to purchase up to five million dollars ($5,000,000) of ordinary shares of capital stock of the Company within the twelve (12) month period immediately following the Effective Date. |
5.3 | Payments Upon Option Exercise (if any). This Section 5.3 shall apply only if MSD exercises a License Option pursuant to Section 3.1 of this Agreement. For each License Option for an individual program assigned a Response Outcome 3 which is exercised by MSD with respect to a Licensed Indication (up to three (3) in total), MSD shall pay to Company a one-time, nonrefundable payment of [***] (a “Response Outcome 3 Option Payment”) within [***] of the written notice contemplated thereby. For each License Option for an individual program assigned a Response Outcome 2 which is exercised by MSD with respect to a Licensed Indication (up to three (3) in total), MSD shall pay to Company a one-time, non-refundable payment of between [***] within [***] of the written notice contemplated thereby; provided, that (i) the foregoing payment range for a License Option for an individual program assigned a Response Outcome 2 represents a range (between [***]) that is based on the Response Outcome 3 Option Payment, (ii) once the specific single percentage that will be applied to such Response Outcome 3 Option Payment has been determined in accordance with Section 2.4.2 and (if applicable) Section 9.7.11, for each such License Option for an individual program assigned a Response Outcome 2, such percentage will be multiplied by the Response Outcome 3 Option Payment to determine the specific dollar amount to be paid following exercise by MSD of each applicable License Option for an individual program assigned a Response Outcome 2 and such dollar amount shall replace the applicable range of dollar amounts set forth above in this Section 5.3 |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
22 |
EXECUTION COPY |
5.4 | Milestone Payments. |
5.4.1 | The Parties acknowledge and agree that (i) there will be no more than three (3) License Options exercised by MSD (if any) under this Agreement and (ii) each Licensed Indication which is the subject of such Licensed Option (x) will be classified according to Schedule 1.54 as having either a Response Outcome 2 or Response Outcome 3 result and (y) will only be paid milestone payments in accordance with either Section 5.4.2 (Response Outcome 2) or Section 5.4.3 (Response Outcome 3). |
5.4.2 | Subject to the terms and conditions of this Agreement, in the event that MSD has exercised a License Option, MSD shall pay to Company the following one-time milestone payments in this Section 5.4.2, following the first occurrence for which MSD achieves the following milestone events for the first Licensed Product for a Licensed Indication that achieved a Response Outcome 2 (as applicable). For clarity, (i) the following milestone payments represent a range (between [***]) that is based on the milestone payment amount set forth opposite each corresponding Response Outcome 3 milestone under Section 5.4.3, (ii) once the specific single percentage that will be applied to each milestone payment in this Section 5.4.2 has been determined in accordance with Section 2.4.2 and (if applicable) Section 9.7.11, for each such milestone payment, such percentage will be multiplied by the corresponding Response Outcome 3 milestone payment set forth under Section 5.4.3 to determine the specific dollar amount to be paid for the achievement of each applicable Response Outcome 2 milestone event set forth below and such dollar amount shall replace the applicable range of dollar amounts set forth opposite each milestone event in this Section 5.4.2 and (iii) the following milestone payments shall be paid once per Licensed Indication and once the specific dollar amount that will be applied to all milestones payments in this Section 5.4.2 has been determined in accordance with the terms of this Agreement: |
(a) | Response Outcome 2 - Development and Regulatory Milestones |
Milestone Event | Milestone Payment | |||
Initiation of a Phase I Clinical Trial of a Licensed Product in a Licensed Indication. | $[***] | |||
Initiation of a Qualifying Phase II Clinical Trial of a Licensed Product in a Licensed Indication. | $[***] | |||
Initiation of a Phase III Clinical Trial of a Licensed Product in a Licensed Indication. | $[***] | |||
Marketing Authorization for a Licensed Product in [***] in a Licensed Indication. | $[***] |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
23 |
EXECUTION COPY |
Milestone Event | Milestone Payment | |||
Marketing Authorization for a Licensed Product in [***] of the Major Markets for a Licensed Indication. | $[***] | |||
Marketing Authorization for a Licensed Product in [***] for a Licensed Indication. | $[***] |
(b) | Response Outcome 2 - Sales Milestones |
Milestone Event | Milestone Payment | |||
The achievement of aggregate total of worldwide Net Sales of Licensed Products in any single Calendar Year of [***] or more but less than [***]. | $[***] | |||
The achievement of aggregate total of worldwide Net Sales of Licensed Products in any single Calendar Year of [***] or more but less than [***]. | $[***] | |||
The achievement of aggregate total of worldwide Net Sales of Licensed Products in any single Calendar Year of [***] or more but less than [***]. | $[***] | |||
The achievement of aggregate total of worldwide Net Sales of Licensed Products in any single Calendar Year of [***]. | $[***] |
(c) | MSD shall notify Company in writing within [***] following the achievement of each milestone set forth in Section 5.4.2(a) and (b). With respect to the achievement of a milestone under Section 5.4.2(a), MSD shall make the appropriate milestone payment within [***] after the achievement of such milestone. With respect to the achievement of a milestone under Section 5.4.2(b), MSD shall make the appropriate milestone payment within [***] after the close of the Calendar Quarter in which such milestone was achieved. The milestone payments set forth in this Section 5.4.2 shall be payable only upon the initial achievement of such milestone and no amounts shall be due hereunder for subsequent or repeated achievement of such milestone. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
24 |
EXECUTION COPY |
5.4.3 | Subject to the terms and conditions of this Agreement, in the event that MSD has exercised a License Option, MSD shall pay to Company the following [***] milestone payments in this Section 5.4.3, following the first occurrence for which MSD achieves the following milestone events for the first Licensed Product for a Licensed Indication that achieved a Response Outcome 3 (as applicable). For clarity, the following milestones shall be paid [***] per Licensed Indication: |
(a) | Response Outcome 3 - Development and Regulatory Milestones |
Milestone Event | Milestone Payment | |||
Initiation of a Phase I Clinical Trial of a Licensed Product in a Licensed Indication. | $[***] | |||
Initiation of a Qualifying Phase II Clinical Trial of a Licensed Product in a Licensed Indication. | $[***] | |||
Initiation of a Phase III Clinical Trial of a Licensed Product in a Licensed Indication. | $[***] | |||
Marketing Authorization for a Licensed Product in [***] in a Licensed Indication. | $[***] | |||
Marketing Authorization for a Licensed Product in [***] of the Major Markets for a Licensed Indication. | $[***] | |||
Marketing Authorization for a Licensed Product in [***] for a Licensed Indication. | $[***] |
(b) | Response Outcome 3 - Sales Milestones |
Milestone Event | Milestone Payment | |||
The achievement of aggregate total of worldwide Net Sales of Licensed Products in any single Calendar Year of [***] or more but less than [***]. | $[***] | |||
The achievement of aggregate total of worldwide Net Sales of Licensed Products in any single Calendar Year of [***] or more but less than [***]. | $[***] | |||
The achievement of aggregate total of worldwide Net Sales of Licensed Products in any single Calendar Year of [***] or more but less than [***]. | $[***] | |||
The achievement of aggregate total of worldwide Net Sales of Licensed Products in any single Calendar Year of [***]. | $[***] |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
25 |
EXECUTION COPY |
(c) | MSD shall notify Company in writing within [***] following the achievement of each milestone set forth in Section 5.4.3(a) and (b). With respect to the achievement of a milestone under Section 5.4.3(a), MSD shall make the appropriate milestone payment within [***] after the achievement of such milestone. With respect to the achievement of a milestone under Section 5.4.3(b), MSD shall make the appropriate milestone payment within [***] after the close of the Calendar Quarter in which such milestone was achieved. The milestone payments set forth in this Section 5.4.3 shall be payable only upon the initial achievement of such milestone and no amounts shall be due hereunder for subsequent or repeated achievement of such milestone. |
5.5 | Royalties. If MSD has exercised a License Option: |
5.5.1 | Royalties Payable By MSD. Subject to the terms and conditions of this Agreement, MSD shall pay Company royalties, calculated on a Licensed Product-by-Licensed Product and country-by-country basis, as set forth in this Section 5.5. |
(a) | Patent Royalties. Subject to the provisions of Section 5.5.1(b), MSD shall pay Company royalties in an amount equal to the following percentage of Net Sales of Licensed Products by MSD or its Related Parties where the sale of Licensed Product would infringe a Valid Patent Claim in the country of sale: |
(i) [***].
(b) | Know-How Royalty. Notwithstanding the provisions of Section 5.5.1(a), in countries where the sale of Licensed Product by MSD or its Related Parties would not infringe a Valid Patent Claim, MSD shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to 5.5.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.5.1(a). |
(c) | Royalty tiers pursuant to Section 5.5.1(a) and Section 5.5.1(b) shall be calculated based on worldwide Net Sales of each Licensed Product, provided, that the determination of whether the royalty shall be calculated under Section 5.5.1(a) or 5.5.1(b) shall be determined on a country-by-country basis. Royalties on each Licensed Product at the rates set forth above shall continue on a country-by-country basis until the expiration of the later of: (i) the last-to-expire Valid Patent Claim; or (ii) for a period of [***] after First Commercial Sale of such Licensed Product in such country (the “Royalty Period”). |
(d) | All royalties are subject to the following conditions: |
(i) [***]
5.5.2 | Change in Sales Practices. The Parties acknowledge that during the Term of this Agreement, MSD’s sales practices for the marketing and distribution of Licensed Product may change to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and reasonably discuss new ways of compensating Company to the extent currently contemplated under Section 5.5.1. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
26 |
EXECUTION COPY |
5.5.3 | Royalties for Bulk Licensed Compound. In those cases in which MSD or a Related Party sells bulk Licensed Compound rather than Licensed Product in packaged form to an independent Third Party, the royalty obligations of this Section 5.5 shall be applicable to the bulk Licensed Compound. |
5.5.4 | Compulsory Licenses. If a compulsory license is granted to a Third Party with respect to Licensed Compound or Licensed Product in any country in the Territory with a royalty rate lower than the royalty rate provided by Section 5.5.1, then the royalty rate to be paid by MSD on Net Sales in that country under Section 5.5.1 shall be reduced to the rate paid by the compulsory licensee. |
5.5.5 | Third Party Licenses. In the event that MSD has or obtains a license under, or other rights to, Patent Rights or know-how or other intellectual property from any Third Party(ies) that is necessary in order to research, develop, make, have made, use, import, offer to sell and/or sell Licensed Product(s) (hereinafter “Third Party Licenses”), [***] of any and all payments (including, without limitation, royalties and any payments for obtaining such right or license) actually paid under such Third Party Licenses by MSD or its Related Parties in connection with the manufacture, use, sale or import, as applicable, of Licensed Product(s) for a Calendar Quarter shall be creditable against the royalty payments due Company by MSD with respect to the sale of such Licensed Product in such Calendar Quarter. Notwithstanding the foregoing, in no event shall the royalties owed by MSD to Company for such Calendar Quarter be reduced by more than [***] pursuant to this Section 5.5.5 (provided, however, that if MSD is not able to fully recover the amounts paid by MSD or its Related Parties under any Third Party License as a result of the foregoing restriction, then MSD shall be entitled to carry forward such right of off-set to future Calendar Quarters with respect to such excess amount). At the request of MSD, Company shall provide reasonable assistance to MSD (or its Related Parties) in obtaining any such Third Party Licenses or otherwise taking action with respect Patent Rights or know -how or other intellectual property of any Third Party(ies) that may be necessary in order to research, develop, make, have made, use, import, offer to sell and/or sell Licensed Product(s). |
5.6 | Reports; Payment of Royalty. To the extent MSD exercises a License Option, if at all, following the First Commercial Sale of a Licensed Product, MSD shall furnish to Company a quarterly written report for the Calendar Quarter showing the Net Sales of all Licensed Products subject to royalty payments sold by MSD and its Related Parties in the Territory during the reporting period and the royalties payable under this Agreement. Reports shall be due on the [***] following the close of each Calendar Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. MSD shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
27 |
EXECUTION COPY |
5.7 | Audits. To the extent MSD exercises a License Option, if at all, following the First Commercial Sale of a Licensed Product: |
5.7.1 | Upon the written request of Company and not more than once in each Calendar Year, MSD shall permit an independent certified public accounting firm of nationally recognized standing selected by Company and reasonably acceptable to MSD, at Company’s expense, to have access during normal business hours to such of the records of MSD as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any Calendar Year ending not more than [***] prior to the date of such request. The accounting firm shall disclose to Company only whether the royalty reports are correct or incorrect and the amount of any discrepancy. No other information shall be provided to Company. |
5.7.2 | If such accounting firm correctly identifies a discrepancy made during such period, the appropriate Party shall pay the other Party the amount of the discrepancy within [***] of the date Company delivers to MSD such accounting firm’s written report so correctly concluding, or as otherwise agreed upon by the Parties.. The fees charged by such accounting firm shall be paid by Company; provided, however, that [***]. |
5.7.3 | MSD shall include in each sublicense granted by it pursuant to this Agreement a provision requiring the sublicensee to make reports to MSD, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by Company’s independent accountant to the same extent required of MSD under this Agreement. |
5.7.4 | Upon the expiration of [***] following the end of any Calendar Year, the calculation of royalties payable with respect to such Calendar Year shall be binding and conclusive upon Company, and MSD and its Related Parties shall be released from any liability or accountability with respect to royalties for such Calendar Year. |
5.7.5 | Company shall treat all financial information subject to review under this Section 5.7 or under any sublicense agreement in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with MSD and/or its Related Parties obligating it to retain all such information in confidence pursuant to such confidentiality agreement. |
5.8 | Payment Exchange Rate. All payments to be made by MSD to Company under this Agreement shall be made in United States dollars and may be paid by check made to the order of Company or bank wire transfer in immediately available funds to such bank account in the United States as may be designated in writing by Company from time to time. In the case of sales outside the United States, the rate of exchange to be used in computing the monthly amount of currency equivalent in United States dollars due Company shall be determined by MSD based on its then-current policies. All amounts and prices are exclusive of sales, use, GST, VAT, excise, and other taxes, duties or charges of a similar nature imposed by any federal, state, provincial, or local government, or other taxing authority. If any sales, use, GST, VAT, excise, and other taxes, duties or charges of a similar nature will be chargeable, MSD shall pay or, upon receipt of invoice from Company, shall reimburse these in addition to the sums otherwise payable, at the rate in force at the due time for payment or such other time as is stipulated under the relevant legislation. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
28 |
EXECUTION COPY |
5.9 | Income Tax Withholding. Company shall be liable for all income and other taxes (including interest) (“Taxes”) imposed upon any payments made by MSD to Company under this Article 5 (“Agreement Payments”). If applicable laws, rules or regulations require the withholding of Taxes, MSD shall make such withholding payments and shall subtract the amount thereof from the Agreement Payments. MSD shall submit to Company appropriate proof of payment of the withheld Taxes as well as the official receipts within a reasonable period of time. MSD shall provide Company reasonable assistance in order to allow Company to obtain the benefit of any present or future treaty against double taxation which may apply to the Agreement Payments. |
5.10 | Products Other Than Human Therapeutics. The Parties acknowledge and agree that the payments set forth in this Article 5 apply to products developed for use in humans. If MSD desires to develop or commercialize a product that incorporates Licensed Compound for use in non-humans, the Parties shall negotiate in good faith reduced milestone and royalty payments with respect to such products and MSD agrees not to develop or commercialize such a product until such reduced milestone and royalty payments have been agreed upon by Company and MSD. |
ARTICLE 6 REPRESENTATIONS AND WARRANTIES
6.1 | Representations and Warranties of Each Party. Each Party represents and warrants to the other Party that as of the Effective Date: |
6.1.1 | such Party is duly organized and validly existing under the laws of the state or jurisdiction of its organization and has full corporate right, power and authority to enter into this Agreement and to perform its obligations hereunder; |
6.1.2 | the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by the necessary corporate actions of such Party. This Agreement has been duly executed by such Party. This Agreement and any other documents contemplated hereby constitute valid and legally binding obligations of such Party enforceable against it in accordance with their respective terms, except to the extent that enforcement of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors; and |
6.1.3 | the execution, delivery and performance by such Party of this Agreement and any other agreements and instruments contemplated hereunder will not (i) in any respect violate any statute, regulation, judgment, order, decree or other restriction of any governmental authority to which such Party is subject, (ii) violate any provision of the corporate charter, by-laws or other organizational documents of such Party, or (iii) constitute a material violation or breach by such Party of any provision of any material contract, agreement or instrument to which such Party is a party or to which such Party may be subject although not a party. |
6.2 | Company Representations and Warranties. Company represents and warrants to MSD that as of the Effective Date: |
29 |
EXECUTION COPY |
6.2.1 | all Patent Rights within the Company Patent Rights are in full force and effect, and, to the best of Company’s knowledge, the Company Patent Rights and Company Know-How exist and are not invalid or unenforceable, in whole or in part; |
6.2.2 | it has the full right, power and authority to enter into this Agreement, to perform the activities hereunder, including the Research Program, and to grant the licenses granted hereunder (including under Article 3); |
6.2.3 | it (and its Affiliates) has not prior to the Effective Date (i) assigned, transferred, conveyed or otherwise encumbered its right, title and interest in Company Patent Rights or Company Know-How or (ii) entered into any agreements (written or oral) granting any licenses or rights to any Third Parties (a) relating to the LBPs, Company Patent Rights or Company Know-How or (b) that would conflict with the rights granted to MSD hereunder; |
6.2.4 | to the best of Company’s knowledge, it is the sole and exclusive owner of the Company Patent Rights and Company Know-How, all of which are (and shall be, in the case of Company Information and Inventions) free and clear of any liens, charges and encumbrances, and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership whatsoever with respect to the Company Patent Rights and Company Know-How; |
6.2.5 | neither it nor any of its Affiliates has received any written notification from a Third Party that the research, development, manufacture, use, sale or import of LBPs infringes or misappropriates the Patent Rights or know-how owned or controlled by such Third Party, and Company has no knowledge that a Third Party has any basis for any such claim; |
6.2.6 | Company has complied with all existing country-specific laws and regulations involving inventor remuneration associated with the Company Patent Rights, including Article 6 of the Third Amendment of Chinese Patent Law; |
6.2.7 | there are no claims, judgments or settlements against or owed by Company (or any of its Affiliates) and no pending or threatened claims or litigation relating to the Company Patent Rights and Company Know-How; |
6.2.8 | to the knowledge of Company after due inquiry, Company owns or controls (through licenses, grant of rights or other similar arrangements with Affiliates or Third Parties) all intellectual property necessary to perform its obligations under this Agreement; |
6.2.9 | Company has obtained all necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by it as of the Effective Date, as applicable, in connection with the execution, delivery and performance of this Agreement by Company; |
6.2.10 | Company (and its Affiliates) has not employed or otherwise used in any capacity, and wil not employ or otherwise use in any capacity, the services of any Person debarred under United States law, including under Section 21 USC 335a or any foreign equivalent thereof, in performing any portion of the Research Program; |
30 |
EXECUTION COPY |
6.2.11 | all research and development (including non-clinical studies and Clinical Trials (as applicable)) related to the LBPs prior to the Effective Date has been conducted in accordance with all applicable laws; |
6.2.12 | all information and data provided by or on behalf of Company to MSD on or before the Effective Date in contemplation of this Agreement is and was true, accurate and complete in all material respects at the time of disclosure, and Company has not disclosed, failed to disclose, or cause to be disclosed, any information or data that would reasonably be expected to cause the information and data that has been disclosed to be misleading in any material respect; and |
6.2.13 | it has or ensures that it will have the resources and capabilities to do the work contemplated by the Work Plan. |
6.3 | Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, PATENTS, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT, AND EACH PARTY HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. THE PARTIES ACKNOWLEDGE THAT ANY BIOLOGICAL MATERIAL PROVIDED BY ONE PARTY TO ANOTHER HEREUNDER, ARE PROVIDED “AS IS” WITH NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED. |
ARTICLE 7 PATENT PROVISIONS.
7.1 | Filing, Prosecution and Maintenance of Patents. |
7.1.1 | Company Patent Rights. |
(a) | MSD shall have the first right to file patent applications claiming Company Information and Inventions; provided that, following MSD’s selection of the final Selected LBP, MSD’s right to file patent applications claiming Company Information and Inventions shall be limited to Company Information and Inventions related to Selected LBPs, Licensed Compounds or Licensed Products or compositions, methods of use, or methods of manufacture thereof (“Company Product Related Inventions”). Company shall promptly disclose to MSD in writing the conception, creation and/or discovery of such Company Information and Inventions to which one or more patent applications may be filed. MSD shall give Company an opportunity to review the text of any patent application before filing, shall consult with Company with respect thereto, and shall supply Company with a copy of the application as filed, together with notice of its filing date and serial number. |
31 |
EXECUTION COPY |
(b) | MSD has the first right to prosecute and maintain in the Territory, upon appropriate consultation with Company, the Company Patent Rights licensed to MSD under this Agreement; provided that, following MSD’s selection of the final Selected LBP, MSD’s right to prosecute and maintain Company Patent Rights shall be limited to Company Patent Rights that claim or cover Company Product Related Inventions (“Company Product Related Patent Rights”). MSD shall keep Company advised of the status of the Company Patent Rights for which MSD is responsible for the prosecution and maintenance and, upon Company’s request, shall provide advance copies of any papers related to the prosecution and maintenance of such Company Patent Rights. MSD shall promptly give notice to Company of the grant, lapse, revocation, surrender, invalidation or abandonment of any Company Patent Rights for which MSD is responsible for the prosecution and maintenance. MSD shall give notice to Company of any desire to cease prosecution and/or maintenance of any Company Patent Rights for which MSD is responsible or abandon particular subject matter disclosed therein on a country-by-country basis in the Territory and, in such case, MSD shall permit Company, in its sole discretion, to continue prosecution or maintenance of such Company Patent Rights or maintain and prosecute patent applications that claim such subject matter at its own expense. MSD shall execute documents in a timely manner as may be reasonably necessary to allow Company to continue such prosecution or maintenance, including filing patent applications that claim such subject matter to be abandoned. |
(c) | Following MSD’s selection of the final Selected LBP, Company has the first right to file, prosecute and maintain in the Territory, upon appropriate consultation with MSD, the Company Patent Rights licensed to MSD under this Agreement that are not Company Product Related Patent Rights. Company shall keep MSD advised of the status of the such Company Patent Rights and, upon MSD’s request, shall provide advance copies of any papers related to the prosecution and maintenance of such Company Patent Rights. Company shall give MSD an opportunity to review the text of any patent application before filing, and shall consult with MSD with respect thereto; provided that Company shall have final say on any subject matter in any application except for subject matter that affects, or could reasonably be expected to affect Inventions that are Selected LBPs, and/or Licensed Compound and/or Licensed Products, or compositions, methods of use, or methods of manufacture thereof. Company shall promptly give notice to MSD of the grant, lapse, revocation, surrender, invalidation or abandonment of any Company Patent Rights for which Company is responsible for the prosecution and maintenance. Company shall give notice to MSD of any desire to cease prosecution and/or maintenance of any Company Patent Rights for which Company is responsible or abandon particular subject matter disclosed therein on a country-by-country basis in the Territory and, in such case, Company shall permit MSD, in its sole discretion, to continue prosecution or maintenance of such Company Patent Rights or maintain and prosecute patent applications that claim such subject matter to be abandoned at its own expense. Company shall execute documents in a timely manner as may be reasonably necessary to allow MSD to continue such prosecution or maintenance, including filing patent applications that claim such subject matter to be abandoned. |
7.1.2 | Joint Patent Rights. MSD shall have the first right to file, prosecute, and maintain patents and patent applications claiming Joint Information and Inventions. MSD shall keep Company advised of the status of any actual and prospective patent filings and upon Company’s request, shall provide advance copies of any papers related to the filing of Joint Information and Inventions and the prosecution and maintenance of Joint Patent Rights. |
32 |
EXECUTION COPY |
MSD shall give notice to Company of any desire to cease prosecution and/or maintenance of Joint Patent Rights or abandon any particular subject matter disclosed therein on a country-by-country basis in the Territory and, in such case, shall permit Company, in its sole discretion, to continue prosecution or maintenance of such Joint Patent Rights or maintain and prosecute patent applications that claim such subject matter to be abandoned at its own expense. If Company elects to continue prosecution or maintenance of such Joint Patent Rights, MSD shall execute documents in a timely manner as may be reasonably necessary to allow Company to continue such prosecution or maintenance, including filing patent applications that claim such subject matter to be abandoned.
7.1.3 | Patent Term Extension. The Parties shall cooperate fully with each other to provide necessary information and assistance, as the other Party may reasonably request, in obtaining patent term extension or supplemental protection certificates or their equivalents in any country in the Territory where applicable to Company Patent Rights and Joint Patent Rights. In the event that elections with respect to obtaining such patent term extension are to be made, MSD shall have the right to make the election and Company agrees to abide by such election. |
7.1.4 | Other Cooperation. The Parties agree to cooperate fully and provide any information and assistance that either may reasonably request for the filing, prosecution and maintenance of Company Patent Rights and Joint Patent Rights. The Parties further agree to take reasonable actions to maximize the protections available under the safe harbor provisions of 35 U.S.C. 102(c) for U.S. patents and patent applications. |
7.1.5 | Filing, Prosecution and Maintenance Expenses. With respect to all filing, prosecution and maintenance activities under this Section 7.1, the filing and/or prosecuting Party shal be responsible for payment of all costs and expenses related to such activities. |
7.1.6 | Inventor Remuneration. Company shall comply with all applicable country-specific inventor remuneration laws and regulations, including Article 6 of the Third Amendment of Chinese Patent Law associated with Company Patent Rights and Joint Patent Rights when inventor remuneration obligations are triggered by an employee of Company and/or its Affiliates, or a Third Party acting on behalf of Company and/or its Affiliates. |
7.2 | Interference, Derivation, Opposition, Reexamination, Reissue, Supplemental Examination, Inter Partes Review and Post-Grant Review Proceedings. |
7.2.1 | Third Party Initiated Proceedings. Each Party shall, within [***] of learning of such event, inform the other Party of any request for, or filing or declaration of, any interference, derivation proceeding, opposition, reexamination requested by a Third Party, inter partes review, post-grant review or similar contested administrative proceeding involving a Third Party relating to Company Product Related Patent Rights or Joint Patent Rights. MSD and Company shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding. MSD shall have the first right to control such proceedings with respect to Company Product Related Patent Rights or Joint Patent Rights, and Company shall have the right to review and approve any submission to be made in connection with such proceeding, which approval will not be unreasonably withheld or delayed provided that Company shall have final say on any actions or proceedings that affect, or could reasonably be expected to affect Company's use and/or exploitation of the Company Information and Inventions, Company Know-How and/or Company Patent Rights. In the event that MSD chooses not to initiate a proceeding under this Section 7.2.1, Company shall have the right and discretion to initiate such proceedings. The initiating Party shall have the first right to control such proceedings. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
33 |
EXECUTION COPY |
7.2.2 | Party Initiated Proceedings. MSD shall have the first right to initiate a reexamination, supplemental examination, reissue or similar administrative proceeding relating to Company Product Related Patent Rights or Joint Patent Rights. Notwithstanding the foregoing, MSD shall not initiate any such proceeding without the prior written consent of Company, which consent shall not be unreasonably withheld or delayed. Company shall have the right to review and approve any submission to be made in connection with such proceeding, which approval will not be unreasonably withheld or delayed. If there is disagreement regarding whether a reexamination, supplemental examination, reissue or similar administrative proceeding relating to Company Product Related Patent Rights or Joint Patent Rights should be initiated, such disagreement shall be referred to the senior intellectual property officers of the Parties. In the event that these two executives do not, after reasonable good faith efforts, reach agreement, the resolution and/or course of conduct shall be determined by MSD. In the event that MSD chooses not to initiate a proceeding under this Section 7.2.2, Company shall have the right to initiate such proceeding. The initiating Party shall have the first right to control such proceedings. |
7.2.3 | Cooperation. In connection with any administrative proceeding under Section 7.2.1 or 7.2.2, MSD and Company shall cooperate fully and provide each other with any information or assistance that either may reasonably request. The Parties shall keep each other informed of developments in any such action or proceeding, including the status of any settlement negotiations and the terms of any offer related thereto. For any proceeding not controlled by MSD, Company shall obtain prior approval from MSD of any settlement offer or settlement agreement. |
7.2.4 | Expenses. The Party controlling any administrative proceeding pursuant to Section 7.2.1 and 7.2.2 shall bear all expenses related thereto. |
7.3 | Enforcement and Defense. |
7.3.1 | The Parties shall give notice to each other of either (i) any infringement of Company Product Related Patent Rights or Joint Patent Rights, or (ii) any misappropriation or misuse of Company Know-How or Joint Information and Inventions, that may come to its attention. MSD and Company shall thereafter consult and cooperate fully to determine a course of action, including but not limited to the commencement of legal action by either or both MSD and Company, to terminate any infringement of Company Product Related Patent Rights or Joint Patent Rightsor any misappropriation or misuse of Company Know-How or Joint Information and Inventions. MSD, upon notice to Company, shall have the first right to initiate and prosecute such legal action at its own expense and in the name of MSD and/or Company, or to control the defense of any declaratory judgment action relating to Company Product Related Patent Rights or Joint Patent Rights or Company Know-How or Joint Information and Inventions. Each Party shall have the right to be represented by counsel of its own choice. |
34 |
EXECUTION COPY |
7.3.2 | MSD shall promptly inform Company if it elects not to exercise its first right under Section 7.3.1 to initiate and prosecute legal action, and Company shall thereafter have the right and the discretion to either initiate and prosecute such action or to control the defense of such declaratory judgment action in the name of Company and, if necessary, MSD. If Company elects to do so, the costs of any agreed-upon course of action to terminate infringement of Company Product Related Patent Rights or Joint Patent Rights or misappropriation or misuse of Company Know-How or Joint Information and Inventions, including without limitation the costs of any legal action commenced or the defense of any declaratory judgment, shall be paid by Company. Each Party shall have the right to be represented by counsel of its own choice. |
7.3.3 | For any action to terminate any infringement of Company Product Related Patent Rights or Joint Patent Rights or any misappropriation or misuse of Company Know-How or Joint Information and Inventions, in the event that a Party is unable to initiate or prosecute such action solely in its own name, the other Party will join such action voluntarily and will execute and cause its Affiliates to execute all documents necessary for the Party to initiate litigation to prosecute and maintain such action under this Section 7.3. In connection with any action or potential action, MSD and Company will cooperate fully and will provide each other with any information or assistance that either may reasonably request, including cooperating with regard to any pre-litigation review of the Company Product Related Patent Rights or Joint Patent Rights. Each Party shall keep the other informed of developments in any action or proceeding provided that Company shall have final say on any action or proceedings that affects, or could reasonably be expected to affect Company's use and/or exploitation of the Company Information and Inventions, Company Know -How and/or Company Patent Rights for uses outside the scope of the provisions set forth in the Agreement. For any proceeding not controlled by MSD, Company shall obtain prior approval from MSD of any settlement offer or settlement agreement. |
7.3.4 | Any recovery obtained by either or both MSD and Company in connection with or as a result of any action contemplated by this Section 7.3, whether by settlement or otherwise, shall be shared in order as follows: |
(a) | the Party which initiated and prosecuted the action shall recoup all of its costs and expenses incurred in connection with the action; |
(b) | the other Party shall then, to the extent possible, recover its costs and expenses incurred in connection with the action; and |
(c) | the amount of any recovery remaining shall then be allocated between the Parties on a pro rata basis taking into consideration the relative economic losses suffered by each Party. |
35 |
EXECUTION COPY |
7.3.5 | Each Party shall inform the other Party of any certification regarding any Joint Patent Rights it has received pursuant to either 21 U.S.C. §§355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV), or its successor provisions or any similar provisions in a country in the Territory other than the United States, and shall provide a copy of such certification within [***] of receipt. MSD has the first right to initiate and prosecute any legal action as a result of such certification; provided, however, that MSD shall inform Company of such decision to initiate such action within [***] of receipt of the certification, after which time Company shall have the right to initiate and prosecute such action. Regardless of which Party has the right to initiate and prosecute such action, both Parties shall, as soon as practicable after receiving notice of such certification, convene and consult with each other regarding the appropriate course of conduct for such action. The non-initiating Party shall have the right to be kept fully informed and participate in decisions regarding the appropriate course of conduct for such action, and the right to join and participate in such action. Company’s and MSD’s rights and obligations with respect to the prosecution of any legal action as a result of such certification and any recovery obtained as a result of such legal action shall be as defined in Sections 7.3.3 and 7.3.4 |
Company shall inform MSD of any matter of which it becomes aware concerning the submission of an application to the U.S. Food & Drug Administration under Section 351(k) of the U.S. Public Health Services Act (42 USC 262(k)), or to a similar agency under any similar provisions in a country in the Territory, seeking approval of a biosimilar or interchangeable biological product with regard to which MSD is a reference product sponsor involving Company Product Related Patent Rights or Joint Patent Rights (“Biosimilar Application”). Company shall provide MSD with the unopened Biosimilar Application within three (3) days of receipt. Notwithstanding the foregoing provisions of Section 7.3, MSD shall have the sole right, in its discretion, to control any legal action and any activity taken to resolve a Dispute with respect to any infringement of Company Product Related Patent Rights or Joint Patent Rights with respect to any Biosimilar Application, including selection of any patents for listing under 42 U.S.C. §262(l), and Company shall have no rights in connection therewith. For any action with respect to any infringement of Company Product Related Patent Rights or Joint Patent Rights with respect to any Biosimilar Application, in the event that MSD is unable to initiate or prosecute such action solely in its own name, Company will join such action voluntarily and will execute and cause its Affiliates to execute all documents necessary for MSD to initiate, prosecute and maintain such action. In connection with any action, Company shall cooperate with MSD and provide MSD with information and assistance that MSD may reasonably request, including as defined in Section 7.3.3.
7.4 | Patent Committee. The Parties hereby establish a committee to facilitate the filing, prosecution and maintenance of Company Patent Rights, MSD Patent Rights, and Joint Patent Rights as follows: |
7.4.1 | Establishment. Within [***] after the Effective Date, the Parties shall establish a patent committee (the “Patent Committee”) to discuss, oversee and coordinate the filing, prosecution, maintenance and enforcement of Company Patent Rights, MSD Patent Rights, and Joint Patent Rights in accordance with Section 7.1; and defense against claims of infringement of Third Party patents related to the intellectual property licensed or practiced under this Agreement. The Patent Committee will provide recommendations to the Parties regarding the filing, prosecution, maintenance and enforcement of the Company Patent Rights, MSD Patent Rights, or Joint Patent Rights, Company Information and Inventions, MSD Information and Inventions, or Joint Information and Inventions and related intellectual property matters, including coordinating patent strategy to ensure that strong patent rights are obtained for the mucosal vaccines to be developed. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
36 |
EXECUTION COPY |
7.4.2 | Membership; Meetings. The Patent Committee shall be composed of one (1) employee from each of MSD and Company knowledgeable in patent law and the technology areas that are the subject of this Agreement. The Patent Committee shall meet, by teleconference, or by video-teleconference, at least one (1) time per Calendar Quarter, or more or less often as the Parties shall determine. The first such meeting shall be within [***] after the Effective Date. Any member of the Patent Committee may designate a substitute, who shal be an employee of the applicable Party, to attend with prior written notice to the other Party. Ad hoc guests who are subject to written confidentiality obligations at least as stringent as the provisions in Article 4 may be invited to Patent Committee meetings. Each Party may replace its Patent Committee members with other of its employees with the qualifications set forth in this Section 7.4.2, at any time, upon written notice to the other Party. |
7.4.3 | Recommendations; Limitations on Patent Committee. Recommendations of the Patent Committee shall be made by consensus, with each Party having collectively one (1) vote in all decisions. The Patent Committee shall have only such powers as are specifically delegated to it in this Agreement and such powers shall be subject to the terms and conditions set forth herein. Without limiting the generality of the foregoing, the Patent Committee shall have no power to amend this Agreement, the Research Programs or any written Research plan. Recommendations where the Patent Committee is unable to reach a consensus are determined as follows: |
(a) | Decision Making Authority. Subject to the terms of Article 7, MSD shall have final decision-making authority with respect to any Dispute relating specifically to (i) Joint Information and Inventions, including all Joint Patent Rights associated therewith, (ii) Company Product Related Inventions, including all Company Product Related Patent Rights and (iii) MSD Information and Inventions, including all MSD Patent Rights associated therewith. |
(b) | Disputes. The Patent Committee shall seek to resolve Disputes concerning recommendations on all other Company Patent Rights licensed to MSD under this Agreement. If the Patent Committee is unable to reach a consensus recommendation on a matter that relates to the Company Patent Rights licensed to MSD under this Agreement within [***] after it has met and attempted to reach such recommendation, then either Party may refer such matter for resolution in accordance with Sections 9.7.1 and 9.7.9. |
7.4.4 | Updates. The Patent Committee shall provide status updates to the Committee periodically as agreed to by the Parties for as long as the Committee is in existence and, thereafter, to the Parties. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
37 |
EXECUTION COPY |
7.4.5 | Duration of Patent Committee. The Patent Committee shall endure for the Term and, by mutual agreement, beyond the Term. |
7.5 | MSD Patent Rights, MSD Know-How and MSD Information and Inventions. Notwithstanding anything to the contrary in this Agreement, MSD shall have the sole right and discretion to (i) file, prosecute and maintain any MSD Patent Rights in the Territory; and (ii) enforce any MSD Patent Rights, and protect against any misappropriation or misuse of MSD Information and Inventions and MSD Know-How in the Territory. |
ARTICLE 8 TERM AND TERMINATION
8.1 | Term and Expiration. This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Sections 8.2 or 8.3, this Agreement shall continue in full force and effect until the expiration of the later of: [***] (the “Term”). Upon expiration of the Term (provided MSD has exercised a License Option during the Option Exercise Period), MSD's licenses pursuant to Sections 3.3 and 3.6 shall become fully paid-up, royalty-free, irrevocable and perpetual, exclusive and sublicensable licenses. |
8.2 | Termination due to License Option Expiration; Termination by MSD other than for Cause. |
8.2.1 | Termination by MSD. MSD shall have the right to terminate this Agreement at any time in its sole discretion by giving [***] advance written notice to Company. For the avoidance of doubt, termination by MSD under this Section 8.2 can be effected only through a written notice specifically referring to this Section. |
8.2.2 | Termination due to License Option Expiration. If MSD does not exercise a License Option on or before the end of the Option Exercise Period, this Agreement shall terminate automatically with no further action of the Parties. |
8.2.3 | Effect of Termination under Section 8.2. |
(a) | No later than [***] after the effective date of termination under this Section 8.2, each Party shall return or cause to be returned to the other Party all Information in tangible form received from the other Party and all copies thereof; provided, however, that each Party may retain any Information reasonably necessary for such Party’s continued practice under any license(s) which do not terminate pursuant to this Section 8.2, and may keep one copy of Information received from the other Party in its confidential files for record purposes or to demonstrate compliance with its obligations, or assert its rights, under this Agreement; and further, provided, that a Party shall not be required to erase electronic files created in the ordinary course of business during automatic system back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information so long as such electronic files are (i) maintained only on centralized storage servers (and not on personal computers or devices), (ii) not accessible by any of its personnel (other than its information technology specialists), and (iii) are not otherwise accessed subsequently except with the written consent of the other Party or as required by law or legal process. Such retained copies of Information shall remain subject to the confidentiality and non-use obligations herein. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
38 |
EXECUTION COPY |
(b) | In the event of any termination under this Section 8.2: (i) each Party shall pay all amounts then due and owing as of the termination date; and (ii) except for the surviving provisions set forth in Section 8.4 and as otherwise set forth in this Section 8.2.3, the rights and obligations of the Parties hereunder shall terminate as of the date of such termination. |
(c) | In the event of a termination under this Section 8.2 following exercise of a License Option, if at all: |
(i) | MSD shall have a fully paid-up non-exclusive license to use Company Information and Inventions and Company’s interest in Joint Information and Inventions for internal research purposes only; |
(ii) | MSD and its Affiliates, sublicensees and distributors shall be entitled, during the [***] period immediately following the effective date of termination, to finish any work-in-progress and to sell any Licensed Compound or Licensed Product remaining in inventory, in accordance with the terms of this Agreement. |
8.3 | Termination for Cause. |
8.3.1 | Cause for Termination. This Agreement may be terminated at any time during the Term of this Agreement: |
(a) | upon written notice by either Party if the other Party is in breach of its material obligations hereunder by causes and reasons within its control and has not cured such breach within [***] days after notice requesting cure of the breach; provided, however, in the event of a good faith Dispute with respect to the existence of a material breach, the [***] day cure period shall be tolled until such time as the Dispute is resolved pursuant to Section 9.7; and provided, further, that any cure period shall apply solely to the extent such breach is capable of cure; or |
(b) | by either Party upon the occurrence of an Insolvency Event or filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing thereof. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
39 |
EXECUTION COPY |
8.3.2 | Effect of Termination for Cause. |
(a) | No later than thirty (30) days after the effective date of termination under this Section 8.3, each Party shall return or cause to be returned to the other Party all Information in tangible form received from the other Party and all copies thereof; provided, however, that each Party may retain any Information reasonably necessary for such Party’s continued practice under any license(s) which do not terminate pursuant to this Section 8.3, and may keep one copy of Information received from the other Party in its confidential files for record purposes or to demonstrate compliance with its obligations, or assert its rights, under this Agreement; and further, provided, that a Party shall not be required to erase electronic files created in the ordinary course of business during automatic system back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information so long as such electronic files are (i) maintained only on centralized storage servers (and not on personal computers or devices), (ii) not accessible by any of its personnel (other than its information technology specialists), and (iii) are not otherwise accessed subsequently except with the written consent of the other Party or as required by law or legal process. Such retained copies of Information shall remain subject to the confidentiality and non-use obligations herein. |
(b) | Except for the surviving provisions set forth in Section 8.4 and as otherwise set forth in this Section 8.3.2, the rights and obligations of the Parties hereunder shall terminate as of the date of a termination under Section 8.3. |
(c) | If MSD terminates this Agreement under Section 8.3.1(a) prior to exercise of a License Option, effective as of the date of termination, Company hereby assigns to MSD its right, title and interest in and to (i) the Company Information and Inventions and the Joint Information and Inventions and (ii) all LBPs that were the subject of and included in the Research Program. In lieu of such termination, however, MSD may, in its sole discretion, not terminate, in which case, upon exercise of a License Option, if at all, any and all payments upon exercise of a License Option, milestones and royalties payable pursuant to Sections 5.3, 5.4 and 5.5 shall be reduced by [***]. |
(d) | If MSD terminates this Agreement under Section 8.3.1(a) after exercise of a License Option, if at all, effective as of the date of termination, Company hereby assigns to MSD its right, title and interest in and to (i) the Company Information and Inventions and the Joint Information and Inventions that arose out of and were the subject of the License Option exercised by MSD and (ii) all LBPs that were the subject of and included in the Research Program. |
(e) | If Company terminates this Agreement under Section 8.3.1(a) prior to exercise of a License Option, MSD hereby grants to Company, effective as of the date of termination, a non-exclusive license under MSD’s interest in (x) Joint Information and Inventions, (y) MSD Information and Inventions and (z) Patent Rights claiming each of the foregoing for all purposes; provided, that in the event of such termination, MSD shall not, for a period of [***] following the effective date of such termination, clinically develop Vaccine Product for an Indication. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
40 |
EXECUTION COPY |
(f) | If Company terminates this Agreement under Section 8.3.1(a) after exercise of a License Option, if at all, effective as of the date of termination, MSD and its Affiliates, sublicensees and distributors shall be entitled, during the [***] period immediately following the effective date of termination, to finish any work-in-progress and to sell any Licensed Compound or Licensed Product remaining in inventory, in accordance with the terms of this Agreement. |
(g) | In the event that this Agreement is terminated by MSD under Section 8.3.1(b) due to the rejection of this Agreement by or on behalf of Company due to an Insolvency Event, all licenses and rights to licenses granted under or pursuant to this Agreement by Company to MSD are and shall otherwise be deemed to be licenses of rights to “intellectual property”. The Parties agree that MSD, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under any applicable insolvency statute, and that upon commencement of an Insolvency Event by or against Company, MSD shall be entitled to a complete duplicate of or complete access to (as MSD deems appropriate), any such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments thereof shal be promptly delivered to MSD (i) upon any such commencement of a bankruptcy proceeding upon written request therefore by MSD, unless Company elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of Company upon written request therefore by Company. The provisions of this Section 8.3.2(g) shall be (i) without prejudice to any rights MSD may have arising under any applicable insolvency statute or other applicable law and (ii) effective only to the extent permitted by applicable law. |
8.4 | Effect of Expiration or Termination; Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including without limitation the obligation to pay royalties for Licensed Compounds or Licensed Product(s) sold prior to such expiration or termination. The provisions of Article 4 shall survive the expiration or termination of this Agreement and shall continue in effect for [***]. In addition, the provisions of Article 1, Article 7, Article 8 and Article 9, and Sections 2.8, 3.4, 3.7, and 3.10 shall survive any expiration or termination of this Agreement. |
ARTICLE 9 MISCELLANEOUS
9.1 | Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including, but not limited to, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, cyberattacks, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
41 |
EXECUTION COPY |
9.2 | Assignment; Change of Control. |
9.2.1 | Assignment. Except as provided in this Section 9.2.1, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party; provided, however, that MSD may, without such consent, assign, in whole or in part, this Agreement and its rights and obligations hereunder to an Affiliate or in connection with the transfer or sale of all or substantially all of its assets related to the subject matter of this Agreement, or in the event of its merger or consolidation or change in control or similar transaction. Any attempted assignment not in accordance with this Section 9.2.1 shall be void. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. |
9.2.2 | Change of Control. Upon a Change of Control of Company: (i) Company shall adopt reasonable procedures to be agreed upon in writing with MSD to prevent the disclosure of all information of MSD and its Affiliates and other information with respect to development and commercialization of Licensed Compounds and Licensed Products and conduct any activities under the Research Program separately from all of its other activities and its Affiliates’ activities, including the maintenance of separate lab notebooks and records; (ii) Company shall establish reasonable firewall protections and safeguards designed to ensure the activities of its personnel under, if any, the Research Program are segregated from all other activities. |
Any attempted assignment not in accordance with this Section 9.2 shall be void. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.
9.3 | Use of Affiliates. MSD shall have the right to exercise its rights and perform its obligations under this Agreement either itself or through any of its Affiliates. |
9.4 | Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. |
42 |
EXECUTION COPY |
9.5 | Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if (a) delivered personally, (b) sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), (c) sent by nationally-recognized overnight courier, (d) sent by registered or certified mail, postage prepaid, return receipt requested, or (e) in the case of notice to MSD, delivered by electronic mail followed by delivery via one of the foregoing methods, in each case addressed as follows: |
if to Company, to: | [***] |
and: | [***] |
if to MSD, to: | [***] |
With a copy (which shall not constitute notice) to: | [***] |
or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile or, in the case of MSD, emailed on a business day (or if delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail. The Parties hereby agree that, to the extent permitted by law, any notice provided in accordance with this Section 9.5 shall constitute due service of process with respect to any legal proceeding between the Parties arising hereunder and that compliance with the Hague Convention for the Service of Process, if otherwise applicable, shall not be required.
9.6 | Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of England and Wales without reference to any rules of conflict of laws or renvoi. |
9.7 | Dispute Resolution. |
9.7.1 | The Parties shall negotiate and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the breach thereof (a “Dispute”). Any Party shall give the other Party written notice of any Dispute not resolved in the normal course of business. Within twenty (20) days from the date of delivery of such notice, the receiving Party shall submit to the other Party a written response. The notice and response shall include (A) a statement of that Party's position and a summary of arguments supporting that position, and (B) the name and title of the executive who will represent that Party and of any other person who will accompany the executive. Within [***] days from the date of delivery of the initial notice, executives of both Parties shall meet at a mutually acceptable time and place, and thereafter as often as they reasonably deem necessary, to attempt to resolve the Dispute. These executives shall have the authority to settle the Dispute and shall be at a higher level of management than the persons with direct responsibility for administration of this Agreement. All negotiations pursuant to this paragraph are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
43 |
EXECUTION COPY |
9.7.2 | If the Parties do not fully settle following the procedure in Section 9.7.1, and a Party wishes to pursue the matter, each Dispute that is not an “Excluded Claim” (as defined below) shall be finally resolved by binding arbitration in accordance with the Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association (“AAA”), except that, unless the Parties agree otherwise: |
(1) the arbitration panel will be guided by the Parties’ decision to use arbitration as a less expensive and more expeditious alternative to litigation, and shall order only such pre-hearing exchanges of information as will facilitate fair, speedy and cost-effective resolution;
(2) no interrogatories may be permitted;
(3) production of documents shall be limited to those which are relevant to the Dispute;
(4) (i) the arbitration panel shall permit discovery depositions only upon good cause shown and consistent with the expedited nature of arbitration, and only from such persons who may possess information determined by the arbitrator(s) to be necessary to the determination of the matter; (ii) absent exceptional circumstances, no party may take more than four (4) discovery depositions of fact witnesses and three (3) discovery depositions of expert witnesses; (iii) no corporate designee depositions are permitted;
(5) absent exceptional circumstances, the arbitration hearing shall take no more than five (5) days and each side shall be permitted no more than fifteen (15) hours to present its case (including conducting any cross-examination);
(6) the arbitrators may hear and decide pre-discovery and post-discovery dispositive motions;
(7) the arbitrators shall issue a written award that contains a reasoned opinion setting forth the findings of fact and conclusions upon which the award is based, including the calculation of any damages awarded;
44 |
EXECUTION COPY |
(8) absent exceptional circumstances, the time between the service of the initial arbitration claim and the issuance of the arbitration award shall not exceed one (1) year; and
(9) the arbitrators shall take appropriate actions to prevent, remediate, and/or sanction abusive conduct or other actions that threaten to undermine the fair, speedy and cost-effective resolution of the matter.
9.7.3 | The arbitration shall be conducted by a panel of three (3) persons with relevant experience. The arbitrators will be selected as follows: The AAA will provide the Parties with a list of no less than fifteen (15) proposed arbitrators within five (5) business days of receipt of the notice of arbitration. Within ten (10) business days of receiving such list, the Parties shal identify which if any of the proposed arbitrators they strike for cause. Each Party will also be entitled to two (2) peremptory challenges to the list of proposed arbitrators, which shall be identified at the same time as any strikes for cause. Within three (3) business days of receipt of any challenges, each Party shall select one arbitrator from the remaining proposed arbitrators. The two (2) Party-selected arbitrators shall within two (2) business days select the third (3rd) Arbitrator from the list of remaining arbitrators. The third (3rd) arbitrator shall be the Lead Arbitrator. If both Parties initially select the same arbitrator, that arbitrator shall be the Lead Arbitrator. Within two (2) business days thereafter, the Parties shall then each select another arbitrator from the remaining proposed arbitrators. At no point during the selection process may any Party have direct communication with any proposed arbitrator, nor shall the Party-selected arbitrators be advised which Party selected them. All arbitrators must consent to abide by the provisions in Section 9.7.2 prior to their appointment. The place of arbitration shall be New York, New York, and all proceedings and communications shall be in English. |
9.7.4 | The arbitrators shall have no power to grant interim or permanent injunctive relief. Notwithstanding anything contained in this Agreement to the contrary, each Party shall have the right to institute judicial proceedings against the other Party, or anyone acting by, through or under such other Party, in order to seek specific performance, injunction or similar equitable relief. |
9.7.5 | Each Party shall bear its own costs and expenses and attorneys' fees and an equal share of the arbitrators' fees and any administrative fees of arbitration. |
9.7.6 | Neither a Party nor an arbitrator may disclose the existence, results or content of an arbitration (including any testimony, briefs, documents exchanged, written decisions, or other arbitration-related materials) without the prior written consent of both Parties, except to the extent required by law, or to the extent required by a Party to solicit expert advice or communicate with third parties believed to possess relevant information. Any Party seeking to confirm, modify, or vacate an award, or seeking enforcement of an award, shall, to the extent consistent with the law and ethical legal practice, request judicial relief to preserve the confidentiality of the arbitration to the greatest extent practicable. |
9.7.7 | In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the Dispute would be barred by the applicable statute of limitations under the laws of England and Wales consistent with Section 9.6. |
45 |
EXECUTION COPY |
9.7.8 | The Parties agree that, in the event of a good faith Dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the Dispute through arbitration or other judicial determination. The Parties further agree that any payments made pursuant to this Agreement pending resolution of the Dispute shall be refunded if an arbitrator or court determines that such payments are not due. |
9.7.9 | As used in this Section, the term “Excluded Claim” shall mean a dispute, controversy or claim that concerns (a) a decision by the Committee (other than a Dispute related to the matter set forth in Section 9.7.11), Patent Committee or MSD within the proper scope of the Committee’s or Patent Committee’s authority pursuant to Sections 2.4 and 7.4, or an issue concerning the integrity of data submitted to a regulatory agency, neither of which shall be arbitrable or justiciable in any forum; (b) the validity or infringement of a patent, trademark or copyright; or (c) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. Any action concerning Excluded Claims identified in clauses (b) and (c) of this Paragraph may be brought in any court having jurisdiction. |
9.7.10 | Any action seeking to confirm, vacate, or modify the arbitration award shall be brought exclusively in the federal court for the District of New Jersey, if federal jurisdiction is available, or, alternatively, in the state courts in Union County, New Jersey. Each of the Parties hereby submits to the exclusive jurisdiction of such courts for the purpose of any such litigation; provided, that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Each party irrevocably and unconditionally agrees not to assert (a) any objection which it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such litigation brought in any such court has been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect to such litigation. |
9.7.11 | Accelerated Arbitration. To the extent a Dispute is related to the determination of the specific, single percentage between [***] and [***] that will be applied (in accordance with the processes set forth in Sections 5.3 and 5.4.2, as applicable) to all future upfront payments (as set forth in Section 5.3), development and regulatory milestone payments, and sales milestones payments associated with each of the three (3) individual programs to be undertaken under the Work Plan which may be assigned [***], the following procedures will apply: |
(a) | For purposes of arbitration under this Section 9.7.11, the arbitrator will be appointed pursuant to Section 9.7.3, but will be a single independent, conflict-free arbitrator with the requisite licensing and pharmaceutical industry experience (such arbitrator, the “Expert”). The Parties may select a different Expert for each Dispute depending on the nature of the issues presented and desired expertise. |
(b) | Each Party will prepare and submit a written summary of [***] in support thereof to the Expert within [***] of the selection of the Expert. Upon receipt of such summaries from both Parties, the Expert will provide copies of the same to the other Party. The Expert will be authorized to solicit briefing or other submissions on particular questions. Within [***] of the delivery of such summaries by the Expert, each Party will submit a written rebuttal of the other Party’s summary and may also amend and re-submit its original summary. Oral presentations will not be permitted unless otherwise requested by the Expert. The Expert will make a final decision with respect to the arbitration matter within [***] following receipt of the last of such rebuttal statements submitted by the Parties and will make a determination by [***]. |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
46 |
EXECUTION COPY |
(c) | The Parties further agree that the decision of the Expert will be the sole, exclusive and binding remedy between them regarding determination of the arbitration matter so presented. Confirmation of, or judgment upon any award rendered pursuant to this Section 9.7.11 may be entered by any court of competent jurisdiction. The Expert will have no authority to award any type of damages excluded under Section 9.8. Each Party shall bear its own costs and expenses and attorneys' fees and an equal share of the arbitrators' fees and any administrative fees of arbitration. |
9.8 | Limitation of Liability. Notwithstanding anything to the contrary contained herein, no Party shall be liable to another Party under any theory for any special, incidental, indirect, consequential or other similar damages, or any punitive damages, whether arising directly or indirectly out of the transactions contemplated by this Agreement. To be clear, neither Party shall be entitled to recover for any lost profit or lost sale damages of any kind, whether those claimed damages are direct or indirect. |
9.9 | Entire Agreement; Amendments. This Agreement, together with the Schedules and Exhibits hereto, and the Stock Purchase Agreements, contains the entire understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect to the subject matter hereof are superseded by the terms of this Agreement and the Stock Purchase Agreements. The Schedules and Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto. |
9.10 | Headings. The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. |
9.11 | Independent Contractors. It is expressly agreed that Company and MSD shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Company nor MSD shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. |
47 |
EXECUTION COPY |
9.12 | Waiver. The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise. |
9.13 | Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. |
9.14 | Certain Conventions. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. Unless the context of this Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, and (d) any list or examples following the word “including” shall be interpreted without limitation to the generality of the preceding words. |
9.15 | Business Day Requirements. In the event that any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a business day, then such notice or other action or omission shall be deemed to be required to be taken on the next occurring business day. |
9.16 | Counterparts. This Agreement may be signed in any number of counterparts (including by facsimile or electronic transmission), each of which shall be deemed an original, but all of which shall constitute one and the same instrument. After facsimile or electronic transmission, the Parties agree to execute and exchange documents with original signatures. |
[SIGNATURE PAGE IMMEDIATELY FOLLOWS]
48 |
EXECUTION COPY |
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.
MERCK SHARP & DOHME CORP. | 4D PHARMA PLC | |||
By: | /s/ Benjamin Thorner | By: | ||
Name: Benjamin Thorner | Name: | |||
Title: SVP & Head, BD&L | Title: | |||
By: | ||||
Name: | ||||
Title: | ||||
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date,
MERCK SHARP & DOHME CORP. | 4D PHARMA PLC | |||
By: | By: | /s/ Duncan Peyton | ||
Name: | Name: Duncan Peyton | |||
Title: | Title: Director | |||
By: | /s/ Alex Stevenson | |||
Name: Alex Stevenson | ||||
Title: Director |
1 |
EXECUTION COPY
SCHEDULE 1.31
LIST OF EXCLUDED LBPs
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] | ||||
[***] | [***] |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
EXECUTION COPY |
SCHEDULE 1.54
RESPONSE OUTCOMES
“Response Outcome 1” shall mean [***].
“Response Outcome 2” shall mean [***].
Criteria for Response Outcome 3 for the [***]
[***]
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
1 |
[***]
[***]
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
SCHEDULE 2.1
RESEARCH PROGRAM –
WORK PLAN
Attached.
EXECUTION COPY |
[***]
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
1 |
EXECUTION COPY |
SCHEDULE 2.2
COMPANY PRE-APPROVED THIRD PARTIES AND RELATED ACTIVITIES
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] | ||||||||||
[***] | [***] | [***] | [***] |
[***] | |
[***] | |
[***]41 |
*** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
2 |
SCHEDULE 4.4
FORM OF COMPANY PRESS RELEASE
Regulatory
4D pharma plc
(the “Company” or “4D”)
4D pharma collaborates with MSD to develop Live Biotherapeutics for vaccines
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces that the Company has entered into a research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics (“LBPs”) for vaccines.
Under the terms of the agreement 4D’s proprietary MicroRx® platform will be paired with MSD’s expertise in the development and commercialisation of novel vaccines, to discover and develop LBPs as vaccines in up to three undisclosed indications. 4D has the right, subject to certain conditions, to cause MSD to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration. In addition to an upfront cash payment, for each indication, 4D will be eligible to receive up to $347.5 million in option exercise and development and regulatory milestone payments, plus tiered royalties on annual net sales of any licensed products derived from the collaboration. MSD will be responsible for development, manufacturing and commercialisation following the exercise of any of its exclusive options.
Duncan Peyton, 4D’s Chief Executive Officer, commented: “This research collaboration agreement brings together 4D’s innovation in the microbiome space and MSD’s track record of developing cutting-edge vaccines. MSD and 4D have worked closely combining world leading science to develop a workplan to advance the understanding of this field, with the aim of generating a new class of vaccines in areas of high unmet need.”
Daria Hazuda, Chief Scientific Officer of MSD’s Exploratory Science Center and MSD’s Vice President of Infectious Diseases and Vaccines Discovery Research, commented: “A key element of our focus in the Exploratory Science Center is the evaluation of emerging new areas of biology that have the potential to offer major beneficial impact to human health. By applying 4D’s MicroRx® technology we hope to gain meaningful insights into the role for the host microbiome in modulating the immune response and ultimately protection conferred by vaccines.”
For further information please contact:
Duncan Peyton, Chief Executive Officer | +44 (0)113 895 0130 | |
N+1 Singer - Nominated Adviser and Joint Broker | +44 (0)20 7496 3000 | |
Aubrey Powell/ Justin McKeegan/ Alex Bond (Corporate Finance | ||
Tom Salvesen (Corporate Broking) | ||
Bryan Garnier & Co. Limited - Joint Broker | +44 (0)20 7332 | |
2500 Dominic Wilson /Phil Walker | ||
About 4D |
Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutic s based on a deep understanding of function and mechanism. 4D’s Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has four clinical studies in progress, namely a Phase II clinical study of Blautix in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours and a Phase I/II study of MRx-4DP0004 in asthma. Other focus programmes include disease areas such as CNS disease.
About 4D
For more information, refer to https://www.4dpharmaplc.com/
This announcement contains inside information as defined in Article 7 of the Market Abuse
Regulation No. 596/2014 ("MAR"). Upon the publication of this announcement, this inside
information is now considered to be in the public domain.
1 |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use in this Registration Statement on Form F-4 of 4D pharma plc of our report dated November 25, 2020, relating to the consolidated financial statements of 4D pharma plc, appearing in the Proxy Statement/Prospectus, which is part of this Registration Statement.
We also consent to the reference to our firm under the heading "Experts" in such Proxy Statement/Prospectus.
/s/ RSM US LLP
Boston, MA
November 25, 2020
1
Exhibit 23.2
Independent Registered Public Accounting Firm’s Consent
We consent to the inclusion in this Registration Statement of 4D Pharma on Form F-4, of our report dated April 30, 2020, with respect to our audits of the financial statements of Longevity Acquisition Corp. as of February 29, 2020 and February 28, 2019 and for the years ended, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum llp
Marcum llp
New York, NY
November 25, 2020